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ABSTRACT
Ocular infections with Herpes Simplex virus (HSV) can have damaging consequences
one of which is the loss of vision due to a chronic inflammatory reaction. T cells of the
Th1 subset appear to be the main orchestrators of the inflammatory reaction. Certain
components of the host immunity help to suppress the severity of lesions. My research
focuses on one such protective component - CD4 regulatory T cells (Treg). We showed
that Treg can initially function to suppress lesion development but this function can be
lost and become pro-inflammatory. This provided the challenge of why this so-called
plasticity occurred and how might it be prevented from developing. I was able to show
that inhibiting the epigenetic modification occurring within the Foxp3 gene curbed the Treg
plasticity. This reversal of plasticity was sufficient to enhance the control of SK lesion
severity.
Another focus of my research was to find ways to rebalance immune subsets in
SK lesions. We pioneered a new approach which exploited different metabolic
requirements for the pro-inflammatory and regulatory T cells in lesions. Pro-inflammatory
T cells such as Th1 use glucose for its function, whereas Treg rely on fatty acid oxidation
and to a lesser extent on glucose. Using 2-Deoxyglucose which inhibits glucose
utilization, the pro-inflammatory Th1 were affected but not Treg thereby reducing lesion
severity. It was important not to impair glucose utilization when replicating virus was
present since this could result in virus spreading to the brain to cause encephalitis.
We also evaluated if Treg were involved in repairing SK lesions. We could show
that Treg within the cornea made a tissue repair molecule called Amphiregulin peaking
during lesion development. This expression of Amphiregulin was partly dependent on the
cytokines IL-18 and IL-12 which acted together to induce the expression of Amphiregulin.
Moreover, enhancing the levels of IL-18 in the cornea using an expression plasmid helped
resolve SK lesion severity, an effect which correlated with increased Amphiregulin
expression by Treg.
In conclusion, my studies revealed several innovative approaches which might be
moved to the clinic to help minimize the consequence of an important cause of human
blindness.
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CHAPTER 1
BACKGROUND AND OVERVIEW
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Some of the Information in this chapter is reproduced from a publication accepted in
Current opinion in virology by Siva Karthik Varanasi, Barry T Rouse.
Siva Karthik Varanasi, Barry T Rouse. How host metabolism impacts on virus
pathogenesis. Current opinion in virology. 2018 Feb 28
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Herpes simplex virus Infection
Herpes viruses are a group of large enveloped DNA viruses that contribute to one
of the most common virus infections in the world. Herpes simplex virus belongs to the
alpha herpes virus subfamily which primarily targets neurons for their long-term residency
. While Herpes Simplex Virus type 1 (HSV-1) is often transmitted and associated with
facial lesions or cold sores, type 2 (HSV-2) is sexually transmitted and usually shows
genital lesions . Herpes simplex viruses develop an intricate relationship with the host
and upon infection the virus replicates in the mucosal epithelia while gaining access to
the sensory ganglion to set up latency. Periodically, the virus reactivates in the sensory
ganglion and sheds back to the mucosal surface causing lesions. Although there are
multiple reasons for why and when the virus reactivates, dysregulation of immune
signaling has been implicated to be one of the mechanisms involved . With HSV-1
infection, reactivation of virus in the trigeminal ganglion can lead to three main outcomes
depending on the location of shedding. 1. Virus can shed to the oral mucosa to cause
cold sores. 2. Virus can shed to the cornea to cause keratitis 3. Rarely virus can enter the
brain to cause encephalitis .
Herpes stromal keratitis
With more than 500,000 people infected with ocular herpes, Herpes stromal
keratitis (SK) is one of the leading causes of infectious blindness in developed countries
. Stromal keratitis in humans is usually a consequence of an overt immune inflammatory
response to repeated virus reactivation episodes in the cornea resulting in the corneal
tissue damage. Both primary infection and reactivation mouse models have provided
valuable information on mechanisms involved in SK pathogenesis. In the primary infection
mouse model the initial phase of virus replication results in a robust immune response
that results both in viral clearance as well as triggering a chronic inflammation that causes
tissue damage . The innate and adaptive immune contributions to SK are briefly
described below.
Innate immune responses
Innate immune responses are critical for the control of virus replication in the
cornea. Various innate immune cells such as dendritic cells, macrophages, natural killer
cells, neutrophils and monocytes have been identified during the acute phase of infection.
Viral components trigger innate immune cells to secrete various inflammatory
components that include various cytokines like IFN-α/β, IL-1β, IL-6 and TNF-α and
chemokines such as MIP-1α, MIP-1β, MIP-2 and MCP-1. Together, these molecules help
clear virus but in doing so they also bring in more inflammatory cells of both innate and
adaptive immune origin that contributes to tissue damage . Defects in these innate
immune responses results in uncontrolled virus replication and often lead to virus induced
encephalitis as observed in humans and mouse models .
Adaptive immune responses
The initial wave of innate immune responses causes the release of various
chemokines and activation of adaptive immune cells, mainly T cells and B cells. Although,
the contribution of B cell responses to SK lesion severity is not yet clear, B cells play a
protective role by controlling virus replication. Thus, B-cell deficient mice were shown to
be more susceptible to virus induced encephalitis compared to wild type animals . The
SK lesion is mainly orchestrated by T cells, particularly CD4 T cells . CD8 T cells appear
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to be more relevant in the trigeminal ganglion where they play a protective role and may
help sustain latency . Thus mice showing defective CD8 T cells responses show
increased susceptibility to HSV infection which can result in the encephalitis . On the
contrary, CD4 T cells that are primary orchestrators in corneal inflammation, play a helper
hand in TG .
CD4 T cells
Upon antigen presentation by antigen presenting cells (APC), naive CD4 T cells
quickly differentiate into at least four T cell subsets (lineages) depending on the cytokine
environment. For example, IL-12 induces IFN-gamma secreting Th1, IL-6 and TGF-beta
induces IL-17A secreting Th17 cells, IL-4 induces IL-4 secreting Th2 cells and TGF-beta
induces Foxp3 expressing regulatory T cells (Treg) . Various transcription factors are
associated with and are critical for the differentiation of individual T cell subsets. For
instance the transcription factor T-bet mediates the differentiation of Th1 cells, the
transcription factor RORgt for the differentiation of Th17 cells, the transcription factor
GATA3 for the differentiation of Th2 subsets and the transcription factor Foxp3 for Treg
differentiation. While Th1, Th17 and Th2 subset of T cells have pro-inflammatory
functions, Treg play an anti-inflammatory role, however, functional and phenotypic
plasticity within lineages do exist . Both Th1 and Th17 cells were shown to orchestrate
lesion development by inducing the recruitment of inflammatory innate immune cells such
as neutrophils and macrophages to cause tissue damage. In contrast, Treg play a
protective role. For instance, depletion of Treg or reduction in their function results in
increased lesion severity .
Regulatory T cells
Regulatory T cells (Treg) are a subset of T cells that have both anti-inflammatory
and tissue reparative properties. Treg are characterized by their expression of the
transcription factor Foxp3 which is critical for maintenance of the anti-inflammatory
functions that include expression of surface molecules such as CTLA-4, GITR, OX-40,
NRP-1, CD39, Lag-3, CD25, secretory molecules such as IL-10, ROS TGF-beta,
granzymes, and IL-35 . Based on their developmental origin, Treg can be classified into
natural Treg (nTreg) if they derive from the thymus or referred to as induced Treg (iTreg)
if the Treg originate in the periphery. While the expression of molecules such as
Neuropilin-1, Helios, IKAROS and IL-2ra (CD25) has been associated with nTreg in an
unimmunized host, inflammation drives the expression of these molecules (CD25, Nrp1,
Helios etc.) in iTreg. Another significant difference between nTreg and iTreg is in their
differential CpG DNA methylation pattern within the Foxp3 gene locus especially in the
intron-2 region also referred to as Treg Specific Demethylated Region (TSDR) . While,
the TSDR is methylated in the iTreg population, TSDR stays demethylated in the nTreg.
Thus the methylation status of TSDR acts as a good marker to distinguish nTreg and
iTreg population. . TSDR methylation patterns are not only important to distinguish Treg
populations but also indicate the stable nature of Foxp3 gene expression and thus the
maintenance Treg specific anti-inflammatory functions. For instance, Treg that have a
methylated TSDR (iTreg), lose their Foxp3 expression when exposed to pro-inflammatory
cytokines and attain the characteristics of effector T cells (Th1/Th17/Th2). However, Treg
whose TSDR region is demethylated (nTreg) are resistant to such plasticity . Hence,
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approaches that inhibits the methylation or promotes demethylation of TSDR region may
enhance the stability of Treg and can be likely useful to control SK.
Besides anti-inflammatory functions, Treg also perform tissue reparative functions
to maintain tissue homeostasis. Studies on various tissues such as intestines, skin, lungs
and muscles have shown that Treg can be involved in tissue repair and promote wound
healing . Although the complete list of tissue repair molecules secreted by Treg is yet to
be identified, two molecules were shown to initiate the tissue reparative process are
Amphiregulin (Areg) and Jag-1. While the role of Jag-1 signaling in cornea and other
tissues remain elusive, Areg has long been studied for its role wound healing in various
tissues. However, the role of Treg in promoting tissue repair or wound healing during HSV
induced damage is currently being studied.
Host-Immune metabolism
Few if any viruses kill all the hosts they infect but instead cause a broad range of
consequences. The outcome is affected by properties of the virus itself, the
circumstances of infection (such as dose and route of delivery) and several variables
within the host which include genetics, age, and previous experience with other agents
and the makeup of microbes that inhabit the gut and other locations . A poorly studied
variable that could affect the outcome of virus infections is host metabolism, the topic of
this brief review. We strive to answer a number of questions and speculate if manipulating
the metabolic status of infected persons could be a useful strategy to shape the
consequences of a virus infection.
Some lessons to be learned
Immunologists rediscovered their biochemistry of metabolism quite recently and
several informative reviews have been written . Basically, cellular components of both
innate and adaptive immunity adopt different primary means of generating energy and
biosynthetic products to support their immune functions. In addition, activated cells
responding to immune stimuli reprogram their metabolism and use different pathways
compared to those adopted by resting cells. As elegantly recounted by Luke O’Neil,
there are six major metabolic pathways which immune cells differentially employ to subserve their functions . These pathways include glycolysis, oxidative phosphorylation,
pentose phosphate pathway, fatty acid oxidation, fatty acid synthesis and amino acid
metabolism. To date, most investigations have focused on pathways that provide cells
with energy, biosynthesis, and redox balance. For instance, naïve T cells, memory T cells
and some T cells with regulatory function (Treg) require few nutrients and all use oxidative
phosphorylation (oxphos) supported by oxidation of fatty acids to supply their energy.
However, activated immune cells that are involved in pathogen clearance and
inflammation, such as CD4, CD8 T cells and M1 type macrophages, derive their energy
mainly from glucose via aerobic glycolysis . These effectors also take up amino acids,
such as glutamine, to generate intermediates which enter the tricarboxylic acid cycle. This
generates products that include coenzymes and fatty acids which provide metabolic
precursors for energy and biosynthesis (see Fig 1.1). Hence, nutrient availability and how
they are used by an immune cell becomes a critical issue which helps determine the
efficacy of an immune response. A major interest has been to explore how manipulating
the balance of oxphos and glycolytic metabolism can be used to shape the course of
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immune events in autoimmunity and cancers , but few studies have related metabolic
events to the outcome of infectious diseases. We demonstrate that host metabolism can
have a major effect on virus infections and speculate about the value of metabolic profiling
to predict the outcome of infections.
Does nutrient availability influence the outcome of virus infection?
It seems logical to assume that malnutrition could affect the outcome of a virus
infection and observations have linked starvation, obesity or dietary deficiencies to
changes in responses to some virus infections . However, at least with human virus
infections, the cause and effect evidence is scanty and usually provides no mechanistic
explanation for observed changes in susceptibility. It is known that nutritional effects such
as increased sugars and fat intake can change the number and function of immune cell
types , but how this relates to the expression of virus infection requires further
investigation. One of the more complete studies on nutritional consequences to infections
was reported by the Medzhitov group . They evaluated the effects of calorie deprivation
and supplementation on the outcome of some viral and bacterial infections in mice. They
showed that deprivation increased susceptibility to a neurotropic strain of influenza virus,
yet increased resistance to bacterial infections. In addition, force-feeding with extra
glucose saved the mice from virus infection, but made them more susceptible to bacteria.
They associated these effects with glucose metabolism, since inhibiting glucose utilization
with 2-deoxy glucose (2DG) led to virus-induced lethality, but survival from bacterial
infection. This outcome did not correlate with effects of 2DG on immune responsiveness,
but was attributed to effects on ER stress responses in the brain to virus–induced
interferon induction. This uncontrolled ER stress response resulted in neuronal apoptosis
through induction of a pro-apoptotic protein - CHOP. Thus, inhibition of glucose utilization
during virus infection led to CHOP dependent death of mice. Additionally, in a system
using poly (I:C) to mimic a virus infection, animals treated with 2DG also succumbed to a
similar ER stress mediated apoptotic response in the CNS .
Another example where inhibition of glucose utilization led to severe
consequences was observed following ocular HSV infection in mice . When treated with
2DG during acute infection, the majority of animals developed lethal encephalitis and
virus was present in the CNS. The outcome was proposed to result from inadequate
control of virus replication at the infection site because of suppressed innate immunity,
along with less efficacious CD8 T cell control of virus in the local nerve ganglia.
There are situations where impaired glucose utilization can limit the damage
caused by a virus infection. Such a circumstance was observed where virus caused tissue
lesions by an immunopathological mechanism . Accordingly, animals ocularly infected
with HSV develop chronic inflammatory lesions of stromal keratitis (SK) and express mild
hyperglycemia. However, if given 2DG when lesions were initiating these were minimized
and animals recovered. This 2DG therapy appeared to act by inhibitory effects on the
lesion orchestrating pro-inflammatory T cells, but spared the function of the antiinflammatory Treg population known to constrain SK severity .
Another nutritional situation suspected to influence viral pathogenesis is protein
deprivation. For example, mice fed a low protein diet experienced increased mortality to
influenza, LCMV as well as Sendai virus infections . The diet was associated with higher
viral titers and reduced numbers and function of virus specific CD8 T cells and NK cells.
In addition, total number of IFN-γ, TNF-α and IL-2 producing memory CD8 T cells were
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reduced likely accounting for less protection from reinfection . More studies are needed
at a mechanistic level to explain how protein deprivation results in heightened
susceptibility to virus infection.
Other essential components of nutrition are fatty acids, but few studies have linked
lipid availability, or its utilization, to effects on viral pathogenesis. One study in mice did
associate a diet rich in omega-3 fatty acids (considered anti-inflammatory) with increased
susceptibility to influenza virus infection . The outcome was associated with reduced NK
cell and neutrophil responses as well as reduced CD8 T cell activity which together
resulted in diminished antiviral and immunopathological responses in the lungs. The
dietary intake of both saturated and polyunsaturated fatty acids are also likely to affect
virus infections. Saturated fatty acids are usually pro-inflammatory, whereas some
polyunsaturated fatty acids and short chain fatty acids are usually anti-inflammatory . In
one study, mice unable to use long chain polyunsaturated fatty acids, because the
receptor-Fatty acid binding protein 5 (FABP5) was genetically deleted, became more
susceptible to influenza infection . Although such animals controlled virus replication more
effectively, the increased disease severity was attributed to more severe inflammatory
responses in the lungs involving increased numbers of macrophages, neutrophils and
pro-inflammatory T cells. Since FABP5 is also robustly expressed on other cell types such
as lung epithelial cells and fibroblasts in addition to immune cells, a direct link between
FABP5 knockdown and immunopathology still needs to be formally demonstrated.
Another potential mechanism, by which the dietary intake and utilization of fatty
acids affect the antiviral response, is their surprising influence on the persistence of CD8+
resident memory T cells (TRM). In fact, a key metabolic difference between the two
subsets of memory cells (central vs TRM) is the source of fatty acids they use to power
fatty acid oxidation. While central memory T cells rely on cell intrinsic lipolysis to generate
intracellular fatty acids , resident memory T cells take up fatty acids from the environment
. Thus, knockdown of FABP5, or inhibition of fatty acid-oxidation in vivo with the drug
etomoxir, resulted in a significantly reduced TRM response in the skin following dermal
infection with vaccinia virus . Exactly how inhibition of FABP5 or etomoxir treatment led
to the reduced TRM response requires further study.
The effect of dietary components on the expression of a virus infection is likely to
be mediated at least in part by the balance of microbes in the gut. This balance can
influence numerous systemic diseases that include cancers, autoimmunity and allergies,
as well as responses to infections and vaccines. For example, dietary intake which
favored the dominance of a particular species of Clostridium was protective against
severe influenza virus infections in mice . The proposed mechanism involved was
breakdown by Clostridia species of naturally occurring compounds called flavonoids
(commonly found in certain foodstuffs like cranberries) to produce the metabolite
desaminotyrosine (DAT). This molecule was proposed to enter the lungs and protect
against influenza infection by enhancing type I IFN signaling . However, if levels of DAT
were elevated once infection was already underway then the outcome was
immunopathology and lethality. Thus, timing is relevant since some nutrients that
potentially prevent virus infections might make matters worse if given at a different time.
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What effect do metabolic diseases have on virus infections?
Based on the evidence presented above, one might expect that metabolic
diseases should influence susceptibility to virus infections, but the issue is far from settled.
Most reports focus on diabetes with some associating human diabetes with increased risk
to influenza infection , but others finding no such association . Diabetic patients also have
additional conditions not involving glucose metabolism, such as physical changes in
several organs that could influence susceptibility to infection. The issue of relating
metabolic changes in diabetes to susceptibility to virus infection should be resolvable
using animal models of diabetes. The favored models have been induction of insulin
dependent type one diabetes in mice using the drug streptozotocin, as well as a leptin
receptor deficient mouse model which spontaneously develops a type two form of
diabetes . Multiple observations indicate that diabetes in both models increased
susceptibility to influenza ; but how this occurs and if it is the direct consequence of altered
glucose metabolism remains unclear. Direct effects of hyperglycemia are perhaps
unlikely, at least if the Medzhitov observations are generalizable. Thus in those studies,
supplementing glucose levels made mice more resistant to influenza infection . It is
possible that the increased susceptibility of diabetic mice to virus infections has nonmetabolic explanations. These could include reduced antigen presentation , structural
changes in the lung such as collapsed alveolar epithelia, increased vascular permeability
, changes in fat tissues and effects on the gut microbiota . Thus, ascribing a cause for the
increased susceptibility will be challenging.
The other metabolic disease with apparent association with susceptibility to virus
infections is obesity with obese patients being prone to influenza-related hospitalizations
and death. In fact, obese patients have many changes which could make them
susceptible to infection. These include hyperglycemia, dyslipidemia, excess
glucocorticoids and hyperinsulinemia , but how these signs might explain virus
susceptibility is uncertain. Mouse models are being used to resolve the issues which
include diet induced obesity (DIO) mice which suffer greater mortality during both primary
and secondary influenza infections. In this instance, the reduced resistance was attributed
to higher antigen specific CD8 T IFN-gamma responses that mediated lung
immunopathology . Defective memory responses were advocated to explain susceptibility
to secondary challenge . In obese mice, influenza infections may be more severe as a
consequence of reduced wound healing of the lungs . However how metabolic events
that occur during obesity explain increased viral susceptibility needs further study
especially to identify the mechanisms involved.
Can metabolism be manipulated to influence the outcome of virus infection?
As mentioned before, the idea of manipulating metabolic events to counteract
diseases has so far focused on cancer and autoimmunity. However, metabolic
manipulation to control some virus disease syndromes is ripe for the taking although the
topic at present largely represents unharvested fruit. We already discussed the potential
of manipulating glucose metabolism since immune cells with different functions may differ
on how they use glucose. Hence targeting glucose metabolism represents an approach
to rebalance immune responsiveness. So far, the completed studies have focused on
preventing glucose metabolism of aerobic glycolysis using 2DG therapy, but other
approaches should be explored. For example, a potential target in the glucose
metabolism field is the gene PFKFB3 (encoding 6-phosphofructo-2-kinase/fructose-2,6-
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biphosphatase3) involved in glycolysis. Type I IFN driven expression of PFKFB3 is
responsible for the hyperglycolytic state and the antiviral function of macrophages .
Accordingly, inhibition of macrophage PFKFB3 resulted in poor control of RSV infection
in mice . Expression of PFKFB3 may also be needed for T cell activation and proinflammatory function . In consequence, if a convenient way is found to increase PFKFB3
this could be a useful therapy against many virus infections.
Another potential approach to strengthen immunity against multiple viruses could
be to augment the expression and activity of Hypoxia inducible factor 1a (HIF-1a). This
molecule activates several glycolytic genes that include Glut1, PFKFB3, PGK1 and
PKM2. Small molecule activators of HIF-1a are already available but these may not have
been tested for antiviral effects. However, a recent study has shown that genetic ablation
of VHL, a negative regulator of HIF-1a, selectively in CD8 T cells provided more effective
control of chronic LCMV. However, increased mortality occurred which was associated
with the enhanced function of immunopathological CD8+ T cells Thus, as with HSV
pathogenesis, timing of procedures that modulate metabolism can be a critical issue . An
alternative to targeting glucose for metabolic therapy is to use the amino acid glutamine
which as mentioned before provides an alternate source of energy. Recently, a report
showed that glutamine supplementation acted to stabilize HSV latency in mice . Thus,
reactivation from latency was inhibited in mice fed glutamine, an outcome correlated with
enhanced HSV specific CD8 T cell responses. Such responses act to prevent neurons in
local nerve ganglia from replicating virus .
The hot topic of immune exhaustion might also benefit from therapies that target
metabolism. Several chronic viral infections remain uncontrolled because their T cells fail
to function adequately . Recently, it became evident that antiviral exhausted CD8 T cells
displayed extensive mitochondrial changes that included elevated mitochondrial ROS
production and reduced levels of PPARα co-activator 1α (PGC1α), a key transcriptional
regulator controlling energy metabolism and mitochondrial biogenesis. Conceivably,
these metabolic consequences could be reversed chemically which should be a far more
economical approach than counteracting exhausted T cells with monoclonal antibodies
(Fig 1.2).
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Figure 1. Metabolic differences in immune cells with effector functions versus cells
with regulatory or memory functions.
(1) Effector immune cells take up glutamine and glucose to generate ATP and
intermediates for amino acids and fatty acid synthesis (2) Regulatory and memory
immune cells take up less glucose and glutamine molecules but instead take up more
fatty acids that power mitochondria to generate ATP. Dominant metabolic pathways are
shown in solid lines; less critical or studied pathways are shown in dotted lines.
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Figure 2. Proposed model of link between nutrition and immune responses to virus
infection.
Both Hyper-nutrition and malnutrition have effects on immune function. Thus malnutrition
can suppress immune functions and increase susceptibility to infections. Hyper-nutrition
or dysregulated nutrition may cause overt immune responses and cause
immunopathology. Thus, optimal nutritional and metabolic homeostasis is an important
part of appropriate immune function and good health.
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CHAPTER 2
THE PLASTICITY AND STABILITY OF REGULATORY T CELLS DURING VIRALINDUCED INFLAMMATORY LESIONS
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Abstract
Ocular infection with Herpes Simplex Virus causes a chronic T-cell mediated
inflammatory lesion in the cornea. Lesion severity is affected by the balance of different
CD4 T-cell subsets with greater severity occurring when the activity of regulatory T-cells
is compromised. In the present report, fate-mapping mice were used to assess the
stability of Treg function in ocular lesions. We show that cells that were once FoxP3+
functional Treg may lose FoxP3 and become Th1 cells which themselves could contribute
to lesion expression. The instability mostly occurred with IL-2 receptor low Treg and was
shown to be in part the consequence of exposure to IL-12. Lastly, in-vitro generated iTreg
were shown to be highly plastic and capable of inducing SK when adoptively transferred
into Rag1-/- mice, with 95% of iTreg converting into ex-Treg in the cornea. This plasticity
of iTreg could be prevented when they were generated in the presence of Vitamin-C and
Retinoic acid. Importantly, adoptive transfer of these stabilized iTreg to HSV-1 infected
mice more effectively prevented the development of SK lesions than did the control iTreg.
Our results demonstrate that CD25lo Treg and iTreg instability occurs during a viral
immuno-inflammatory lesion and that its control may help avoid lesion chronicity.
Introduction
Ocular infection with herpes simplex virus type 1 (HSV-1) can result in a chronic
immuno-inflammatory reaction in the cornea, which represents a common cause of
human blindness . Studies in animal models have revealed that stromal keratitis (SK)
lesions are orchestrated mainly by IFN-γ–producing CD4+ T cells (Th1) cells . The lesions
are less severe and can even resolve if regulatory T cells (Treg), such as CD4 Foxp3 T
cells, dominate over the proinflammatory CD4 T cell subsets . Lesions become far more
severe if Treg are depleted prior to infection or even if suppressed in the face of ongoing
infection . Thus lesions can be limited in severity if Treg function is optimized. Recent
studies on some experimental models of autoimmunity have revealed that the function of
Treg may be unstable in the face of an inflammatory environment . In fact Treg may lose
their regulatory function and even take on proinflammatory activity and contribute to lesion
expression. So far it is not known if Treg plasticity happens during a viral immuneinflammatory lesion and if the event helps explain why lesions become chronic and
eventually fail to resolve. This issue is evaluated in the present report using a fate
mapping mouse model system.
Reasons for plasticity are thought to be the consequence of either epigenetic
modifications or posttranslational modifications . Several studies have shown that DNA
demethylation of the Foxp3 conserved noncoding sequence 2 (CNS2), also named Tregspecific demethylated region (TSDR), is critical for stable expression of FoxP3 .
Demethylation of CpG motifs allows critical transcription factors, such as Foxp3 itself and
Runx1–Cbf-β complex, to bind to the TSDR region and keep the transcription of Foxp3
active in the progeny of dividing Treg . Another layer of epigenetic control involves the
acetylation of the Foxp3 gene, which enforces FoxP3 expression and stability . Several
other external stimuli such as proinflammatory cytokines can also influence Treg stability
either by influencing the epigenetic status of the FoxP3 gene or by making
posttranslational modification . Accordingly, activation of Treg in the presence of IL-6
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leads to a STAT3-dependent decrease in Foxp3 protein and message accompanied by
increased DNA Methyltransferase 1 (DNMT1) expression. These effects lead to
methylation of the TSDR region of the Foxp3 gene, as well as reduced acetylation of
histone 3 at the upstream promoter region of the gene . Another important cytokine that
influences Treg stability is IL-2 . Accordingly, several recent studies correlate robust
surface expression of the high affinity IL-2 receptor (CD25) with enhanced Foxp3
expression, suppressive function, and stability of the Treg phenotype .
In this report we use fate mapping mice to show that Treg plasticity occurs in a
virus induced inflammatory reaction and might contribute to stromal keratitis lesion
severity and chronicity by secreting proinflammatory cytokine IFN-γ. This plasticity of Treg
occurred more readily in the CD25lo population of Treg and was in part due to
proinflammatory cytokine IL-12. Additionally, we also show that iTreg are highly plastic in
the SK microenvironment. Lastly of therapeutic interest we could limit iTreg plasticity both
in-vitro and in-vivo by generating induced Treg in the presence of Vitamin C and Retinoic
acid. Moreover these stabilized iTreg could reduce SK lesions more effectively compared
to unstable iTreg when adoptively transferred to HSV infected mice. All these results
suggest that stabilizing Treg might represent a process to be targeted to minimize lesion
expression and their chronicity.
Results
Treg lose FoxP3 expression in the cornea after ocular HSV-1 infection and acquire
a Th1 cell phenotype
To directly examine Treg plasticity in the cornea after HSV-1 ocular infection invivo, FoxP3Cre-GFP: Rosa26lsl-Td-Tomato mice (now referred to as fate mapping mice
(FM mice)) were used. These mice allow Treg fate mapping and the ability to distinguish
between cells that currently express from the cells that once expressed FoxP3 but now
lack its expression (ex-Treg). FM mice have cells that can be distinguished by flow
cytometric analysis into three main T cell populations that participate in SK lesions.
Accordingly, Treg are (CD4+ GFP+ Tomato+), ex-Treg are (CD4+ Tomato+ GFP-) and
lastly effector CD4 T cells are (CD4+ Tomato- GFP-) (Supplementary figure S2.1). It was
evident that after HSV-1 ocular infection of FM mice that some of the Treg lineage cells
in the cornea lost their GFP expression indicating their likely loss of Treg function. Such
ex-Treg accounted for 38% of the total Treg population at day 8, 60% at day 15 and 35%
at day 21 pi (Figure 2.1A). Curiously, the peak numbers of ex-Treg were evident in day
15 pi samples, which is the usual time when lesions are at their peak (Figure 2.1B).
To quantify the cytokine producing abilities of these ex-Treg, single cell
suspensions of 3-4 collagen-digested pooled corneas from ocularly HSV-1 infected FM
mice were stimulated at different times pi with PMA/ionomycin, followed by an intracellular
cytokine detection assay. As shown in figure 2.1C at days 8 and 21 pi 33% of the ex-Treg
became IFN- γ producers but at day 15, which is the peak of the disease, 80% of the exTreg were IFN-γ producers. Additionally, similar to ex-Treg numbers, the IFN- γ producing
ex-Treg cells peaked at day 15 pi. Of particular interest, the percentage of exFoxp3 cells
was increased particularly in the corneas (approx. 50%), as compared to DLN and spleen
(approx. 19% and 25% respectively) at day 15pi (Supplementary figure 2.2A). The
frequencies of IFN- γ produced by exFoxp3 cells were also higher in corneas (approx. 80
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%) as compared to DLN and spleen (approx. 7% and 16% respectively) when measured
at the same time pi (Supplementary figure 2.2B). Furthermore, intracellular cytokine
production by corneal cells stimulated with a UV-inactivated viral Ag revealed a high
percentage of ex-Treg (approx. 22%) that were HSV-specific Th1 cells at day 15pi (Figure
2.1E). All these results indicate that a substantial proportion of corneal Treg convert into
Th1 ex-Treg after HSV-1 ocular infection. Of interest, some of the ex-Treg were HSV
antigen specific indicating that such ex-Treg may have derived from the HSV specific
Treg population.
CD25lo Foxp3+CD4+ Treg generate ex-Treg during HSV-1 induced inflammation
Several reports suggest that Treg are comprised of Foxp3-stable CD25hi and
Foxp3-unstable CD25lo populations. These reports also show that CD25lo Treg have
defective suppression, express less Foxp3 expression and had a moderately less
demethylated TSDR compared to the CD25hi Treg. Similarly, in our system we could
show that HSV-1 immune FACS sorted CD25lo Treg at day 15pi were less suppressive.
and had a moderately less demethylated TSDR as compared to the CD25hi Treg (Figure
2.2A and B). Additionally, CD25lo Treg also showed less Foxp3 expression as compared
to the CD25hi Treg, as measured by MFI (Figure 2.2C). These results led us to
hypothesize that CD25lo Treg might be the main population that harbored uncommitted
Treg in SK lesions. To evaluate if such CD25lo Treg were unstable in-vitro, CD4+ GFP+
T cells were sorted into CD25lo and CD25hi cells with purity >95% (Supplementary figure
2.3) from HSV-1 infected FoxP3-GFP mice at day 15pi and stimulated with antiCD3/CD28+IL-2 (control) or CD3/CD28+IL-12 for 5 days. As shown in figure 2.2D, in the
presence of pro-inflammatory cytokines IL-12, 25% of the CD25lo, but only 10% of the
CD25hi Treg lost FoxP3 expression. However, in the control cultures that received IL-2
alone, minimal loss of FoxP3 expression was observed (approx. 10%). These results
indicate that pro-inflammatory cytokine IL-12 can promote the conversion of antigen
experienced CD25lo Treg into ex-Treg.
To evaluate FoxP3 stability of the two CD25lo and CD25hi Treg populations in
vivo, FACS sorted HSV-1 immune Thy1.2 CD25lo and CD25hi Treg (gated on GFP+
cells) from FM mice were adoptively transferred into congenic Thy1.1 mice and these
were infected via the footpad with HSV-1 24 hours later. The recipient mice were analyzed
for the presence of donor T cells in the popliteal lymph node (PLN) and spleen at day 5
pi by reacting with anti-CD4 and anti-Thy1.2. As is evident from Figure 2.2E, 50% of the
donor CD25lo Treg lost GFP expression and converted into ex-Treg. This compared to
only 16.4% in the donor CD25hi Treg in the PLN of recipient animals (Figure 2.2E).
Similar results were found in the spleen (data not shown).
To determine if ex-Treg could be derived from activated conventional T cells that
transiently express Foxp3 or if ex-Treg could be converted back into Treg. The same
experimental setup as above was used. Accordingly, similar numbers of FACS sorted
effector T cells or ex-Treg cells from immunized FM mice were adoptively transferred into
congenic Thy1.1 mice and these were infected via the footpad with HSV-1 24 hours later.
The recipient mice were analyzed for the presence of donor T cells in the PLN and spleen
at day 5 pi by reacting with anti-CD4 and anti-Thy1.2. As is evident from figure 2.2F, none
of effector T cells or the ex-Treg cells showed any conversion into Treg. This suggests
that transient upregulation of FoxP3 on effector T cells is not contaminating the ex-Treg
population and that the ex-Treg population does not convert back into Treg during HSV-
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1 induced inflammation. Taken together, our results show that HSV-1 immune CD25lo
Treg showed defective suppression, had a partially methylated TSDR and were highly
unstable cells that convert to ex-Treg under inflammatory conditions.
CD25lo Treg were increased in the cornea after HSV-1 ocular infection
To determine if the population of unstable CD25lo Treg increased in the cornea
after HSV-1 ocular infection, FoxP3-GFP mice were ocularly infected with HSV-1 and
corneas were collected, collagen digested and the recovered cells reacted with anti-CD4
and anti-CD25 antibodies at days 8, 15 and 21 pi. As shown in figure 2.3A, the frequency
of CD25lo Treg remained stable over time, but the numbers of CD25lo Treg increased as
the disease progressed and reached a peak at day 15 pi. These results suggest that
unstable CD25lo Treg population is present in the cornea at different days post infection
and could contribute to the generation of ex-Treg in corneal lesions.
Ex-Treg are pathogenic and can cause SK
Previous results showed the presence of ex-Treg, Treg as well as conventional
effector T cells in corneal lesions. To measure and compare the pathogenicity of ex-Treg,
Treg and CD44hi T effectors, ex-Treg, CD25hi Treg and CD44hi FoxP3- T effectors were
FACS sorted from DLNs and spleens of day 15 post infected FM mice. Equal numbers of
each cell population were then transferred into T cell and B cell deficient Rag1-/-, which
were infected ocularly 24h later with HSV-1. The recipients were monitored clinically over
the next 10 days. Because HSV-1 infected Rag1-/- mice usually develop lethal herpetic
encephalitis, infected recipient mice were given a source of anti-HSV-1 antibody (human
IVIG) 2 days after infection, which allows mice to survive beyond day 6 pi and ensures
optimal HSK development in surviving mice . Using this protocol our results showed that
CD44hi T effectors and ex-Treg induced similar levels of SK severity (lesion score < 2.5)
at day 10 pi (Figure 2.4A), while the control animals that received no cells or CD25hi Treg
showed minimal lesions. In addition, T effectors and ex-Treg cells in subpools of collagendigested corneas produced similar levels of IFN-γ (approx. 70%) as seen by the ICS
assay after PMA/ionomycin stimulation (Figure 2.4B), while the control animals that
received CD25hi Treg showed minimal IFN-γ production (approx. 15%). These results
demonstrate that ex-Treg cells can function as pathogenic effector cells producing IFN-γ
in the cornea and that these ex-Treg can induce SK with a similar severity to that caused
by CD44hi T effector cells.
iTreg covert into ex-Treg and induce SK disease in Rag1-/- recipients
Previous reports show that naive T cells converted in-vitro into iTreg cells by TCR
stimulation in the presence of IL-2 and TGF-β had methylated CpG sites in the FoxP3
CNS2 region, but could lose Foxp3 expression rapidly . However, whether or not FoxP3
instability of in-vitro induced iTreg results in pathogenic ex-Treg during HSV-1 infection
remains to be substantiated. To test this possibility iTreg were generated from sorted
naïve CD4+T cells from FM mice by stimulating them with anti-CD3/CD28 in the presence
of IL-2 and TGF-β for 5 days. Tomato+ GFP+ iTreg cells were then FACS sorted and
adoptively transferred into T cell and B cell deficient Rag1-/- mice 24 hours after ocular
infection with HSV-1. Recipients were monitored clinically over the next 10 days. These
mice were also given IVIG at day 2pi to protect them from lethal encephalitis as described
in the previous section. At day 10 pi typical HSK lesions (score ≥2.5) were evident in the
iTreg recipients at the time of sacrifice whereas only minimal lesions were evident at the
same time in control animals that were infected but received no cell transfer (Figure 2.5A).
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More importantly, 95% of the cells recovered from the corneas of the iTreg recipients lost
FoxP3 expression and converted into ex-Treg in the SK lesions (Figure 2.5B). Moreover,
26% of the infiltrating CD4 T cells in the cornea produced IFN-γ as measured by the ICS
assay after PMA/ionomycin stimulation (Figure 2.5C). This supports the notion that the
iTreg had converted into Th1 cells in the SK microenvironment. Taken together our data
show that iTreg were highly unstable and could convert into Th1 ex-Treg in an SK
inflammatory micro- environment and that these cells contributed to SK expression.
iTreg generated in the presence of Vitamin C and RA were highly stable and
resistant to conversion into ex-Treg.
A previous report had indicated that iTreg generated in the presence of Vitamin C
and RA could substantially stabilize FoxP3 expression both in-vitro and in- vivo . This
occurred in part by demethylating the TSDR region of the Foxp3 locus. Similarly, we could
show that iTreg generated in the presence of Vitamin C + RA had an almost completely
demethylated TSDR region (90%), whereas, in the control iTreg (without Vitamin C + RA)
the TSDR was only minimally demethylated (12%) (Figure 2.6A). Furthermore, to show
that Vitamin C + RA could stabilize iTreg in the face of inflammatory cytokines in the SK
system, splenocytes from DO11.10 RAG2-/- animals (ova peptide specific and 98% naïve
CD4+ T cells) were cultured in the presence of Treg differentiating conditions (antiCD3/CD28 stimulation +IL-2 and TGF-β) either in the presence or absence of Vitamin C
+ RA. After 5 days of culture a few cells were harvested and cell numbers that expressed
Foxp3 were recorded. The remaining cells were exposed either to IL-2 or IL-12 (Th1
condition) or IL-6 and TGF-beta (Th17 conditions) for an additional 3 days. FoxP3
expression was analyzed again at this time point and the % Foxp3 expression lost was
calculated. In these experiments, IL-2 alone led to minimal loss of Foxp3 expression
(approx. 8%), whereas exposure to IL-12 and IL-6 +TGF-β resulted in a significant loss
of Foxp3 expression (approx. 30%) in control iTreg. In contrast, iTreg generated in the
presence of Vitamin C + RA were significantly more stable and lost minimal (5-10%)
Foxp3 expression when exposed to either Th1 or Th17 differentiating conditions (Figure
2.6B).
To evaluate in vivo stability of Foxp3 expression of iTreg cells generated in the
presence of Vitamin C + RA, naive CD4+ T cells from FM mice were cultured in the
presence of Treg differentiating conditions (anti-CD3/CD28 stimulation +IL-2 and TGF-β)
either in the presence or absence of Vitamin C + RA. The control iTreg and Vitamin C +
RA generated iTreg were adoptively transferred into congenic, HSV-1 ocularly infected
Thy1.1 mice at 72hpi. Recipient mice were then analyzed for the presence of donor T
cells in the DLN and spleen at day 15 pi by reacting with anti-CD4 and anti-Thy1.2. As
evident from Figure 2.6C, 26-28% of the donor control iTreg lost GFP expression and
converted into ex-Treg. This compared to a loss of only 3-7% in the recipients of Vitamin
C + RA generated iTreg.
These results demonstrate that HSV-1 induced inflammation and pro-inflammatory
cytokines IL-12 and IL-6 could promote the conversion of iTreg into ex-Treg and this
conversion could be markedly inhibited when iTreg were generated in the presence of
Vitamin C and RA.
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Vitamin C+ RA stabilized iTreg more efficiently suppress SK lesions than do control
iTreg
To evaluate if iTreg populations stabilized in vitro by induction in the presence of Vitamin
C + RA were more effective at controlling SK lesions than un-stabilized iTreg, adoptive
experiments were performed. The donor cell populations used to generate the both
stabilized iTreg and control unstable iTreg were from DO11.10 RAG2-/- (OVA specific)
mice as described in materials and methods. These mice were used because they
provide a highly enriched naïve CD4 T cell population . Groups of Balb/c mice received
the adoptive transfer 3 days after ocular infection and disease severity were followed until
termination on day 15 pi. As shown in Figure 2.7A mice that received the stabilized iTreg
population expressed significantly reduced lesions compared to those that received no
iTreg. Similarly, mice that received the stabilized iTreg population showed a trend of
reduced lesions compared to those that received unstable control iTreg population
although no significance was achieved. Additionally, there were 1.8 fold reduced number
of CD4+T cells and Th1 cells infiltrating the cornea in the mice that received the stabilized
iTreg compared to those that received no iTreg (Figure 2.7B). Taken together, our data
demonstrate that stabilized Vitamin C +RA generated iTreg were better at suppressing
SK lesions compared to un-stabilized control iTreg.
Discussion
In this report, using fate mapping mice, we showed that Treg present in the cornea
during a viral induced inflammatory reaction are unstable and can become ex-Treg with
a Th1 phenotype. We also showed that the CD25lo Treg were highly plastic and
converted into ex-Treg more readily than the stable CD25hi Treg subpopulation.
Interestingly, the unstable CD25lo Treg were present in the cornea and this population
increased with the progression of disease and followed the same pattern as the
appearance of ex-Treg. The pro-inflammatory cytokine IL-12 and IL-6 was in part
responsible for the generation of ex-Treg during SK development. Furthermore, ex-Treg
displayed equivalent disease causing potential as effector T cells when cells were
adoptively transferred in HSV-1 infected Rag1-/- animals. We also showed that the
population of Treg generated in vitro from naïve CD4 T cells were highly unstable when
transferred into lymphopenic Rag1-/- recipients with almost 95% of the iTreg converting
into ex-Treg. Finally, we could show that Treg generated in-vitro in the presence of
Vitamin C and RA produced a population with increased stability when exposed to an
inflammatory environment either in-vitro or in-vivo. More importantly, the stabilized iTreg
population was more efficient at reducing SK lesions as compared to control unstable
iTreg when adoptively transferred in day 3 HSV-1 infected mice. Taken together our
results demonstrate that instability of Treg function occurs in the inflammatory
environment of a virus-induced lesion and that the converted ex-Treg can also participate
in tissue damage, an event that may help explain chronicity.
It is becoming increasingly evident that diverse environmental stimuli can affect
Treg stability acting by modulating epigenetic programing or posttranslational
modifications . For example, proinflammatory cytokines such as IL-12, IL-6 and IL-1β
could trigger a signaling pathway through their receptors on Treg. This could cause a loss
of Foxp3 expression by several mechanisms. Thus, IL-1β induces the ubiquitinase
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enzyme Stub1 that permits the ubiquitination of FoxP3 and its degradation . In addition,
IL-6 leads to a STAT3-dependent decrease in Foxp3 protein and mRNA accompanied by
increased DNMT1 expression. This effect results in methylation of the TSDR region of
the Foxp3 gene, as well as diminished acetylation of histone 3 at the upstream promoter
region of the gene . Additionally, IL-12 can activate the IL-12R-β2/STAT4-mediated
signaling pathway, which causes the polarization towards the Th1 type Treg and loss of
FoxP3 expression . In our report we showed that IL-12 and IL-6 could cause the loss of
FoxP3 expression especially in CD25lo Treg and iTreg populations. A cytokine that has
been shown to stabilize Treg is IL-2 by signaling through the IL-2R (CD25) on the Treg
cells . Accordingly, several recent studies in mice and humans showed that robust CD25
expression on Treg correlated with enhanced FoxP3 expression, suppressive function
and stability of the Treg phenotype . Similarly, we observed that the CD25lo population
of Treg in SK system were less suppressive and were highly unstable with 50% of them
losing FoxP3 expression when adoptively transferred into HSV-1 footpad infected WT
mice.
An interesting observation was that CD25lo Treg infiltration into the cornea
mirrored the appearance of ex-Treg which could mean that the ex-Treg generated in the
cornea were derived mainly from the CD25loTreg population. However, some question
whether ex-Treg observed in some autoimmune settings represent the loss of Foxp3 by
bonafide Treg, or whether they represent conventional proinflammatory T cells that
transiently induced endogenous FoxP3 and so induced FoxP3-Cre recombinase, leading
to activation of the lineage tracer (Tomato) expression. We favor the notion that in our
system of SK the ex-Treg represents true ex-Treg and not proinflammatory T cells that
transiently expressed FoxP3 based largely on the results of adoptive transfer
experiments. Accordingly, adoptive transfer of Foxp3-CD4+ T cells from FM mice into
HSV-1 infected WT mice did not show any conversion to ex-Treg (Figure 2.1F), thus
showing that T conv cells transiently expressing FoxP3 did not occur in our system or that
the transient expression of Foxp3 was not enough to induce FoxP3-Cre recombinase. In
addition, adoptive transfer of FACS sorted CD25lo Treg from HSV-1 infected FM mice
into Thy1.1 mice that were infected with HSV-1 in the footpad showed conversion of these
Treg into ex-Treg. This would support the idea that the conversion of Treg to ex-Treg is
occurring in the infectious disease system we investigated.
Explanations for Treg plasticity include epigenetic and posttranslational
modifications . Accordingly, demethylation of CpG islands in the TSDR region of the
Foxp3 locus is considered a hallmark of Treg stability and functionality . Demethylation of
the CpG islands in the TSDR region ensures that critical transcription factors such as
Foxp3 and Runx1–Cbf-β complex, to bind to the TSDR region and maintain Foxp3 activity
in the progeny of dividing Treg . Epigenetic regulation of stable Foxp3 expression is also
regulated by FoxP3 acetylation . Previous reports show that the TSDR region is
demethylated in thymic Treg expressing Foxp3, but in iTreg TSDR region is fully
methylated making them unstable . We could also show that iTreg have a fully methylated
TSDR and displayed plasticity when adoptively transferred in Rag1-/- mice. Moreover,
almost 95% of these iTreg lost FoxP3 expression and became ex-Treg with the Th1
phenotype. Post-translation modifications that regulate Treg plasticity include
phosphorylation and ubiquitination of FoxP3 and these events are being further explored
in our system.
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It is important from a lesion management perspective to find appropriate measures
to limit or prevent Treg plasticity. Approaches under consideration include agents that
cause demethylation of the TSDR region of the FoxP3 gene such as Azacytidine, which
was investigated for its effects on SK lesion severity . The results showed that Azacytidine
therapy after disease process had been initiated effectively diminished lesions. Other
agents that prevent methylation of the TSDR region or promote acetylation of the FoxP3
gene may also show therapeutic promise to contain Treg plasticity . Vitamin C induces
CNS2 demethylation in iTreg in a ten-eleven-translocation 2 (Tet2)/Tet3-dependent
manner to increase the stability of Foxp3 expression . Similarly, RA also has a stabilizing
effect on Foxp3 protein expression. It acts by suppressing IL-1 receptor upregulation, and
accelerating IL-6 receptor downregulation along with increasing histone acetylation of the
FoxP3 TSDR without affecting the methylation status of the TSDR region .
In the present communication we explored the value of Vitamin C and RA and
could show that iTreg generated in the presence of Vitamin C and RA were more stable
both in-vitro and in-vivo. Accordingly, when iTreg were adoptively transferred into WT
HSV-1 ocularly infected mice at day 3 pi (a time at which levels of pro-inflammatory
cytokines is high in the DLN), almost 30% of these iTreg lost Foxp3 expression. In
contrast when iTreg were generated in the presence of Vitamin C and RA conversion was
minimal (3-7%). Similar stabilizing effects were observed when iTreg generated with
Vitamin C and RA, were exposed to proinflammatory cytokines IL-6 or IL-12 in-vitro.
Moreover, these results might also explain previous findings that adoptive transfer of
iTreg before infection effectively controlled SK lesion development yet transfers given
later when the proinflammatory cytokines such as IL-6 were highly elevated were without
notable lesion control . Our current finding explains this phenomenon since many iTreg
converted and become ex-Treg without regulatory activity. Interestingly, we could stop
this plasticity by generating iTreg in the presence of Vitamin C + RA and more importantly
adoptive transfer of stabilized Vitamin C+ RA generated Treg suppressed SK lesions
more efficiently than the control unstable iTreg when transferred to day 3 HSV-1 infected
mice. It remains to be evaluated if Vitamin C + RA could stabilize CD25lo Treg and if the
combination of Vitamin C and RA treatment in-vivo might hold promise as a therapeutic
means of controlling virus induced inflammatory lesions.
Our results indicate that conversion of Treg or iTreg into Th1 cells may have a
critical role in the severity of viral induced inflammatory lesions. Blocking pathways to
prevent the conversion of these Treg into pathogenic T cells could represent a useful
approach to control an important cause of human blindness.
Materials and methods
Mice
Female 6 to 8 week old C57BL/6 and Balb/c mice were purchased from Harlan Sprague
Dawley Inc. (Indianapolis, IN). CD45.1 congenic (B6.SJL-Ptprca Pepcb/BoyJ), Rag1deficient (B6.129S7-Rag1tm1Mom/J) and B6 ROSA26-Td Tomato reporter mice were
purchased from Jackson Laboratory. Foxp3-GFP-Cre mice were provided by Dr. Jeffery
Bluestone (San Francisco, CA). To generate Treg fate mapping mice Foxp3-GFP-Cre
were crossed with B6 ROSA26-Td Tomato mice. Foxp3-GFP (C57BL/6 background)
mice were a kind gift from M.Oukka (Brigham and Women’s Hospital, Harvard Medical
School), BALB/c DO11.10 RAG2 -/- mice were purchased from Taconic and kept in
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pathogen free facility where food, water, bedding and instruments were autoclaved. All
mice were housed in facilities at the University of Tennessee (Knoxville, TN) approved by
the American Association of Laboratory Animal Care. All investigations followed
guidelines of the Institutional Animal Care and Use Committee.
Ethics Statement
This study was carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocol was approved by the University of Tennessee Animal Care and Use committee
(protocol approval numbers 1253-0412 and 1244-0412). All procedures were performed
under tribromoethanol (avertin) anesthesia, and all efforts were made to minimize
suffering.
Virus
HSV-1 strain RE Tumpey and HSV-1 KOS was propagated in Vero cell monolayers
(number CCL81; ATCC, Manassas, VA), titrated, and stored in aliquots at –80°C until
used. Ultraviolet (UV) inactivation of the HSV-1 RE virus was performed for 10 minutes.
Corneal HSV-1 Infection and Scoring
Corneal infections of mice were performed under deep anesthesia. The mice were lightly
scarified on their corneas with a 27-gauge needle, and a 3-μL drop that contained 104
plaque-forming units of HSV-1 RE was applied to one eye. Mock-infected mice were used
as controls. These mice were monitored for the development of SK lesions. The SK lesion
severity and angiogenesis in the eyes of mice were examined by slit-lamp biomicroscopy
(Kowa Company, Nagoya, Japan). The scoring system was as follows: 0, normal cornea;
+1, mild corneal haze; +2, moderate corneal opacity or scarring; +3, severe corneal
opacity but iris visible; +4, opaque cornea and corneal ulcer; and +5, corneal rupture and
necrotizing keratitis.
Flow Cytometric Analysis
At day 15 pi, corneas were excised, pooled group-wise, and digested with liberase (Roche
Diagnostics Corporation, Indianapolis, IN) for 45 minutes at 37°C in a humidified
atmosphere of 5% CO2. After incubation, the corneas were disrupted by grinding with a
syringe plunger on a cell strainer and a single-cell suspension was made in complete
RPMI 1640 medium. The single-cell suspensions obtained from corneal samples were
stained for different cell surface molecules for fluorescence-activated cell sorting (FACS)
analyses. All steps were performed at 4°C. Briefly, cells were stained with respective
surface fluorochrome-labeled Abs in FACS buffer for 30 minutes, then stained for
intracellular Abs. Finally, the cells were washed three times with FACS buffer and
resuspended in 1% paraformaldehyde. The stained samples were acquired with a FACS
LSR II (BD Biosciences, San Jose, CA) and the data were analyzed using FlowJo
software (Tree Star, Inc., Ashland, OR).
To determine the number of IFN-γ producing T cells, intracellular cytokine staining was
performed. In brief, corneal cells were either stimulated with Phorbol myristate acetate
(PMA) (50ng) and Ionomycin (500ng) for 4 hours in the presence of brefeldin A (10 μg/mL)
or stimulated with UV-inactivated HSV-1 RE (1 MOI) overnight followed by 5 hour
brefeldin A (10 μg/mL) in U-bottom 96-well plates. After this period, Live/Dead staining
was performed followed by cell surface and intracellular cytokine staining using Foxp3
intracellular staining kit (ebioscience) in accordance with the manufacturer's
recommendations.
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Reagents and antibodies.
CD4 (RM4-5), IFN-γ (XMG1.2), CD25 (PC61, 7D4), CD44 (IM7), Foxp3 (FJK-16S), antiCD3 (145-2C11), anti-CD28 (37.51), GolgiPlug (brefeldin A) from either ebiosciences or
BD biosciences. PMA and Ionomycin from sigma. Cell Trace Violet and Live/Dead Fixable
Violet Dead Cell Stain Kit from Life Technologies. Recombinant IL-2, IL-12, IL-6 and TGFb from R&D systems.
TSDR assay
A quantitative real-time PCR method was used as described by Floess et al., 2007 .
Briefly, two subsets of Treg (CD4+ Foxp3+ GFP+ CD25lo and CD4+ Foxp3+ GFP+
CD25hi) from HSV-1 ocularly infected Foxp3-GFP male mice (day 15 pi) or iTreg
generated with or without the supplementation of Vitamin C +RA from naïve CD4 + T cells
isolated from the spleens of Foxp3 GFP male mice as described above (2 × 105 each)
were sorted and processed using the EZ DNA Methylation-Direct kit (Zymo Research)
according to the manufacturer’s protocol. Purified bisulfite-treated DNA was used in a
quantitative PCR reaction. Primers and probes sequences used were the following:
forward primer, 5′-GGTTTATATTTGGGTTTTGTTGTTATAATTT-3′; and reverse primer,
5′-CCCCTTCTCTTCCTCCTTATTACC-3′. Probe sequences were: methylated (CG)
probe, 5′-TGACGTTATGGCGGTCG-3′; and unmethylated (TG) probe, 5′ATTGATGTTATGGTGGTTGGA-3′. PCR was performed with 10 µl Universal Master Mix
II (Applied Biosystems), 1 µl eluted DNA, primer/probe mix, and enough water to bring
the total volume to 20 µl. Final concentration of primers were 900 nM and concentration
of probes were 150 nM. Reactions were run for 10 min at 95°C for 10 min and 50 cycles
of 95°C for 15 s and 61°C for 1.5 min (7500 Real-Time PCR System; Applied Biosystems).
Percent demethylation was calculated using the formula percent demethylation = 100/[1
+ 2(CtTG−CtCG)], where CtTG represents the threshold cycle of the TG (unmethylated)
probe and CtCG represents the threshold cycle of the CG (methylated) probe .
T cell isolation, sorting and adoptive transfer experiments
Single-cell suspensions were obtained from DLNs and the spleens from footpad or ocular
HSV-1 infected mice at day 5 and day 15 pi respectively. Splenic erythrocytes were
eliminated with red blood cell lysis buffer (Sigma-Aldrich). To purify the peripheral CD4+
T cell subpopulation obtained from FM mice, pooled spleen and DLN cells were isolated
using a mouse CD4+ T cell isolation kit according to the manufacturer's instructions
(Miltenyi Biotec, Auburn, CA). Cells were then stained and subject to FACS sorting. The
purity of all the sorted cells was >95%. The sorted cells were subsequently used for
adoptive transfer experiments.
For adoptive transfer experiments in Balb/c mice, splenocytes isolated from
DO11.10 RAG2 -/- mice were used as a precursor population for the induction of Foxp3+
in CD4+ T cells as described elsewhere . Briefly, (1×106/ml) splenocytes after RBC lysis
and several washings were cultured in RPMI media containing rIL-2 (100 U/ml) and TGFβ
(5ng/ml) in the presence or absence of Vitamin C and RA with plate bound anti-CD3/28
Ab (1 µg/ml) for 5 days at 37°C in a 5% CO2 incubator. After 5 days, a few cells were
characterized for Foxp3 intracellular staining (ebioscience staining kit) analyzed by flow
cytometry. Based on the frequency of Live Foxp3+ cells generated in the different cultures
conditions 10 x 106 Vitamin C + RA stabilized iTreg or control unstable iTreg were
adoptively transferred i.v into HSV-1 infected Balb/c mice at day 3 pi.
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Administration of IVIGs
Intravenous immunoglobulins (IVIGs; Gammagard Liquid) was obtained from Baxter
(Deerfield, IL). Rag1-/- mice were intraperitoneally injected with IVIG (3.75 mg per mouse)
at day 2 after infection. The dose of IVIG was chosen to be 3.75 mg per mouse, based
on previous studies .
In vitro Treg and Treg stability assays
Splenocytes isolated from DO11.10 RAG2 -/- or Foxp3 GFP mice were used as a
precursor population for the induction of Foxp3+ in CD4+ T cells. Briefly, 1×106
splenocytes after RBC lysis and several washings were cultured in 1ml RPMI media
containing rIL-2 (100 U/ml) and TGFβ (5ng/ml) in the presence or absence of Vitamin C
and RA with plate bound anti-CD3/28 Ab (1 µg/ml) for 5 days at 37°C in a 5% CO2
incubator. After 5 days, samples were characterized for Foxp3 intracellular staining
(ebioscience staining kit) or GFP expression (Foxp3 GFP mice) analyzed by flow
cytometry. Treg were either sorted (TSDR methylation analysis) or cultured in 96-well
round bottom plate in the presence of IL-2 (100U/ml) or IL-12 (5ng/ml) or IL-6 (25ng/ml)
+TGF-b (1ng/ml) for 3 days followed by flow cytometry analysis of Live CD4+ Foxp3+
cells.
In vitro suppression assay
To measure the suppressor function of CD25lo and CD25hi Treg, FACS sorted CD25lo,
CD25hi GFP+ cells and naïve CD4+ cells (CD62L+ CD44-) from DLN and spleens (day
15 pi) of HSV-1 ocularly infected FM mice were cultured with anti-CD3 (1 μg/well) and
anti-CD28 (0.5 μg/well) antibodies in a U-bottom 96-well plate. The suppressive capacity
of the subsets of Treg was measured by co-culturing Treg and T conventional cells
(Tconv) at different ratios (Treg/Tconv, 1:1 to 1:8). After 3 days of incubation, the extent
of CTV dilution was measured in CD4+ cells by flow cytometry. Percent suppression by
different subsets of Treg was calculated by using the formula 100 − [(frequency of cells
proliferated at a particular Treg/effector T cell ratio)/(frequency of cells proliferated in the
absence of Treg)].
Statistical Analysis
Statistical significance was determined by Student t test unless otherwise specified. A P
value of <0.05 was regarded as a significant difference between groups: *P ≤ 0.05, **P ≤
0.01, ***P ≤ 0.001. GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA)
was used for statistical analysis.

32

References
1.Liesegang, T. J. 2001. Herpes simplex virus epidemiology and ocular importance.

Cornea 20: 1-13.
2.Niemialtowski, M. G., and B. T. Rouse. 1992. Predominance of Th1 cells in ocular
tissues during herpetic stromal keratitis. J Immunol 149: 3035-3039.
3.Hendricks, R. L., T. M. Tumpey, and A. Finnegan. 1992. IFN-gamma and IL-2 are
protective in the skin but pathologic in the corneas of HSV-1-infected mice. J Immunol
149: 3023-3028.
4.Suvas, S., A. K. Azkur, B. S. Kim, U. Kumaraguru, and B. T. Rouse. 2004. CD4+CD25+
regulatory T cells control the severity of viral immunoinflammatory lesions. J Immunol
172: 4123-4132.
5.Sehrawat, S., S. Suvas, P. P. Sarangi, A. Suryawanshi, and B. T. Rouse. 2008. In vitrogenerated antigen-specific CD4+ CD25+ Foxp3+ regulatory T cells control the severity
of herpes simplex virus-induced ocular immunoinflammatory lesions. J Virol 82: 68386851.
6.Veiga-Parga, T., A. Suryawanshi, S. Mulik, F. Gimenez, S. Sharma, T. Sparwasser, and
B. T. Rouse. 2012. On the role of regulatory T cells during viral-induced inflammatory
lesions. J Immunol 189: 5924-5933.
7.Zhou, X., S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Martinez-Llordella, M.
Ashby, M. Nakayama, W. Rosenthal, and J. A. Bluestone. 2009. Instability of the
transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.
Nat Immunol 10: 1000-1007.
8.Bailey-Bucktrout, S. L., and J. A. Bluestone. 2011. Regulatory T cells: stability revisited.
Trends in immunology 32: 301-306.
9.Miyao, T., S. Floess, R. Setoguchi, H. Luche, H. J. Fehling, H. Waldmann, J. Huehn,
and S. Hori. 2012. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression
in conventional T cells but not reprogramming of regulatory T cells. Immunity 36: 262275.
10.Sujino, T., M. London, D. P. Hoytema van Konijnenburg, T. Rendon, T. Buch, H. M.
Silva, J. J. Lafaille, B. S. Reis, and D. Mucida. 2016. Tissue adaptation of regulatory
and intraepithelial CD4(+) T cells controls gut inflammation. Science 352: 1581-1586.
11.Sakaguchi, S., D. A. Vignali, A. Y. Rudensky, R. E. Niec, and H. Waldmann. 2013.
The plasticity and stability of regulatory T cells. Nat Rev Immunol 13: 461-467.
12.Floess, S., J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H. D.
Chang, T. Bopp, E. Schmitt, S. Klein-Hessling, E. Serfling, A. Hamann, and J. Huehn.
2007. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS biology 5: e38.
13.Huehn, J., J. K. Polansky, and A. Hamann. 2009. Epigenetic control of FOXP3
expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol 9: 83-89.
14.Zheng, Y., S. Josefowicz, A. Chaudhry, X. P. Peng, K. Forbush, and A. Y. Rudensky.
2010. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory Tcell fate. Nature 463: 808-812.
15.van Loosdregt, J., Y. Vercoulen, T. Guichelaar, Y. Y. Gent, J. M. Beekman, O. van
Beekum, A. B. Brenkman, D. J. Hijnen, T. Mutis, E. Kalkhoven, B. J. Prakken, and P.
J. Coffer. 2010. Regulation of Treg functionality by acetylation-mediated Foxp3 protein
stabilization. Blood 115: 965-974.

33

16.Barbi, J., D. Pardoll, and F. Pan. 2014. Treg functional stability and its responsiveness
to the microenvironment. Immunol Rev 259: 115-139.
17.Hodge, D. R., E. Cho, T. D. Copeland, T. Guszczynski, E. Yang, A. K. Seth, and W.
L. Farrar. 2007. IL-6 enhances the nuclear translocation of DNA cytosine-5methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence
by the AKT kinase. Cancer genomics & proteomics 4: 387-398.
18.Samanta, A., B. Li, X. Song, K. Bembas, G. Zhang, M. Katsumata, S. J. Saouaf, Q.
Wang, W. W. Hancock, Y. Shen, and M. I. Greene. 2008. TGF-beta and IL-6 signals
modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl
Acad Sci U S A 105: 14023-14027.
19.Lal, G., and J. S. Bromberg. 2009. Epigenetic mechanisms of regulation of Foxp3
expression. Blood 114: 3727-3735.
20.Chen, Q., Y. C. Kim, A. Laurence, G. A. Punkosdy, and E. M. Shevach. 2011. IL-2
controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo.
J Immunol 186: 6329-6337.
21.Komatsu, N., M. E. Mariotti-Ferrandiz, Y. Wang, B. Malissen, H. Waldmann, and S.
Hori. 2009. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell
lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci
U S A 106: 1903-1908.
22.Huynh, A., M. DuPage, B. Priyadharshini, P. T. Sage, J. Quiros, C. M. Borges, N.
Townamchai, V. A. Gerriets, J. C. Rathmell, A. H. Sharpe, J. A. Bluestone, and L. A.
Turka. 2015. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage
stability. Nat Immunol 16: 188-196.
23.Komatsu, N., K. Okamoto, S. Sawa, T. Nakashima, M. Oh-hora, T. Kodama, S.
Tanaka, J. A. Bluestone, and H. Takayanagi. 2014. Pathogenic conversion of Foxp3+
T cells into TH17 cells in autoimmune arthritis. Nat Med 20: 62-68.
24.Bhela, S., S. Mulik, P. B. Reddy, R. L. Richardson, F. Gimenez, N. K. Rajasagi, T.
Veiga-Parga, A. P. Osmand, and B. T. Rouse. 2014. Critical role of microRNA-155 in
herpes simplex encephalitis. J Immunol 192: 2734-2743.
25.Yue, X., S. Trifari, T. Aijo, A. Tsagaratou, W. A. Pastor, J. A. Zepeda-Martinez, C. W.
Lio, X. Li, Y. Huang, P. Vijayanand, H. Lahdesmaki, and A. Rao. 2016. Control of Foxp3
stability through modulation of TET activity. J Exp Med 213: 377-397.
26.Sasidharan Nair, V., M. H. Song, and K. I. Oh. 2016. Vitamin C Facilitates
Demethylation of the Foxp3 Enhancer in a Tet-Dependent Manner. J Immunol 196:
2119-2131.
27.Chen, Z., J. Barbi, S. Bu, H. Y. Yang, Z. Li, Y. Gao, D. Jinasena, J. Fu, F. Lin, C. Chen,
J. Zhang, N. Yu, X. Li, Z. Shan, J. Nie, Z. Gao, H. Tian, Y. Li, Z. Yao, Y. Zheng, B. V.
Park, Z. Pan, J. Zhang, E. Dang, Z. Li, H. Wang, W. Luo, L. Li, G. L. Semenza, S. G.
Zheng, K. Loser, A. Tsun, M. I. Greene, D. M. Pardoll, F. Pan, and B. Li. 2013. The
ubiquitin ligase Stub1 negatively modulates regulatory T cell suppressive activity by
promoting degradation of the transcription factor Foxp3. Immunity 39: 272-285.
28.Lal, G., N. Zhang, W. van der Touw, Y. Ding, W. Ju, E. P. Bottinger, S. P. Reid, D. E.
Levy, and J. S. Bromberg. 2009. Epigenetic regulation of Foxp3 expression in
regulatory T cells by DNA methylation. J Immunol 182: 259-273.

34

29.Koch, M. A., K. R. Thomas, N. R. Perdue, K. S. Smigiel, S. Srivastava, and D. J.
Campbell. 2012. T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to
impaired expression of IL-12 receptor beta2. Immunity 37: 501-510.
30.Hall, A. O., D. P. Beiting, C. Tato, B. John, G. Oldenhove, C. G. Lombana, G. H.
Pritchard, J. S. Silver, N. Bouladoux, J. S. Stumhofer, T. H. Harris, J. Grainger, E. D.
Wojno, S. Wagage, D. S. Roos, P. Scott, L. A. Turka, S. Cherry, S. L. Reiner, D. Cua,
Y. Belkaid, M. M. Elloso, and C. A. Hunter. 2012. The cytokines interleukin 27 and
interferon-gamma promote distinct Treg cell populations required to limit infectioninduced pathology. Immunity 37: 511-523.
31.Hori, S. 2010. Developmental plasticity of Foxp3+ regulatory T cells. Curr Opin
Immunol 22: 575-582.
32.Miyara, M., Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T.
Heike, D. Valeyre, A. Mathian, T. Nakahata, T. Yamaguchi, T. Nomura, M. Ono, Z.
Amoura, G. Gorochov, and S. Sakaguchi. 2009. Functional delineation and
differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription
factor. Immunity 30: 899-911.
33.Rudra, D., T. Egawa, M. M. Chong, P. Treuting, D. R. Littman, and A. Y. Rudensky.
2009. Runx-CBFbeta complexes control expression of the transcription factor Foxp3 in
regulatory T cells. Nat Immunol 10: 1170-1177.
34.Li, B., A. Samanta, X. Song, K. T. Iacono, K. Bembas, R. Tao, S. Basu, J. L. Riley, W.
W. Hancock, Y. Shen, S. J. Saouaf, and M. I. Greene. 2007. FOXP3 interactions with
histone acetyltransferase and class II histone deacetylases are required for repression.
Proc Natl Acad Sci U S A 104: 4571-4576.
35.Tao, R., E. F. de Zoeten, E. Ozkaynak, C. Chen, L. Wang, P. M. Porrett, B. Li, L. A.
Turka, E. N. Olson, M. I. Greene, A. D. Wells, and W. W. Hancock. 2007. Deacetylase
inhibition promotes the generation and function of regulatory T cells. Nat Med 13: 12991307.
36.Varanasi, S. K., P. B. Reddy, S. Bhela, U. Jaggi, F. Gimenez, and B. T. Rouse. 2017.
Azacytidine treatment inhibits the progression of Herpes Stromal Keratitis by
enhancing regulatory T cell function. J Virol.
37.Lu, L., Q. Lan, Z. Li, X. Zhou, J. Gu, Q. Li, J. Wang, M. Chen, Y. Liu, Y. Shen, D. D.
Brand, B. Ryffel, D. A. Horwitz, F. P. Quismorio, Z. Liu, B. Li, N. J. Olsen, and S. G.
Zheng. 2014. Critical role of all-trans retinoic acid in stabilizing human natural
regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A 111: E34323440.
38.Cottrell, S., K. Jung, G. Kristiansen, E. Eltze, A. Semjonow, M. Ittmann, A. Hartmann,
T. Stamey, C. Haefliger, and G. Weiss. 2007. Discovery and validation of 3 novel DNA
methylation markers of prostate cancer prognosis. The Journal of urology 177: 17531758.
39.Veiga-Parga, T., A. Suryawanshi, and B. T. Rouse. 2011. Controlling viral immunoinflammatory lesions by modulating aryl hydrocarbon receptor signaling. PLoS Pathog
7: e1002427.
40.Bhela, S., S. Mulik, F. Gimenez, P. B. Reddy, R. L. Richardson, S. K. Varanasi, U.
Jaggi, J. Xu, P. Y. Lu, and B. T. Rouse. 2015. Role of miR-155 in the Pathogenesis of
Herpetic Stromal Keratitis. Am J Pathol.

35

APPENDIX

36

D

IFN-γ

Unstimulated

E

80

40
20

Day 15

10

D

21

0

40

60

Day 8

20

15

**

30

D

**

100

40

8

21

15

0

*

50

D

20

0

CD4

Number of ex-Tregs (GFP- Tomato+)
per cornea

40

Number of IFN-γ+
ex-Treg cells/ cornea

Day 21

Day 15

% IFN-Y+ exTreg cells

Day 8

*

D

C

*

60

D

GFP

80

8

B

Day 21

D

Day 15

Tomato

Day 8

% ex-Tregs from toal Td-Tomato+ cells

A

**

30
20
10
0

Day 21

**

Day 8

Day 15

Day 21

HSV stimulated
Teff

Treg

IFN-γ

% IFN-Y of CD4 T cells

ex-Treg

CD4

40
30

ns

**

***

20
10
0

ex-Tregs

Teff

Treg

Figure 2.1. Kinetic analysis of ex-Treg in the corneas of HSV-infected mice.
FM mice were infected ocularly with 1× 104 PFU of HSV, and at each time point (d8, 15
and day 21) three to four corneas were collected, pooled, and digested with Liberase and
analyzed for various cell types. A) Representative FACS plots, frequencies and average
numbers of corneal ex-Treg cells at each time point pi. B) Intracellular staining was
conducted to quantify Th1 and Th17 ex-Treg cells by stimulating them with
PMA/ionomycin. Representative FACS plots, frequencies and average numbers of exTreg cells producing IFN-g or IL-17A after stimulation with PMA/ionomycin. Plots shown
were gated on ex-Treg cells. C) For quantification of Ag-specific ex-Treg cells, corneal
single cell suspensions were stimulated for 16 h with UV-inactivated HSV-KOS, with the
addition of brefeldin A for the last 5 h of stimulation. Representative FACS plots shown
are gated on ex-Treg cells. The level of significance was determined by a Student t test
(unpaired). Error bars represent means ± SEM (n = 8 – 10 mice). Experiments were
repeated at least three times. P≤0.0001(****), P≤0.01(**), P≤0.05(*).
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Figure 2.2. CD25loFoxp3+CD4+ Treg are unstable Treg cells that convert into exTreg in an inflammatory environment.
(A-E) FM mice were infected ocularly with 1× 104 PFU of HSV. DLNs and spleens were
collected at day 14 pi and CD25lo and CD25hi Treg cells were sorted. A) An equal
number of each population (1 x 105 cells) was cultured with CTV-labeled sorted effector
T cells (Treg/Teff, 1:1) in the presence of anti-CD3 and anti-CD28 antibodies.
Representative histograms show the extent of CTV dilution at a 1:1 Treg/Teff ratio. Bar
graphs show the percent suppression of CD25lo Treg and CD25 Treg at 1:1 ratio to Teff.
B) Demethylation of TSDR region at Foxp3 locus of the sorted CD25lo and CD25hi Treg
was determined as described in materials and methods. C) Bar graph shows the MFI of
FoxP3 expression on CD25lo and CD25hi Treg. D) Sorted CD25lo and CD25hi Treg were
exposed to 100U/ml IL-2 or 5ng/ml IL-12 or 25ng/ml IL-6 and 1ng/ml TGF-beta for 3 days.
Cells were measured for ex-Treg cells before exposure and after exposure. Histograms
represent the frequency of Foxp3 lost by CD25lo and CD25hi Treg exposed to different
conditions. E) Sorted CD25lo and CD25hi Treg were adoptively transferred into HSV-1
footpad infected congenic Thy1.1 mice at 24hpi and transferred cells were analyzed for
ex-Treg. Representative FACS plots show the frequency of ex-Treg after adoptive
transfer. Plots are gated on CD4+Thy1.2+Tomato+ cells. F) Sorted effector T cells and
ex-Treg from immunized FM mice were adoptively transferred into HSV-1 footpad
infected congenic Thy1.1 mice at 24h pi and transferred cells were analyzed for Treg.
Representative FACS plots show the frequency of Treg after adoptive transfer. Plots are
gated on CD4+Thy1.2 + cells. Each experiment was repeated at least two times with at
least 3 mice per group. Statistical significance was calculated by one-way ANOVA with
Tukey multiple-comparison test. P≤0.01(**), P≤0.05(*).
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Figure 2.4. ex-Treg are pathogenic in-vivo.
FM mice were infected ocularly with 1× 104 PFU of HSV. DLNs and spleens were
collected at day 15 pi and ex-Treg and CD44hi FoxP3- T effectors cell were FACS sorted.
Rag1-/- were ocularly infected with HSV-1 and were divided into groups. One group of
mice received 5 x 105 ex-Treg cell at 24hpi. One group of mice received 5 x 105 CD44hi
FoxP3- T effectors cell 24h pi and one group received no cells. All mice were treated with
IVIG at day 2 pi. A) SK lesion severity at day 10 after infection is shown. B) Mice were
sacrificed on day 10 after infection, and corneas were harvested and pooled group wise
for the analysis of various cell types. Intracellular staining was conducted to quantify Th1
cells by stimulating them with PMA/ionomycin. Representative FACS plots, frequencies
and average numbers of CD4 T cells producing IFN-γ after stimulation with
PMA/ionomycin. Plots shown were gated on CD3+CD4+ T cells. Data compiled from two
separate experiments consisting of 3-4 animals in each group. The level of significance
was determined by a Student t test (unpaired). Error bars represent means ± SEM.
P≤0.01(**).
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cells/well) with 100U/ml IL-2, 1µg/ml anti-CD3/CD28, 5ng/ml TGFβ and in the presence
or absence of Vitamin C and RA for up to 5 days. Foxp3 GFP+ T cells were FACS sorted.
Demethylation of TSDR region at Foxp3 locus was determined as described in Materials
and methods. B) Splenocytes from DO11.10 RAG2-/- animals were cultured in the
presence of 1µg/ml anti-CD3/CD28, 100 U/ml IL-2, 5ng/ml TGF-β in the presence or
absence of Vitamin C and RA for 5 days. Then exposed to 100U/ml IL-2 or 5ng/ml IL-12
or 25ng/ml IL-6 and 1ng/ml TGF-beta for another 3 days. Cells were measured for Live
CD4+ Foxp3+ cells before exposure and after exposure. Bar graphs show the frequency
of Foxp3 lost by cells of control and Vitamin C and RA induced iTreg exposed to different
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of Vitamin C and RA for 5 days. Cells Control iTreg and Vitamin C + RA generated Treg
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CD4+Thy1.2+Tomato+ cells. Each experiment was repeated at least two times with at
least 3 mice per group. Statistical significance was calculated by one-way ANOVA with
Tukey multiple-comparison test P≤ 0.0001(****),P≤0.001 (***),P≤0.01(**), P≤0.05(*).
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Figure 2.7. Vitamin C+ RA generated Treg suppress SK lesions better than control
iTreg.
Balb/c mice ocularly infected with 1x105 PFU of HSV-1 were divided into groups. One
group of mice received stabilized Vitamin C + RA generated iTreg (10 x 106) at day 3 after
infection. One group of mice received control unstable iTreg (10 x 106) at day 3 after
infection, and one group of mice received no transfer of cells. Disease severity and
immune indicators in the cornea were evaluated at day 15 after infection. A) SK lesion
severity at day 15 after infection are shown. B) Mice were sacrificed on day 15 after
infection, and corneas were harvested and pooled group wise for the analysis of various
cell types. Intracellular staining was conducted to quantify Th1 cells by stimulating them
with PMA/ionomycin. The bar graph represents total numbers of corneal infiltrating CD4+
T cells, and Th1cells of mice that received no transfer, control iTreg or Vitamin C + RA
generated iTreg. Each experiment was repeated at least two times with at least 8 mice
per group. Statistical significance was calculated by one-way ANOVA with Tukey multiplecomparison test. Error bars represent means ± SEM. P≤0.05(*)
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Figure S2.1. Analysis of corneal CD4 T cells.
Graph shows frequencies of ex-Treg, Treg and T effectors in ocularly HSV-1 infected
FM mice at day 8 pi (left) and ex-Treg and Treg frequency after gating on Tomato+
cell (right).
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Figure S2.2. ex-Treg in lymphoid tissues and cornea after ocular HSV-1 infection.
(A) Graph shows ex-Treg frequencies in DLN, spleen and corneas of day 15 ocularly
HSV-1 infected FM mice. B) Intracellular staining was conducted to quantify Th1 ex-Treg
cells by stimulating them with PMA/ionomycin. Graph shows frequency of IFN-γ
producing ex-Treg in DLN, spleen and cornea of day 15 HSV-1 infected FM mice.
Statistical significance was calculated by one-way ANOVA with Tukey multiple comparison test. Error bars represent means ± SEM. P≤ 0.0001(****), P≤0.05(*).
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Figure S2.3. Purity of sorted CD25lo and CD25hi Treg cells.
Flow cytometric analysis of CD4 and CD25 expression by cells from spleen and lymph
nodes of day 15 ocularly HSV-1 infected FM mice before FACS purification (left) and after
purification (right).
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CHAPTER 3
AZACYTIDINE TREATMENT INHIBITS THE PROGRESSION OF HERPES
STROMAL KERATITIS BY ENHANCING REGULATORY T CELL FUNCTION
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Abstract
Ocular infection with Herpes Simplex Virus type 1 (HSV-1) sets off an inflammatory
reaction in the cornea which leads to both virus clearance as well as chronic lesions that
are orchestrated by CD4 T cells. Approaches that enhance the function of regulatory T
cells (Treg) and dampen effector T cells can be effective to limit Stromal Keratitis (SK)
lesion severity. In this report, we have explored the novel approach of inhibiting DNA
methyltransferase activity using 5-Azacytidine (cytosine analog) to limit HSV-1 induced
ocular lesions. We show that therapy begun after infection when virus was no longer
actively replicating resulted in the pronounced reduction in lesion severity with markedly
diminished numbers of T cells and non-lymphoid inflammatory cells along with reduced
cytokine mediators. The remaining inflammatory reactions had a change in ratio of CD4
Foxp3+Treg to effector Th1 CD4 T cells in ocular lesions and lymphoid tissues with Treg
becoming predominant over the effectors. In addition, compared to controls, Treg from
Aza treated mice showed more suppressor activity in vitro and expressed higher levels
of activation molecules. Additionally, cells induced in vitro in the presence of Aza showed
epigenetic differences in the Treg Specific Demethylated Region (TSDR) of Foxp3 and
were more stable when exposed to inflammatory cytokines. Our results show that therapy
with Aza is an effective means of controlling a virus-induced inflammatory reaction and
may act mainly by the effects on Treg.
Introduction
Once a viral infection becomes established its removal largely depends on the
activity of T lymphocytes. Multiple functional subsets of T cells can participate with the
outcome dependent on the nature of the virus, its location in the body and the types of T
cells that become activated and expanded by the infection (1,2). Chronic tissue damaging
inflammatory reactions can occur when elimination of infection is difficult to achieve, or
the balance of T cell responsiveness emphasizes pro-inflammatory cells that contribute
to tissue damage (3). For example, in stromal keratitis (SK) resulting from ocular infection
by herpes simplex virus (HSV), a chronic inflammatory reaction occurs in the corneal
stroma which is orchestrated mainly by pro-inflammatory CD4 Th1 and Th17 T cells (46). The lesion is less severe and can even resolve if regulatory T cells (Treg), such as
Foxp3+ CD4 T cells, dominant over the other pro-inflammatory CD4 T cell subsets (711). Accordingly, therapies aimed at increasing Treg numbers and/or improving their
regulatory activity is of high relevance.
It is becoming evident that the balance between inflammatory and regulatory T
cells is not fixed, but can change as a consequence of one or the other cell type changing
in number or altering their functional activity (12). For example, functional changes were
observed in vitro when Treg were exposed to some inflammatory mediators (13,14).
Similar functional changes may occur during auto-inflammatory lesions in vivo with Treg
losing their regulatory activity (15,16). Of more concern, these Treg may change and take
on a pro-inflammatory function and then contribute to the severity of tissue damage (1518). The changes in functional phenotype that occur is likely explained by epigenetic
changes that affect expression of the Treg transcription factor Foxp3 (19,20). These
epigenetic changes usually occur in the highly conserved intron-2 also known as Treg
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specific demethylation region (TSDR), which harbors cytosine-phospho-guanine (CpG)
sites subject to methylation (21,22). Thus, when TSDR is demethylated the transcription
factors Ets-1 and Creb can bind and act as enhancers for the continuous transcription of
the Foxp3 gene (23,24). However, when the TSDR is methylated, the enhancer activity
is diminished and only transient expression of Foxp3 occurs. Consequently, for the stable
expression of the Foxp3 gene, demethylation of TSDR is required (25,26). In fact, natural
Treg that derive from the thymus are stable and their TSDR is invariably demethylated
(22). In contrast, in vitro or in vivo induced Treg have a TSDR which is methylated and
such cells show plasticity of both phenotype and function (22,25,27,28).
Approaches to promote the stability of induced Treg are to block TSDR methylation
or to generate Treg that have a demethylated TSDR profile. The later can be achieved
by inhibiting DNA methyltransferase as occurs when 5-Azacytidine (Aza) is used for
therapy (22,25,61). This FDA approved drug is used to treat myelodysplastic syndrome
(29), and is also an effective therapy against some inflammatory disease models (30-32).
The treatment has also been proposed to act by increasing the potency of the Treg
response (31-33), and we further evaluate this notion using an infectious disease model
of inflammation.
In this report, we show that the therapeutic administration of Aza was highly
effective at suppressing the severity of ocular immuno-inflammatory lesions that result
from corneal infection with HSV. The beneficial outcome of the Aza therapy appeared to
be the consequence of restricted infiltration of pro-inflammatory immune cells to the
cornea. The cells that did enter had increased number of Treg in comparison to CD4+
gamma interferon-producing (IFN-γ+) effector T cells. This increased representation of
Treg in Aza treated animals was also evident in the blood and lymphoid tissues.
Significant differences in suppressive efficacy of Treg from control and treated groups
was also observed, with Treg from Aza treated animals being more suppressive, a
property explained at least in part by higher expression levels of Reactive Oxygen
Species (ROS) and activation markers. Furthermore, Treg generated in vitro in the
presence of Aza expressed a fully demethylated TSDR and these cells also displayed
enhanced suppressive activity which correlated with enhanced ROS production and
activation markers. Overall, our results emphasize that the epigenetic modifying drug Aza
may represent a novel approach to control HSV-1 induced ocular immuno-pathological
lesions, the most common infectious cause of blindness in humans in the USA.
Results
Azacytidine reduces SK lesion severity and diminishes pro-inflammatory cytokines
and chemokines after HSV-1 infection
To assess the efficacy of Aza on the extent of ocular lesions caused by HSV
infection, animals were given either Aza or PBS (control) daily starting day 5 post infection
(pi). This is the time point when there is at best minimal replicating virus detectable in the
infected corneas and early inflammatory reactions start to become evident (36). Animals
were examined at intervals to record the severity of SK lesions. The results were clear
cut with animals receiving Aza therapy showing significantly (P < 0.001) reduced SK
lesion severity compared to PBS treated control animals (Fig. 3.1A) Treatment effects
were first evident by day 10, and by day 15, 10% of Aza-treated animals showed a lesion

50

score of ≥ 3 compared to 60% in control PBS treated animals (Fig. 3.1B). This pattern of
reduced inflammatory reaction in Aza treated animals was also evident in histological
sections of corneas taken from animals terminated at day 15pi (10 days after treatment)
(Fig.3.1C).
At the termination of the experiments on day 15 pi, pools of 4 corneas were
collected and processed to identify their cellular composition by FACS analysis. There
was a reduction in inflammatory cell numbers including neutrophils (>500 fold),
macrophages (10 fold), and CD4 T cells (> 10 fold) in Aza treated animals compared to
controls (Fig 3.2A-C). In separate experiments of the same design, pools of corneas were
processed to quantify mRNA of selected cytokines (IL-1β, TNF-α, IL-6 and IL-12) and
chemokines (CCL3, CCL2, CXCL1and MMP1) by quantitative real time PCR (Q-RTPCR).
As shown in Fig 3.3, those treated with Aza showed a reduction in the level of several
pro-inflammatory cytokines and chemokines compared to controls. However, there was
also a reduction in the expression levels of anti-inflammatory IL-10 and TGF-b (Fig 3.3),
likely explained by reduced numbers of infiltrating immune cells. Taken together, our
results show that daily administration of Aza, 5 days after virus infection significantly
diminished HSV-1 induced immunopathology.
Aza treatment changes the balance of Treg to Th1 effectors
Since it is known that the outcome of SK lesion severity is dependent on the ratio
of Treg to Th1 (37), the ratio of the cell types was compared in corneas, blood and DLN
in Aza treated and control infected animals. Pools of corneas were collected at 15 days
p.i from Aza treated and control animals and the infiltrating cell population was recovered
after collagen digestion. These cells were then stimulated in vitro for 4 hours with PMA
and ionomycin and the CD4 T cells were enumerated that were either IFN-γ producers or
expressed the transcription factor Foxp3. (Fig. 3.2D). Changes in representation of the
two cell types occurred as a consequence of Aza therapy. Thus in the corneas of Aza
treated animals, the ratio favored Foxp3+ CD4 T cells to Th1 cells being around 2:1, but
in controls the ratio was around 1:7 (Fig.3.2E). Approximately, 7% of the total CD4 T cells
in the corneas of control animals expressed Foxp3, but in Aza treated animals around
35% were Foxp3+ cells (Fig. 3.2D). As with the corneas, blood from Aza treated mice
displayed an increased Treg frequency with 12% of the CD4 T cells being Foxp3+
compared to only 5% in PBS treated controls at day 15pi (Fig. 3.4A). The total number of
CD4 T cells (per 1 million cells) in the blood was decreased by 2-fold in the Aza treated
animals (Fig. 3.4B). Although less in magnitude similar reduction in Th1 frequency and
number (Fig. 3.4D,E) along with changes in Treg to Th1 ratio occurred in the DLN at day
15pi (Fig. 3.4F). The number of total CD4 T cells and Treg cells in the DLN of the Aza
treated animals were reduced by 1.8 and 1.4 fold respectively (Fig. 3.4C,G). Reduction
in Treg numbers may be as a consequence of reduced inflammatory response.
Additionally, single cell suspensions of DLNs isolated at day 15 pi from control and Aza
treated animals were stimulated overnight with UV-inactivated HSV-1 followed by ICS
assay to measure antigen specific Th1 responses. Results indicated that there was more
than 2-fold reduction in frequency and number of Th1 cells (CD4+ IFN-γ+ cells) in DLN
samples from Aza treated animals that were specific for HSV-1 (Fig. 3.4H). In conclusion,
upon Aza treatment there was a change in the balance in CD4 T cell responses with an
increased representation of Treg which could in part contribute to the reduced lesion
severity.
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Azacytidine increased Treg suppressive function and activation markers
Since Aza treatment of HSV ocularly infected mice resulted in diminished lesions
and increased representation of Foxp3+ CD4 T cells, the question arose as to whether or
not the Treg population showed any changes in regulatory function in response to Aza
therapy. To measure the suppressive activity, Foxp3 GFP mice were infected with HSV1 and Foxp3+ T cells were recovered by FACS sorting from the pools of DLN and spleens
of control and Aza treated animals at day 15 pi. Equal numbers of Foxp3+ T cells were
cultured at different ratios with naïve responders stimulated with anti-CD3/CD28. The
results indicate that Treg from HSV-1 infected Aza treated mice displayed more
suppressive activity against stimulated naïve responders (>20 fold at 1:8 ratio) compared
to Treg from infected controls (Fig.3.5A). Suppression with Treg from Aza treated animals
could be observed in cultures with 1 Treg to 16 responders, whereas with control Treg a
ratio of 1 to 4 was needed to demonstrate significant levels of suppression (Fig. 3.5B).
To provide an explanation for the greater suppressive activity of cells from Aza
treated infected animals, a number of measurements were made. To determine if
differences in IL-10 production was an explanation, DLNs from Aza treated and control
animals were isolated at day 15 pi and 1 million single cell suspensions were stimulated
with PMA/Ionomycin and supernatants were compared for levels of IL-10 using ELISA.
No significant differences were detectable between the cells from Aza treated and control
groups (data not shown). Comparisons were also made between Treg in control and Aza
treated animals for activation markers as well as ROS production, since the latter has
been advocated to be involved in suppressive activity (38). In the DLNs from Aza treated
animals isolated at day 15 pi, Treg displayed only a modest increase in expression
(ranging from 1.3 to 1.6 fold) of activation markers. These included CD25, OX40, GITR,
CD103, FR4 and CD44 on Foxp3+ CD4 T cells (Fig. 3.5C). Differences between the two
Treg populations were greatest in the case of expression of intracellular ROS. Thus the
Treg in DLN from Aza treated animals had around 3-fold increase in ROS activity as
compared to the cells from controls (Fig. 3.5D,E). Additionally, expression of genes
involved in ROS production i.e NOX-2 and NCF-1 genes (components of NADPH oxidase
complex) (39) were also increased 3 and 2.5 fold respectively in the Treg of Aza treated
compared to control animals, as measured by QRT-PCR (Fig. 3.5F). The expression of
IL-10 and TGF-beta was also measured in Treg from Aza treated and control animals
using QRT-PCR. The results indicate similar expression levels of IL-10 and TGF-beta in
both samples (Fig. 3.5G). Based on the above results, we could show that Aza treatment
protected the phenotype and function of Treg cells. In conclusion, Treg show enhanced
suppressive activity after Aza treatment and this may be explained at least in part by their
increased activation markers and ROS producing ability.
Effect of Azacytidine on the lesion severity was dependent on the presence of Treg
Since Aza treatment reduced lesion severity which correlated with changes in Treg
number and function, experiments were done to determine the outcome of Aza treatment
wherein Treg were depleted prior to infection. Depletion was achieved by administration
of mAb against the IL-2 receptor (CD25) given on day 0 of infection. The depletion
procedure, as measured at day 15 pi, was shown to be around 50% effective at reducing
total Foxp3+ T cells in DLN (Fig. 3.6A). SK lesion severity was measured at day 15 pi and
the results indicate that Aza treatment to Treg intact animals led to reduced lesion severity
with an average SK score of 1.7. This compared to an average score of 3.1 in the control

52

groups. However, in animals depleted of Treg and Aza treated, the inhibitory effects on
SK severity were no longer apparent with an average score of 3.8 (Fig. 3.6B). To measure
any effect of Aza therapy on the magnitude of CD4 Th1 response, the numbers of IFN-g
producing CD4 T cells in the DLNs at day 15pi were measured. Unlike in Treg intact
animals where Aza treatment resulted in reduced effector T cells numbers, Aza treatment
to Treg depleted animals displayed no significant difference in effector responses
compared to PBS treated controls. (Fig. 3.6C).
Next, to evaluate the effect of Aza on proliferation of Treg and effectors, DLN were
isolated at day 15pi from Treg depleted and control animals treated with or without Aza.
Single cell suspensions were stained for CD4, Foxp3 and Ki-67 (proliferation marker).
Results indicated that after Aza treatment, the proliferation of effector T cells was reduced
by 1.5 fold in the Treg intact animals compared to the untreated controls. Whereas, Aza
treatment in Treg depleted animals resulted in a 1.5-fold increase in the proliferation of
effector T cells compared to untreated controls (Fig. 3.6D), the proliferation of Treg were
unchanged after Aza treatment in both cases (Fig. 3.6E). Consistent with the role of Treg
in controlling effector cell proliferation, Aza treatment in the Treg depleted animals
increased the proliferation of effector cells, whereas in the presence of Treg Aza
treatment led to reduced proliferation. Accordingly, our results imply that Aza may act
preferentially on the Treg subset that likely express high level of CD25.
Azacytidine promotes differentiation and stability of Treg in vitro
To evaluate the direct effect of Aza on Treg and T effectors (Th1), in vitro
differentiation experiments were performed. For this purpose, naïve splenocytes from
DO11.10 RAG2-/- animals (ova peptide specific and 98% naïve CD4+ T cells) were
cultured in the presence of Treg differentiating conditions (IL-2 and TGF-β) as well as in
the presence or absence of graded amounts of Aza (from 1 µM to 15 µM). The results
show a dose dependent enhancement in Treg differentiation compared to control cells
without Aza with the maximal effect evident at 5µM (Fig. 3.7A). This dose yielded an
approximately 2-fold increase in the frequency of Foxp3+ CD4 T cells induced in cultures
(Fig. 3.7B). Similarly, when naïve DO11.10 RAG2-/- splenocytes were cultured in the
presence of 5µM Aza and Th1 differentiating conditions (IL-12 and anti-IL-4), Aza
increased the frequency of IFN-g by 2-fold (Fig 3.7C). To provide a possible explanation
for the Aza enhancement effects on Treg induction, experiments were done to record
epigenetic changes in the TSDR region of Treg induced in the presence or absence of
Aza. Although, Aza might affect the global methylation status of several other genes with
CpG sites such as Gitr, Ctla4, Ikzf4 and CD25 (27), the methylation status of only the
TSDR region of Foxp3 gene was evaluated, as this region is known to be an indicator of
Treg stability and function (25-27, 55,56). Naïve CD4 T cells isolated from Foxp3 GFP
mice were differentiated into Treg in the presence or absence of Aza (5µM) and equal
numbers of Foxp3 GFP+ cells were harvested 5 d post culture by FACS sorting. The DNA
was bisulfite converted after which the TSDR region was PCR amplified, cloned and
sequence analyzed for methylated CpG sites. Dramatic differences were evident between
cells induced in the presence or absence of Aza. In the presence of Aza, the TSDR region
was demethylated about 80%. In contrast, without Aza the TSDR was only minimally
demethylated (about 5%) (Fig. 3.7D). These methylation differences could have
consequences in terms of Treg stability.
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Since the Treg induced in the presence of Aza displayed a demethylated TSDR
region, the effects of exposing the Treg population induced in the presence or absence
of Aza to inflammatory cytokines which are known to destabilize Treg were measured
(25,40). The two Treg populations were harvested and Foxp3 expression was determined
following exposure for 3 days to IL-2 or IL-12 (Th1 condition) or IL-6 and TGF-b (Th17
conditions). In agreement with previous reports (41), IL-2 alone under non-stimulating
conditions did not cause a change of Foxp3 expression. However, exposure to IL-12 for
3 d resulted in loss of Foxp3 expression in around 40% of cells. In contrast, the Treg
induced in the presence of Aza lost only 20% of their Foxp3 expression after exposure to
IL-12. Similar differences, but less in magnitude, were observed when the two populations
were exposed to Th17 conditions (IL-6 and TGF-b). In those experiments, control induced
Treg lost around 25% of their Foxp3 expression whereas Aza induced Treg lost around
12% (Fig. 3.7E). In conclusion, Treg induced in vitro in the presence of Aza had TSDR
that was demethylated and such cells were more stable in the presence of inflammatory
cytokines (IL-12 or IL-6) than were Treg induced without Aza.
Aza promotes Treg suppressive function and activation markers
To evaluate if enhanced Treg stability may lead to enhanced Treg function,
experiments were done to measure functional differences in Treg induced in vitro in the
presence or absence of Aza. For these experiments, naïve CD4 T cells isolated from
Foxp3 GFP mice were used. The Foxp3 GFP+ cells were harvested 5 d post culture,
FACS sorted and in vitro suppression assays were performed. Equal numbers of Foxp3+
T cells were cultured at different ratios with naïve responders stimulated with antiCD3/CD28. The results indicate that Treg differentiated in the presence of Aza showed
more than 2 fold higher suppressive activity compared to that of control Tregs (Fig. 3.8
A,B). In separate experiments, Treg were differentiated in the presence or absence of
Aza (5µM) to yield a similar frequency of Foxp3+CD4 T cells between the two groups
(high concentration of TGF-b) (Fig. 3.8C). The expression of ROS and the activation
markers was compared. The Treg generated in the presence of Aza displayed around
1.3-1.8 fold increase in the expression of CD25, GITR, FR4, OX40 and ROS compared
to that of control Treg (Fig. 3.8D,E). In conclusion, exposure of Aza during Treg induction
resulted in enhanced Treg suppressive function which could be partly explained by
enhanced activation markers and ROS production in vitro.
Discussion
Ocular infection with HSV sets off an inflammatory cytokine reaction in the cornea
which leads to both virus clearance as well as chronic lesions that are orchestrated by
CD4 T cells (4,36). Approaches that enhance the function of Treg cells and dampen
effector T cells can be effective to limit SK lesion severity (7-10). In this report, we have
explored the novel approach of inhibiting DNA methyltransferase activity using 5Azacytidine (cytosine analog) to limit HSV induced ocular lesions. We show that therapy
begun after infection when virus was no longer actively replicating resulted in the
pronounced reduction in lesion severity with markedly diminished numbers of
inflammatory T cells and non-lymphoid inflammatory cells along with reduced cytokine
mediators. The remaining inflammatory reactions had a change in ratio of CD4
Foxp3+Treg to effector Th1 CD4 T cells in ocular lesions with Treg becoming predominant
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over the effectors. We also show that a consequence of Aza therapy was an increased
suppressive activity of Treg, an effect which correlated with their increased expression of
ROS. Hence treatment with Azacytidine during early stages of lesion development
represents an effective and novel therapy for a lesion that is a common cause of human
blindness (42).
Our results clearly showed markedly reduced lesions in response to HSV-1
infection in Aza treated animals. In the model we used, SK lesions are
immunopathological and are orchestrated mainly by IFN-g producing CD4 T cells.
However, the tissue damage is mediated largely by neutrophils and to lesser extent
macrophages which are recruited to the corneal site of inflammation by signals generated
by the T cells (43,44). In consequence, the inhibitory effects of Aza might be directed
against multiple cell types in the SK response. In fact, some reports have indicated that
Aza therapy can inhibit the generation of neutrophils (45) and pro-inflammatory (M1)
macrophages (46), but we argue that the anti-inflammatory effects of Aza in the SK
system may be explained mainly by its effects on T cells, particularly Treg. Thus whereas
all cell types were reduced in number in Aza treated animals, there was a differential
effect on Th1 effectors and Treg. In fact, in treated animals the ratio of Treg to Th1 cells
was increased substantially in corneal lesions (a change from 1:7 to 2:1) and similar but
less dramatic changes of ratios occurred in the blood and DLN. Our results indicate that
the ratio change may be more the consequence of direct effects on Treg rather than on
T effectors. In fact, our working hypothesis is that Aza serves to stabilize, expand or
change the regulatory potency of Treg and this acts to inhibit the function or perhaps
transport of effectors to the corneal site of inflammation. Support of these ideas came
from the observation that antigen specific effectors were reduced in number in the DLN
of Aza treated animals, an effect likely the consequence of enhanced Treg function. Thus
we observed that Treg induced in the presence of Aza had significantly enhanced
suppressive activity in vitro compared to cells from control animals.
With regard to why the Treg from Aza treated animals were more suppressive
compared to Treg from control animals, we could show that the activation markers such
as CD25, GITR, OX40 and FR4 levels along with ROS were significantly increased as a
consequence of Aza therapy. A possible involvement of ROS activity in Treg function was
noted in models of autoimmune arthritis and colitis, where inhibition of ROS producing
enzyme system, such as NCF-1 or NOX2, led to loss of Treg suppressor function,
enhanced effector responses and aggravated inflammatory lesions (51-53). Conceivably,
increased ROS expression by Treg makes them more inhibitory against T effectors by
inducing T cell death (57,58). However, since Aza induces DNA demethylation across
several genes leading to their increased transcriptional activity, whether or not changes
in ROS expression is the most critical event that explains why Treg after Aza treatment
were more effective to control the inflammatory reactions in the SK system needs further
study. One line of studies we are pursuing is that the promoter, or the intron regions, of
the Treg associated genes such as CD25, GITR, NCF-1 and NOX-2 might be
hypomethylated upon Aza treatment which leads to their increased gene expression.
An alternative potential explanation for increased Treg representation over Th1
effectors in Aza treated animals could be that Aza might render Treg resistant to the
destabilization effects of pro-inflammatory cytokines that are highly expressed at the
lesion and DLN sites (36,59). Although this destabilization phenomenon was not
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evaluated in vivo, we could show that Treg induced in vitro in the presence of Aza, but
not control Treg, displayed enhanced stability when exposed to the pro-inflammatory
cytokines IL-12 and IL-6. The increased stability was explained likely by epigenetic
differences caused by Aza therapy which inhibited DNA methyltransferase that were
induced as downstream signaling events of pro-inflammatory cytokines. Such events
result in methylation of the TSDR and only transient Foxp3 expression (25,60). Evidence
for epigenetic differences in the TSDR region between Treg generated in the presence
or absence of Aza were shown by in vitro studies. Thus Treg generated in the presence
of Aza had a demethylated TSDR region and showed stability when exposed to proinflammatory cytokines, unlike the non Aza exposed Treg which had a methylated TSDR
and lost Foxp3 expression in the presence of pro-inflammatory cytokines.
The final line of evidence implicating Treg as a critical cell type affected by Aza
therapy came from the observation that the anti-inflammatory effects of Aza were blunted
if Treg were depleted from animals prior to infection and subsequent Aza therapy. This
observation also makes it unlikely that Aza acts to cause suppressed lesions via direct
inhibitory effects on effector T cells or on non-lymphoid inflammatory cells such as
neutrophils. Supporting this notion, no inhibitory effects of Aza on effectors were observed
in vitro and in fact when Aza was present during in vitro induction, both Treg and Th1
cells were increased in frequency. This observation that Aza therapy did not limit the
lesion severity and effector responses when Treg were depleted came as a surprise,
since the anti-CD25 mAb depletion procedure was only around 50% effective at depleting
Treg. However, the depletion procedure is known to preferentially deplete Treg with high
expression of the IL-2 receptor (CD25) (54,62) and this population is likely the one from
which antigen specific induced Treg are generated and which regulate the effectors
involved in SK. In fact, in prior studies, we had shown that anti-CD25 depletion results in
enhanced effector function along with more severe lesions of SK (47). Moreover, some
studies have shown CD25 hi Treg are in fact the precursors of antigen-specific Treg (4850), but we lacked the necessary reagents to formally demonstrate the antigen specific
Treg in our system. Nevertheless, Treg without HSV antigen specificity can also express
modulatory effects in the SK system (7), although their CD25 expression level has not
been evaluated. Overall, we take our observations to indicate that Aza therapy acts to
stabilize and increase the regulatory function of Treg, an effect which likely acts in
lymphoid tissue as well as at the corneal inflammatory site to limit the magnitude of
effector T cell responses.
In conclusion, our results are consistent with the observation that inhibiting DNA
methyltransferase activity through the use of Azacytidine plays a role in influencing the
expression of SK lesions. The mechanisms involved to explain the outcome were
multiple, and involve a change in the balance between effector and regulatory T cells. We
anticipate that inhibiting DNA methyltransferase, could represent a useful approach to
control an important cause of human blindness.
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Materials and Methods
Mice and Virus
Female C57BL/6 mice and congenic Thy1.1+ mice were purchased from Harlan
Sprague-Dawley, Inc. (Indianapolis, IN), Foxp3-GFP (C57BL/6 background) mice were a
kind gift from M.Oukka (Brigham and Womens hospital, Harvard Medical School), BALB/c
DO11.10 RAG2-/- mice were purchased from Taconic and kept in pathogen free facility
where food, water, bedding and instruments were autoclaved. All the animals were
housed in American Association of Laboratory Animal Care–approved facilities at the
University of Tennessee, Knoxville, Tennessee. All investigations followed guidelines of
the Institutional Animal Care and Use Committee, and adhered to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research. HSV-l RE strain was used in
all procedures. Virus was grown in Vero cell monolayers (American Type Culture
Collection, Manassas, VA), titrated, and stored in aliquots at −80°C until used.
HSV-1 ocular infection and clinical scoring
Corneal infections of C57BL/6 and Foxp3 GFP mice were conducted under deep
anesthesia induced by intra peritoneal (i.p) injection of tribromoethanol (Avertin). Mice
were scarified on cornea with a 27-gauge needle, and a 3 µl drop containing 1x105 PFU
of HSV in 3 μl volume was applied to the eye. The eyes were examined on different days
post infection (dpi) with a slit-lamp biomicroscope (Kowa Company, Nagoya, Japan), and
the clinical severity of keratitis of individually scored mice was recorded as previously
described (34). Briefly, the scoring system was as follows: 0, normal cornea; +1, mild
corneal haze; +2, moderate corneal opacity or scarring; +3, severe corneal opacity but
iris visible; +4, opaque cornea and corneal ulcer; +5, corneal rupture and necrotizing
keratitis.
Aza Administration
The 5-Azacytidine (MP BIOMEDICALS) was dissolved in PBS and administered
intraperitoneally at 2mg/kg starting from day 5 post infection until day 14 after infection.
The control group either received an equal volume of PBS or left untreated. The dose of
Aza was chosen based on our preliminary studies (data not shown) and previous reports
(35). Most of the experiments were repeated at least three times.
Histopathology
Eyes from control and TCDD treated mice were extirpated on day 15 pi and snap
frozen in OCT compound (Miles, Elkart, IN). Six micron thick sections were cut, air dried
in a desiccation box. Staining was performed with hematoxylin and eosin (Richard Allen
Scientific, Kalamazoo, MI).
Flow Cytometric Analysis
At day 15 pi, corneas were excised, pooled group-wise, and digested with liberase
(Roche Diagnostics Corporation, Indianapolis, IN) for 45 minutes at 37°C in a humidified
atmosphere of 5% CO2. After incubation, the corneas were disrupted by grinding with a
syringe plunger on a cell strainer and a single-cell suspension was made in complete
RPMI 1640 medium. The single-cell suspensions obtained from corneal samples were
stained for different cell surface molecules for fluorescence-activated cell sorting (FACS)
analyses. Draining cervical lymph nodes were obtained from mice sacrificed at 15 days
post infection and single cell suspensions were used. Blood samples were collected at
intervals from Aza treated or control C57BL/6 Foxp3-GFP mice (HSV infected) to record
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the percentage of CD4+ T cells that were Foxp3 positive. All steps were performed at
4°C. Briefly; cells were stained with respective surface fluorochrome-labeled Abs in FACS
buffer for 30 minutes, then stained for intracellular Abs. Finally, the cells were washed
three times with FACS buffer and resuspended in 1% paraformaldehyde. The stained
samples were acquired with a FACS LSR II (BD Biosciences, San Jose, CA) and the data
were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR).
To determine the number of IFN-γ producing T cells, intracellular cytokine staining
was performed. In brief, corneal cells were either stimulated with PMA (50ng) and
Ionomycin (500ng) for 4 hours in the presence of brefeldin A (10 μg/mL) or stimulated
with UV-inactivated HSV-1 RE (1 MOI) overnight followed by 5 hour brefeldin A (10
μg/mL) in U-bottom 96-well plates (6). After this period, Live/Dead staining was performed
followed by cell surface and intracellular cytokine staining using Foxp3 intracellular
staining kit (ebioscience) in accordance with the manufacturer's recommendations.
Reagents and antibodies.
CD4 (RM4-5), CD45 (53-6.7), CD11b (M1/70), Ly6G (1A8), F4/80 (BM8), IFN-γ
(XMG1.2), CD103 (M290), CD25 (PC61, 7D4), GITR (DTA-1), FR4 (eBio12A5), CD44
(IM7), OX40 (OX-86), annexin-V, Foxp3 (FJK-16S), anti-CD3 (145-2C11), anti-CD28
(37.51), GolgiPlug (brefeldin A) from either ebiosciences or BD biosciences. Phorbol
myristate acetate (PMA) and Ionomycin from sigma. Cell Trace Violet, Live/Dead Fixable
Violet Dead Cell Stain Kit and CMH2DCFDA from Life Technologies. Recombinant IL-2,
IL-12, IL-6 and TGF-b from R&D systems.
Quantitative PCR (qPCR)
At day 15 post ocular infection with HSV-1, the corneas were isolated and four
corneas were pooled per sample/group. Regulatory T cells and effector cells were FACS
sorted using Foxp3 GFP mice. Total mRNA from corneal and sorted T cell populations
was isolated using mirVana miRNA isolation kit (Ambion). cDNA was made with 500ng
of RNA (corneal samples) and entire RNA (isolated T cells) by using oligo(dT) primer and
ImProm-II Reverse Transcription system (Promega). Taqman gene expression assays
for cytokines (IL-10, TGF- β, IL-1β, TNF-α, IL-6, IL-12), chemokines (CCL3, CXCL1,
CCL2, and MMP1) and NADPH oxidase components (NCF-1, NOX2) were purchased
from Applied biosystems and quantified using 7500 Fast Real-Time PCR system (Applied
Biosystems). The expression levels of different molecules were normalized to β-actin
using ΔCt calculation. Relative expression between control and experimental groups was
calculated using the 2-ΔΔCt X 1000 formula.
Depletion of regulatory T cells in vivo
C57BL/6 mice were given i.p injection of 500 µg of Anti-CD25 monoclonal antibody
(clone: PC61 rIgG1,BioXcell, West Lebanon, NH, USA) or control rat IgG1 (BioXcell) on
same day of infection (day 0). Depletion efficiency was quantified by measuring
percentage of Foxp3+ CD4 T cells after 15 days post infection.
Purification of CD4+ T cells.
CD4+ T cells (total or naïve) were purified from single cell suspension of pooled
draining cervical lymph nodes (DLNs) and spleen from HSV-infected or naïve Foxp3 GFP
and Thy1.1+ B6 (H-2b) mice using a mouse total or naïve CD4+ T cell isolation kit
according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA). The purity was
achieved at least to an extent of 90%. For methylation studies and suppression assays,
Treg cultures were sorted based on foxp3 GFP using FACS sorter to achieve high purity.
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In vitro suppression assay.
Treg suppression assay was done as previously described (9). Briefly, Foxp3-GFP
mice infected with HSV-1 were divided into multiple groups. Mice in one group were
injected with Aza on day 5 p.i., and control groups were injected with PBS. At day 15 p.i.,
single-cell suspensions from draining cervical lymph nodes (DLN) and spleen were
prepared and CD4+ Foxp3+ T cells were sorted on a FACSAria cell sorter to 99% purity.
To measure the suppressor function of Treg differentiated in vitro, naïve CD4 T cells from
Foxp3 GFP mice were differentiated to Tregs in the presence or absence of Aza and
Foxp3 GFP+ cells FACS sorted. CD4+ Foxp3+ T cells were then cultured with anti-CD3
(1 μg/well) and anti-CD28 (0.5 μg/well) antibodies and cell Trace violet (CTV) labeled
naïve CD4+ Thy1.1 responder cells (purified by a Miltenyi biotech kit) in a 96-well round
bottom plate. The suppressive capacity of Tregs was measured by coculturing Tregs and
T conventional cells (Tconv) at different ratios (Treg/Tconv, 1:1 to 1:16). After 3 days of
incubation, the extent of CTV dilution was measured in Thy1.1 CD4+ cells by flow
cytometry. Percent suppression by Tregs was calculated by using the formula 100 −
[(frequency of cells proliferated at a particular Treg/effector T cell ratio)/(frequency of cells
proliferated in the absence of Tregs)]100 .
In vitro Treg and Th1 differentiation and Treg stability assays
Splenocytes isolated from DO11.10 RAG2 -/- or Foxp3 GFP mice were used as a
precursor population for the induction of Foxp3+ in CD4+ T cells as previously described
(8). Briefly, 1×106 splenocytes after RBC lysis and several washings were cultured in 1ml
RPMI media containing rIL-2 (100 U/ml) and TGFβ (1-5ng/ml) in the presence or absence
of various concentrations of Aza (1-15µM) with plate bound anti-CD3/CD28 Ab (1 µg/ml)
for 5 days at 37°C in a 5% CO2 incubator. After 5 days, samples were characterized for
Foxp3 intracellular staining (ebioscience staining kit) or GFP expression (Foxp3 GFP
mice) analyzed by flow cytometry. Treg were either sorted (TSDR methylation analysis)
or cultured in 96-well round bottom plate in the presence of IL-2 (100U/ml) or IL-12
(5ng/ml) or IL-6 (25ng/ml) +TGF-b (1ng/ml) for 3 days followed by flow cytometry analysis
of Live CD4+ Foxp3+ cells.
For Th1 differentiation, splenocytes from DO11.10 RAG2 -/- mice were stimulated
with plate bound anti-CD3/CD28 Ab (1 µg/ml) in the presence of recombinant mouse IL12 (5-10ng/ml) and anti-IL-4 (10 µg/ml) and in the presence or absence of varying
concentrations of Aza (1-15µM). After 5-days samples were re-stimulated with
PMA/Ionomycin and analyzed for the production of IFN-γ by intracellular cytokine staining
kit (BD biosciences) using flow cytometer.
TSDR methylation assay
Foxp3 GFP+ Cells were FACS sorted and genomic DNA was isolated (Qiagen)
and was bisulfite-converted with an EZ DNA Methylation-Direct kit according to the
manufacturer's protocol (Zymo Research). TSDR region (corresponding to Foxp3
conserved noncoding sequence 2) was PCR amplified using primer sequences 5′GGGTTTTTTTGGTATTTAAG-3′ (forward) and 5′-CCTAAACTTAACCAAATTTT-3′
(reverse). PCR products were sub-cloned into pGEM-T Easy vectors (Promega) and
transformed into bacterial clones. Plasmid DNA samples from each bacterial colony were
sequenced separately at the UTK core facility (at least 10 sequences per sample).
Detection of intracellular redox state
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Single suspension of cells from draining lymph nodes (DLNs) from both Aza
treated and control HSV-infected C57BL/6 or in vitro differentiated Tregs were incubated
with 1µM of CM-H2DCFDA (6- chloromethyl-2′,7′-dichlorodihyrofluorescin diacetate,
acetyl ester) for 30 min at 37oC, followed by washing with PBS and surface staining for
live CD4+ CD25+ cells. Oxidation of dye was detected by FITC fluorescence.
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Figure 3.1. Therapeutic administration of Aza diminishes SK severity.
C57BL/6 animals infected with 1 x 104 PFU of HSV-RE were given either Aza or PBS
from day 5 pi to day 14 pi. The disease progression was analyzed throughout time in a
blinded manner using a scale described in materials and methods. (A) Kinetics of SK
severity is shown. The progression of SK lesion severity was significantly reduced in the
group of mice treated with Aza as compared with control mice. (B) Individual eye scores
of SK lesion severity on day 15 pi. (C) Eyes were processed for cryo-sections on day 15
pi. Hematoxylin and eosin staining was carried out on 6-μm sections and pictures were
taken at different microscope augmentations at ×20 magnification. Data represents the
mean ± SEM of more than 3 independent experiments (n=10 mice/group). All the data
were analyzed with student’s t test and Mann-Whitney U test. P≤0.001(***)
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Figure 3.2. Aza administration diminishes infiltration of both lymphoid and nonlymphoid cells.
C57BL/6 animals infected with 1 x 104 PFU of HSV-RE were given either Aza or PBS
from day 5 pi to day 14 pi. (A) Representative FACS plots showing frequency of
neutrophils (CD45+CD11b+Ly6G+) infiltrating the cornea at day 15 p.i (B) Representative
histogram showing the number of neutrophils and macrophages (CD45+CD11b+F4/80+)
infiltrating the cornea at day 15 p.i (C) Representative FACS plots and histogram
depicting the frequencies and number of total CD4+ T cells infiltrating the cornea at day
15 p.i (D) Pool of corneas were stimulated with PMA/Ionomycin, representative FACS
plots showing Treg (CD4+ Foxp3+) and Th1 (CD4+ IFN-g) cells in the cornea at day 15pi
cells were gated on CD4+ T cells (E) Histogram representing ratio of Treg to Th1 in the
cornea at day 15pi. Data are the combination of atleast 3 independent experiments and
show mean values ± SEM (n = 3). The level of significance was determined by Student’s
t test (unpaired). P≤ 0.0001 (****), P≤0.001(***), P≤0.01(**), P≤0.05(*).
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Figure 3.3. Effect of Aza treatment on cytokines and chemokines in the corneas of
HSV-1 infected animals
C57BL/6 mice infected with 1×104 PFU of HSV-1 RE were given AZA once daily starting
from day 5 until day 14 post infection. Mice were sacrificed at day 15 post infection and
corneas were collected for measuring relative fold change in the mRNA expression using
QRT-PCR of various cytokines and chemokines (TNF-a, IL-1b, IL-6, IL-12, IL-10, TGF-b
MIP-1(CCL3), KC(CXCL1), MCP1(CCL2), MMP1) in pooled corneal samples each
consisting of four cornea in control and Aza treated animals. Data represents means ±
SEM from two different independent experiments (n = 3/group) The level of significance
was determined by Student’s t test (unpaired). P≤0.001(***), P≤0.01(**), P≤0.05(*).
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Figure 3.4. Aza administration changes the balance towards Tregs in the blood and
draining lymph nodes
C57BL/6 or Foxp3 GFP mice infected with 1×104 PFU of HSV-1 RE were treated with
Aza once daily starting from day 5 until day 14 post infection and terminated at day 15
p.i. (A) FACS and histograms showing frequency of Tregs (Foxp3 GFP+) cells in blood
gated on CD4+ T cells. (B) Histogram representing the total number of CD4 T cells per 1
million of cells recorded in the blood. (C) DLN from day 15pi were stimulated with
PMA/Ionomycin and histogram showing the total number of CD4 T cells (D)
Representative FACS plots showing frequency of Treg (CD4+ Foxp3+) and Th1 (CD4+
IFN-g) (E) Histogram representing number of Th1 cells in DLN (F) Histogram representing
the ratio of number of Treg to Th1 in DLN (G) Histogram representing number of Treg
cells in DLN (H) DLN were stimulated with UV-inactivated HSV-1, representative FACS
plots and histogram showing frequency and number of antigen specific Th1 (CD4+ IFNg+) gated on live population. Data represents means ± SEM from three different
independent experiments (n = 3/group) and the level of significance was determined by
Student’s t test (unpaired). P≤ 0.0001 (****), P≤0.01(**), P≤0.05(*).
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Figure 3.5. Aza treatment increases suppressor activity of Tregs
(A-B) Foxp3-GFP mice infected with HSV-1 were treated with Aza on day 5 p.i. until day
14 p.i. CD4+ Foxp3+ T cells were sorted at day 15pi and equal number (1 x 105cells)
were cultured with CTV-labeled CD4+ CD25− Thy1.1 responder cells (Treg/Tconv, 1:1 to
1:16) in the presence of anti-CD3/CD28 antibodies. (A) Line graphs showing the percent
suppression of Tregs from control and Aza treated groups at different ratio of naïve
responders. (B) Representative FACS plots showing the extent of CTV dilution at a 1:8
Treg/effector T cell (Teff) ratio. Each experiment was repeated at least two times with at
least 3 replicates per group. Statistical significance was calculated by one-way ANOVA
with Tukey's multiple-comparison test P≤0.0001(****), P≤0.01(**), P≤0.05(*). (C) C57BL/6
mice infected with 1×104 PFU of HSV-1 RE were treated with Aza once daily starting from
day 5 until day 14 post infection and terminated at day 15 p.i. Histogram showing the
proportion Tregs in DLN expressing CD25, GITR, FR4, OX40, CD103 and CD44 at day
15pi gated on CD4+ Foxp3+ cells Data represent means ± SEMs of at least two
independent experiments and the level of significance was determined by Student’s t test
(unpaired) P≤0.05(*). (D-E) DLNs from C57BL/6 HSV-1 infected control and Aza treated
animals were isolated at day 15pi and stained with ROS indicator dye CM-H2DCFDA. (D)
Representative FACS plot showing the expression of CM-H2DCFDA (E) Histogram
showing MFI of CM-H2DCFDA from control and Aza treated mice gated live CD4+ CD25+
T cells. (F) Foxp3 GFP+ T cells were FACS sorted from HSV-1 infected control and Aza
treated Foxp3 GFP mice and mRNA expression levels were measured by QRT-PCR. Bar
graphs representing relative expression levels of Nox-2 and NCF-1 genes. (G) Bar graphs
representing relative expression levels of TGF-b and IL-10 genes. Relative expression
was calculated compared to expression of beta-actin. Data represents means ± SEM from
two independent experiments (n = 3/group). The level of significance was determined by
Student’s t test (unpaired) P≤0.01(**), P≤0.05(*).
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Figure 3.6. Depletion of CD25+ cells during Aza treatment did not ameliorate lesion
severity
C57BL/6 mice infected with 1×104 PFU of HSV-1 RE were given either anti-CD25
depleting antibody (PC61) or control (IgG) antibody on day 0 and given either AZA or
PBS daily starting from day 5 until day 14 post infection and were terminated at day 15
p.i (A) Histogram showing 50% reduction in Foxp3+ CD4+ T cells in DLN of Treg depleted
animals compared to control animals at day 15p.i (B) Individual eye scores of SK lesion
severity on day 15 pi. (C) DLNs were isolated and single cell suspensions stimulated with
PMA/Ionomycin and representative histogram showing number of Th1 (CD4+ IFN-g+) in
DLN. (D,E) DLNs were isolated and single cell suspensions were surface stained for CD4
and intracellular stained for Foxp3 and Ki-67. (D) Histogram showing proliferation of
effector T cells (CD4+ Foxp3- ) (E) Histogram showing proliferation of Treg (CD4+
Foxp3+). Experiments were repeated at least two times and the level of significance was
determined by Student’s t test (unpaired) and Mann-Whitney U test. Error bars represent
mean ± S.E.M. P≤ 0.0001 (****), P≤0.001(***), P≤0.01(**), P≤0.05(*).
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Figure 3.7. Aza promotes stability of Tregs in vitro (A-C) Splenocytes from DO11.10
RAG2−/− mice were cultured (1 million cells) in the presence of 1 μg/ml of anti-CD3/CD28
antibody with either Treg or Th1 differentiating conditions. (A,B) Treg differentiation was
performed in the presence of 100 U/ml of recombinant IL-2, 1ng/ml TGF-β and varying
concentrations of Aza (1µM-15-µM). After 5 days of culture, cells were analyzed for the
expression of CD4 and Foxp3. Dose-response curve for Foxp3 induction with various
concentrations of 5-Azacytidine (Aza) were indicated. (A) Line graph representing the
Live CD4+ Foxp3+ cells at various concentrations of Aza. (B) Representative FACS plots
showing Foxp3 expression in cells differentiated under Treg differentiating conditions in
the presence or absence of 5µM Aza (C) Representative FACS plots showing the
expression of IFN-g in cells differentiated under Th1 differentiating conditions (5ng/ml IL12 and 10µg/ml anti-IL-4) in the presence or absence of Aza 5µM (D) Naive CD4 T cells
purified from Foxp3 GFP male mouse were cultured (1 million cells) with 100U/ml IL-2,
1µg/ml anti-CD3/CD28, 5ng/ml TGFβ and in the presence or absence of Aza (5µM) for
up to 4 days. Foxp3 GFP+ T cells were FACS sorted. Methylation status of CpG motifs
of the Foxp3 locus was assessed by bisulfite sequencing as described in Materials and
methods. Numbers above boxes (1–10) indicate the 10 CpG islands in CNS2 of the Foxp3
locus (TSDR), from 5′ to 3′. Data are from one experiment with at least 10 bacterial
colonies containing the plasmid encoding TSDR region were sequenced and average
values were represented (E) Splenocytes from DO11.10 RAG2−/− animals were cultured
in the presence of 1µg/ml anti-CD3/CD28, 100 U/ml IL-2, 5ng/ml TGF-β in the presence
or absence of Aza (5µM) for 5 days. Later, exposed to 100U/ml IL-2 or 5ng/ml IL-12 or
25ng/ml IL-6 and 1ng/ml TGF-beta for another 3 days. Cells were measured for Live
CD4+ Foxp3+ cells before exposure and after exposure. Histogram represents the
frequency of Foxp3 lost by cells of control and Aza induced iTreg exposed to different
conditions. Experiments were repeated at least three times. The level of significance was
determined by Student’s t test (unpaired) and error bars represent mean ± S.E.M. P≤
0.0001 (****), P≤0.001(***), P≤0.01(**), P≤0.05(*).
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Figure 3.8. Aza promotes Treg suppressive function (A) Naive CD4 T cells purified
from Foxp3 GFP mice were cultured (500,000 cells/well) with 100U/ml IL-2, 1µg/ml antiCD3/CD28, 5ng/ml TGFβ and in the presence or absence of 5µM Aza for up to 5 days.
Foxp3 GFP+ T cells were FACS sorted and in vitro Treg suppression assay was
performed on both control iTreg and Aza iTregs. CD4+ Foxp3+ T cells were sorted and
equal number of cells (1 x 105) were cultured with CTV-labeled naïve CD4+ Thy1.1
responder cells (Treg/Tconv, 1:1 to 1:8) in the presence of anti-CD3/CD28 antibodies. (A)
Representative histograms showing the extent of CTV dilution at 1:8 Treg/effector T cell
(Teff) ratio. (B) Bar graphs showing the percent suppression by Treg at 1:8 ratio. (C-D)
Splenocytes from DO11.10 RAG2−/− mice were cultured in 1µg/ml anti-CD3/CD28, 100
U/ml IL-2, 5ng/ml TGF-β in the presence or absence of Aza (5µM). After 5 days of culture,
cells were either measured for intracellular Foxp3 expression or surface stained with ROS
indicator dye CM-H2DCFDA for measuring ROS expression. (C) Representative FACS
plots showing the similar Foxp3 expression (gated on Live CD4+ T cells) (D)
Representative FACS plots and histogram showing ROS expression (CM-H2DCFDA) in
cells induced in the presence or absence of Aza (5µM). (E) Representative bar graph
showing expression of CD25, GITR and FR4 in the Treg induced cells in the presence or
absence of Aza (5µM). Data represent means ± SEMs of and representative of two
independent experiments with n=3/group. Statistical significance was calculated by
Student’s t test (unpaired) (P≤0.01(**), P≤0.05 (*)).
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CHAPTER 4
ROLE OF IL-18 INDUCED AMPHIREGULIN EXPRESSION BY TREG ON VIRUS
INDUCED LESIONS
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Research described in this chapter is reproduced from a publication submitted to
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Abstract
This report deals with the possible mechanism by which regulatory T cells contribute to
the control and resolution of inflammatory lesions in the cornea caused by herpes simplex
virus (HSV) infection. Our results demonstrate that the expression of the IL-18R by
regulatory T cells (Treg) was a pivotal event that influenced lesion pathogenesis. The
engagement of IL-18R with its cytokine ligand resulted in Amphiregulin expression a
molecule associated with tissue repair. In support of this scheme of events, lesion severity
became more severe in animals unable to express the IL-18R because of gene knockout
and were reduced in severity when IL-18 was overexpressed in the cornea. These
changes in lesion severity correlated with the frequency of Treg that expressed
Amphiregulin. Additional experiments indicated that IL-12 and IL-18 acted synergistically
to enhance Amphiregulin expression, an event partly dependent on P38 MAPK activity.
Thus, overall our results imply that Treg participate in controlling the severity of SK and
contribute to tissue repair by converting into cells that produce Amphiregulin.
Introduction
Viruses may cause disease in many ways but few do so solely by their uncontrolled
replication . More often lesions are the consequence of host inflammatory reactions to the
infection and this can lead to chronic tissue damage. Resolving chronic reactions is
problematic and these may persist even after the inciting virus is no longer replicating.
Resolution of chronic lesions may require a change in the balance of cellular participants
along with a change in the cytokines that dominate lesions . Cell types involved in limiting
tissue damage include CD4 T cells that express the Foxp3 transcription factor (regulatory
T cells -Treg) . Such Treg express a range of regulatory functions and can act against
several targets in inflammatory responses . Indeed, there is a spectrum of Treg in terms
of functional activities and the spectrum may differ according to location in the body and
the stage of lesion development . Additionally, Treg function may be unstable and under
some circumstances the cells lose their regulatory activities and may even take on a proinflammatory role in tissues . An objective for control of chronic infections is to expand
and maintain subsets of Treg with functions that counteract tissue damaging events and
even contribute to lesion repair.
The idea that Treg can participate in the repair of damaged tissues was realized
recently, but so far has received limited investigation. A critical report on the reparative
function of Treg came from studies on a muscle damage model , where the Treg
population present during muscle lesion repair was dominated by cells which produced
Amphiregulin (Amp) . Amp is a ligand for the epidermal growth factor receptor expressed
mainly on epithelial cells and stem cells and its binding can result in the activation of
downstream signaling kinases resulting in growth, proliferation and migration of cells .
The mechanism that drives the expression of Treg reparative molecules such as Amp
involves cytokines produced by innate immune cells or epithelial cells. For instance, both
IL-33 and IL-18 were shown to cause the expression of Amp by Treg . However, whereas
the participation of IL-33 in tissue repair has been well established , the role played by IL18 needs to be further substantiated.
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IL-18 is a member of the IL-1 family and is mainly produced at barrier tissues and
inflammatory sites when a variety of cell types, which includes epithelial and innate
immune cells, are exposed to microbial products . Whereas, some reports advocate a
pathogenic role of IL-18 during infections and autoimmunity , others demonstrate a tissue
protective role such as occurs following intestinal and ocular injury . One potential
mechanism for the tissue protective function of IL-18 involves Treg. Thus, expression of
the IL-18 receptor (IL-18R) on Treg appeared necessary for their suppressive function .
However the role of IL-18 induced signaling events in Treg involved in the tissue repair
process requires to be clarified.
The present report focuses on events that result in the expression of IL-18R and
how it’s binding to IL-18 results in Amp expression in Treg. We also explored the
participation of IL-18 and Amp expression by Treg during the course of an inflammatory
response caused by herpes simplex virus (HSV) infection in the mouse cornea. We
demonstrate that when lesions were at their peak the majority of Treg in the cornea
expressed IL-18R along with several suppressive markers compared to Treg in lymphoid
organs. The expression of IL-18R was independent of TCR stimulation but was
dependent on the pro-inflammatory cytokine IL-12. IL-12 signaling in Treg resulted in
reduced expression of the enzyme DNA methyltransferase 3a (DNMT3a), which
correlated with enhanced expression of the IL-18R. Thus, knockdown of DNMT3a in CD4
T cells expanded the Treg population that became IL-18R expressers. In fact, IL-18
signaling led to the expression of Amp and, together with IL-12, synergistically enhanced
the expression of Amp. Moreover, IL-18R knockout animals displayed enhanced corneal
lesion severity and had far fewer Treg that were Amp producers. In contrast,
overexpression of IL-18 caused reduced lesion severity, an effect which correlated with
higher numbers of Amp expressing Treg. Taken together, our results indicate that IL-18
plays a tissue protective role in the cornea during SK acting via effects on Treg. This
effect occurred by binding to the IL-18R and induced the expression of the tissue repair
molecule - Amp. Consequently, IL-18 therapy could represent a valuable strategy to
shorten the duration of chronic inflammatory reactions to a viral pathogen.
Results
Treg in cornea upregulate IL-18R and Amp expression
To evaluate the phenotypic and functional status of Treg at different locations after
HSV infection, single cell suspensions of pooled corneas and individual DLN were
collected at 15 days post infection (pi) and the cell populations were analyzed by flow
cytometry for multiple phenotypic markers. Day 15 pi is the time when lesions caused by
HSV in the cornea are fully developed and the inflammation is at its peak. Differences
between the two populations were evident. While the majority of the Treg in corneas
displayed activation and functional suppressive markers (which included Ki-67, CD44,
GITR, OX40, Helios, Nrp1, CD25, CTLA-4) only a minority of the Treg in DLN expressed
those markers (Fig 4.1A). Additionally, a higher proportion of corneal Treg expressed IL33R (ST2) and IL-18R compared to the DLN Treg (Fig 4.1B). Since, the expression of IL18R in the corneal Treg was greater than ST2, we focused on the potential relevance of
IL-18R. We could show that around day 15pi 80% of corneal Treg expressed IL-18R
compared to about 46% which expressed ST2 (Fig 4.1C).
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The expression of the tissue repair molecule Amp was also measured in day 15
samples. About 50% of the corneal Treg were shown to express Amp, whereas less than
25% of DLN Treg were Amp positive (Fig 4.1D). Curiously, about 70% of the corneal Treg
expressing Amp were also IL-18R positive (Fig 4.1E). Collectively, these data indicate
that the Treg in the cornea are functionally more activated than the Treg in lymph nodes,
and the expression of IL-18R by corneal Treg might play a role in driving the production
of Amp.
IL-18R and Amp expressing Treg increase with duration of lesion development
To evaluate the potential relevance of IL-18R and Amp expression on Treg
following ocular infection, corneas were isolated at different time points pi that included
the time of early lesion development (D8), its peak (D15) and the time when most lesions
were decreased in severity (D21). The isolated corneal cells were stimulated with
PMA/Ionomycin followed by the ICS assay to enumerate Treg that expressed IL-18R
and/or Amp. At day 8, approximately 60 % of the Treg population expressed IL-18R. This
increased to about 80% by day 15pi. By day 21, the Treg that expressed IL-18R was
reduced to about 60% (similar differences in number were also observed) (Fig 4.2A). In
the case of Amp expressing Treg, at day 8 approximately 30% of corneal Treg expressed
Amp, but Amp expressing Treg increased to about 50% by day 15 and remained the
same at day 21 (Fig 4.2B). Whereas at day 15 the majority of Amp expressors were IL18R positive, by day 21 the majority of Amp expressors no longer expressed IL-18R (Fig
4.2C). The results indicate that the population of IL-18R expressing Treg changes during
the course of infection. The high frequency of Amp expressing Treg (IL-18R pos & neg)
when lesions were declining might mean that such cells were participating in lesion repair.
IL-12 and IL-18 synergistically induce the expression of IL-18R and Amp
To account for the observed changes in Treg phenotype over time, various
cytokines were measured by multiplex assay and ELISA in the corneas at different time
points pi. While, cytokines such as IL-12, IL-6, TNF-α and IL-1β peaked at day 8 pi (Supp
Fig. 4.1A), the levels of IL-18 peaked at day 15 pi and this was followed by a modest
reduction at day 21pi (Fig 4.3A). We hypothesized that the expression changes in one or
more of these cytokines might have influenced the expression of the IL-18R on Treg. To
evaluate this, Treg were differentiated in vitro (iTreg) from naïve CD4 T cells isolated from
uninfected C57BL/6 animals. Of note, a low percentage of those iTreg expressed the IL18R (<5%). This iTreg population was used as the cell source to test the effects of
changing the cytokine environment on the expression of the IL-18R. The population was
stimulated with IL-2 in the presence or absence of different inflammatory cytokines known
to be present in corneal lesions and anti-CD3+anti-CD28 to mimic TCR stimulation. These
cytokines included IL-2, IL-18, IL-6, IL-12, IFN-g and IL-33 and after 5 days of exposure,
the proportion of Treg that expressed IL-18R and Amp was measured. Surprisingly, of all
the cytokines tested, only IL-12 caused a significant increase (from 3% to 20%) in the
frequency of IL-18R positive Treg compared to controls (Fig 4.3B, Supp Fig 4.1B). Of
note, stimulation with anti-CD3+CD28, or IL-18 alone, did not influence the frequency of
Treg that expressed IL-18R (Fig 4.3B). However, when a combination of both IL-12 and
IL-18 cytokines was used to stimulate Treg, the number of cells that became IL-18R
positive was increased to 60%, well beyond the increase caused by IL-12 stimulation
alone (20%) (Fig 4.3B). Additionally, while IL-12 alone stimulation did not increase the
number of Treg that also expressed Amp, the combination of IL-12 and IL-18 caused a
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large percentage of cells (approximately 4-fold) to become Amp positive (Fig 4.3C). Thus,
the cytokines IL-12 and IL-18, whose levels were maximal in the cornea at day 8 and day
15 pi respectively, appeared to act synergistically to induce the expression of IL-18R and
Amp by Treg.
DNMT3a can regulate the expression of Amp in CD4 T cells via IL-18R
To evaluate the potential mechanism by which IL-12 could induce the expression
of IL-18R, the levels of STAT4 and DNMT3a enzymes were measured in Treg generated
in vivo. This analysis was chosen since, previous observations with Th1 cells indicated
that IL-12 stimulation induced STAT4 mediated down-regulation of DNA
methyltransferase-3a (DNMT3a) . This resulted in demethylation of the IL-18R gene and
hence the expression of IL-18R . In these experiments, iTreg were exposed to IL-2 with
or without IL-12 for 3 days after which the levels of STAT4 phosphorylation were
measured using flow cytometry. Additionally, mRNA levels of DNMT3a were quantified
by QRT-PCR. The results showed that Treg exposed to IL-12 alone significantly induced
the phosphorylation of STAT4 (Fig 4.4A), but reduced DNMT3a mRNA levels (Fig 4.4B)
compared to Treg stimulated with IL-2 or IL-18 alone. However, Amp mRNA levels
increased when exposed to IL-18 or IL-12 and IL-18 combined, but remained unchanged
by exposure to IL-12 or IL-2 alone (Fig 4.4B).
To evaluate if DNMT3a could influence IL-18R and subsequently Amp expression
in vivo, corneal lesion responses was compared following HSV infection in DNMT3a KO
and WT animals. Pools of corneas were stimulated with PMA/Ionomycin at day 15pi and
the proportion of Treg that expressed Amp was measured. The results indicate that the
frequencies and numbers of Amp producing Treg and effector T cells were higher (2-3
fold) in the corneas of DNMT3aKO animals compared to the control animals (Fig 4.4C).
In addition, the frequency and numbers of Amp expressing IL-18R pos Treg were higher
in DNMT3a KO compared to WT animals (Fig 4.4D). Taken together, the results indicate
that DNMT3a may negatively regulate IL-18R expression and subsequently Amp
expression.
Amp induction by IL-12 and IL-18 is P38 MAP kinase dependent
To evaluate the possible mechanism by which IL-18 induced Amp expression, a
lead was taken from previous studies on Th2, Th1 or NK cells where P38 MAP Kinase
was involved in IL-18 induced expression of IL-5 and IFN-γ respectively . The levels of
phosphorylated P38 MAP kinase (p-P38) were compared between IL-18R positive and
negative Treg isolated from the DLN of day 15pi animals. As shown in Fig 4.5A, IL-18R
positive Treg had 2-fold higher expression of p-P38 compared to IL-18R negative cells.
Experiments were also done on in vitro generated Treg wherein iTreg were exposed to
IL-2 in the presence or absence of IL-12, or IL-18, or together for 30 minutes followed by
measurement of p-P38. As shown in Fig 4.5B, exposure of IL-12 and IL-18 together
enhanced the expression of p-P38, while the levels of p-P38 remained unchanged when
exposed either to IL-12 or IL-18, or IL-2 alone (Fig 4.5B). To evaluate whether activation
of P38 MAP kinase was essential for IL-12 and IL-18 induced Amp expression, Treg were
exposed to IL-12 and IL-18 for 5 days in the presence or absence of various doses of
SB203580, a specific inhibitor of mitogen-activated protein kinase p38. The results
indicated that SB203580 dose dependently inhibited Amp expression (Fig 4.5C) without
influencing the survival of Treg (data not shown). Since IL-18 also induces NF-kB along
with P38 MAPK, NF-kB was also inhibited using a cell permeable inhibitor (SN50) at
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various concentrations. However, NF-kB inhibition did not influence Amp expression in
Treg (Supp fig 4.1C). These data indicate that IL-12 and IL-18 induced Amp expression
in Treg may require MAP kinase P38 phosphorylation.
IL-18 signaling is critical for controlling lesion severity
To further evaluate a role for IL-18 in driving the expression of Amp in vivo, IL18r1
knockout mice (IL-18R KO) were used wherein a subunit of the receptor-IL18R1 was
deleted. Both WT (C57BL/6) and IL-18R KO mice were ocularly infected with HSV-1 and
lesion severity was compared. The results indicate that IL-18R KO animals displayed
enhanced lesion severity when compared to WT animals at day 8pi (Fig 4.6A). Pools of
corneas were collected and evaluated from both groups to measure the frequency and
number of Amp expressing Treg in the cornea. It was evident that the Treg population
that was Amp positive was significantly decreased in the IL-18R KO populations (Fig
4.6B). Of note, no significant differences in the number and frequency of Th1 and Amp
expressing Treg was observed in the DLN of WT and IL-18R KO animals (Fig 4.6C). In
addition, the knockout of IL-18R did not influence the expression of various activation
markers on Treg in the DLN that included GITR, CTLA4 and CD25 (Fig 4.6D). Together,
these data indicate that the lack of IL-18R signaling can result in enhanced tissue damage
and this was accompanied by a diminished number of Treg that expressed Amp.
Over-expression of IL-18 diminishes SK lesions and expand Amp Treg
Finally, the therapeutic potential of IL-18 in driving the generation of Amp
expressing Treg in the cornea was evaluated. For this, an IL-18 overexpressing plasmid
which was previously shown to inhibit the development of SK lesions in mice , was used.
C57BL/6 animals were ocularly injected with the IL-18 overexpressing plasmid 4 and 2
days before ocular infection with HSV. Control animals received empty vector at the same
time points. As reported previously , animals that received the IL-18 plasmid showed
significantly reduced (p<0.01) SK lesions at day 15pi compared to controls (Fig 4.7A).
Single cell suspensions of corneas were stimulated with PMA/Ionomycin at day 8 to
compare with empty plasmid recipients the numbers of Treg that were Amp positive. As
a consequence of IL-18 plasmid exposure all cell types was reduced in number. However,
the frequency of Amp expressing Treg and effector CD4 T cells (CD4+ Foxp3-) were both
significantly increased at day 8pi (Fig 4.7B) compared to the empty plasmid control group.
Collectively, these data indicate that IL-18 may play a tissue protective role during ocular
lesions and it may be acting by inducing the expression of Amp in Treg.
Discussion
Stromal keratitis is an inflammatory reaction that occurs in the cornea in response
to HSV infection. Lesion severity is known to be influenced by the relative abundance of
the pro-inflammatory, mainly CD4 type Th1 cells, and regulatory T cells . The later cell
type appears to limit tissue damage caused by the activities of Th1 cells along with the
cells recruited to the cornea such as neutrophils and macrophages . Currently, it is not
clear how Treg exert their anti-inflammatory function, or if they actively contribute to tissue
repair. However, the results in this report support the idea that the expression of the IL18R by Treg is a relevant event and that the engagement of IL-18R with its cytokine ligand
results in the expression of Amphiregulin, a molecule associated with tissue repair in
several situations . Our results also show that when Treg were unable to express IL-18R,
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SK lesions became more severe and that overexpression of IL-18 in the eye using an
expression plasmid was an effective means of limiting lesions. The later outcome
correlated with the increased proportion of Treg that were Amp producers. Thus, overall
our results imply that Treg participate in controlling the severity of SK and contribute to
tissue repair by converting into cells that produce Amphiregulin.
Past studies had clearly associated the presence of Treg with diminished tissue
damage caused by ocular infection with HSV . Treg may express numerous regulatory
functions and it is not clear which ones participate in limiting the corneal damage caused
by the effects of T cells and other inflammatory cells. In addition to constraining the proinflammatory activities of several cell types, evidence accumulates from studies in other
systems that Treg may also participate in the repair of tissue damage . Tissue repair is a
particularly relevant topic with an organ whose function is totally dependent on
maintaining tissue clarity along the visual axis from the cornea to the retina. Thus, it would
be valuable to discover how any cell type could orchestrate repair of the damaged cornea.
Corneal tissue repair involves numerous events and one of these could be Amphiregulin
production . Amphiregulin engages the epidermal growth factor receptor expressed on
corneal epithelial cells and stem cells and causes cell proliferation, differentiation, and
migration to participate in tissue repair . Several cell types, such as innate lymphoid cells
and mast cells can mediate repair of some tissues via their production of Amp , but neither
of these cell types are prominent in corneal lesions. However, Treg are numerous in
corneal lesions and, as was recently shown in repairing muscle and lung lesions , these
Treg were in large part Amp-producers, unlike Treg at other non-inflamed sites. These
observations on repairing muscle and lung inspired the present investigations to
determine how Treg could participate in corneal repair in response to a chronic viral
induced inflammatory event.
Our studies revealed that an essential event leading up to Amp production by Treg
was expression of the IL-18R and engagement by its cytokine ligand IL-18. Previous
studies by Rudensky and colleagues had noted that a consequence of triggering the IL18R on Treg was their conversion to become Amp producers . Of many cytokines
evaluated for inducing Amp, only IL-18 and IL-33 were effective. Our studies focused on
the IL-18R since Treg that expressed this receptor were around two-fold more frequent
that those that expressed the IL-33R. We could demonstrate that the frequency of Treg
that expressed IL-18R increased as lesions progressed but then declined after lesions
diminished. This raised the question of what caused Treg to express IL-18R. Many
cytokines were tested but IL-12 appeared to be the most likely candidate. Prior studies
had shown that IL-12 is prominently expressed during SK lesion development, perhaps
driven by viral components with TLR ligand activity or by produces released by damaged
cells. In addition to IL-12, we also showed that IL-12 along with IL-18 appeared to act
together to cause more Treg to become IL-18R and Amp expressers but the detailed
mechanism that explained this apparent synergism needs further study.
The mechanism by which IL-12 caused the expression of IL-18R was associated
with STAT4 phosphorylation and down regulation of DNMT3a gene expression. Previous
results supported a role for DNMT3a in controlling IL-18R gene expression with it acting
by methylating the promoter region . Additionally, the knockdown of DNMT3a in CD4 T
cells led to the enhancement of Amp and IL-18R expressing Treg in the cornea. Hence,
inhibitors targeting DNA methyltransferases such as 5-Azacytidine could have potential
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therapeutic implications to enhance both the suppressive function and tissue reparative
function of Treg. In fact, we recently observed that 5-Azacytidine therapy did inhibit the
progression of SK and acted by enhancing the activity of Treg . However, it remains to be
evaluated whether 5-Azacytidine treatment was also associated with an increased
expression of IL-18R and Amp by Treg. Another mechanism by which IL-18 induced Amp
expression was activation of P38 MAPK kinase. Thus inhibition of MAP kinase activity
using a specific inhibitor led to a dose dependent reduction in Amp expression in the
presence of IL-18. These data did not come as a surprise since P38 MAPK activity is
known to be required for IL-18 induced Th2 cytokines (IL-4 and IL-13) in basophils and
IFN-gamma in NK and Th1 cells . Hence, it is possible that IL-18 and P38 MAPK play a
cell specific role in orchestrating the production of cell specific cytokines.
A critical event for Treg to become Amp-producers and contribute to lesion
resolution was the expression of IL-18R. Thus knockout mice unable to express IL-18R
developed more severe SK lesions than did intact control animals and a major
consequence of IL-18R KO was a significant reduction in the frequency of Treg that
produced Amp. Since the IL-18R KO could still produce IL-33, this might argue that if the
IL-33/IL-33R axis is also involved in Amp expression its role is likely to be minor.
A final approach which implicated a critical role for IL-18 in controlling lesion
severity involved using an expression plasmid encoding IL-18. As reported previously ,
use of this plasmid inhibited the severity of SK lesions and in the present study we could
show that a consequence of IL-18 plasmid therapy was expansion of the Treg population
that were Amp producing cells. However, since IL-18 can have effects on immune cells
other than Treg such as neutrophils and macrophages , studies using IL-18R flox and
Amphiregulin flox mice are needed to further depict the role of IL-18 induced Amp
expression by Treg.
In conclusion, our results strongly support the idea that the ongoing events that
occur during HSV–induced ocular lesions serve to cause Treg to express IL-18R and this
event is necessary to subsequently express Amp, a molecule involved in tissue repair.
So far we have been unable to fully verify the concept since we lack access to mice which
lack expression of Amp specifically in Treg. However, preliminary studies on mice with
developing lesions given the Amp protein via the subconjunctival route have resulted in
diminished lesions and such studies are still ongoing.
Materials and Methods
Mice and Virus
C57BL/6 mice (Female) were purchased from Envigo, Inc. (Indianapolis, IN), IL-18R
Knockout, CD4 Cre mice were purchased from Jackson and DNMT3a flox mice were a
kind gift from Dr.Igor Nasonkin (University of Pittsburg Medical center) all were kept in
pathogen free facility where food, water, bedding and instruments were autoclaved. CD4
cre mice were bred with DNMT3a flox mice and cre mice homozygous for flox was used
for the experiments as DNMT3aKO. All the animals were housed in American Association
of Laboratory Animal Care–approved facilities at the University of Tennessee, Knoxville,
Tennessee. All investigations followed guidelines of the Institutional Animal Care and Use
Committee, and adhered to the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. HSV-l RE strain was used in all procedures. Virus was grown in
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Vero cell monolayers (American Type Culture Collection, Manassas, VA), titrated, and
stored in aliquots at −80°C until used.
HSV-1 ocular infection and clinical scoring
Ocular infections with HSV-1 was done as previously described . Briefly, mice were kept
under deep anesthesia by administering an intra peritoneal (i.p) injection of
tribromoethanol (Avertin). Later, the mice eyes were scarified with 27-gauge needle and
and a 3-µl drop containing 1 x 104 plaque-forming units (PFU) of HSV-1 RE was applied
to the eye. The eyes were examined on different days after infection for the development
of clinical lesions by slit-lamp biomicroscope (Kawa Co., Nagoya, Japan), and the clinical
severity of keratitis of individually scored mice was recorded by a blinded observer. The
scoring system was as follows: 0, normal cornea; +1, mild corneal haze; +2, moderate
corneal opacity or scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea
and corneal ulcer; +5, corneal rupture and necrotizing keratitis.
Flow Cytometric Analysis
Flow cytometric analysis on tissue and lymph node samples were described previously .
Briefly, cornea were excised at indicated time points, pooled and digested with liberase
(Roche) for 45 minutes at 37°C in a humidified atmosphere of 5% CO2. Single cell
suspensions were made by grinding the digested tissue and stained for different cell
surface molecules for fluorescence-activated cell sorting (FACS) analyses. Draining
cervical lymph nodes were isolated from mice at indicated time points and single cell
suspensions were used for FACS analyses. To determine the Amp producing T cells,
single cell suspensions were stimulated with PMA (50ng) and Ionomycin (500ng) for 3
hours in the presence of brefeldin A (10 μg/mL) in U-bottom 96-well plates . After this
period, Live/Dead staining was performed to gate out the dead population followed by cell
surface and intracellular cytokine staining using Foxp3 intracellular staining kit
(ebioscience) in accordance with the manufacturer's recommendations. The stained
samples were acquired with a FACS LSR II (BD Biosciences, San Jose, CA) and the data
were analyzed using FlowJo software (Tree Star, Inc., Ashland, OR).
Reagents and antibodies.
All the staining CD4 (RM4-5), CD45 (53-6.7), CD11b (M1/70), Ly6G (1A8), F4/80 (BM8),
IFN-γ (XMG1.2), CD25 (PC61), CD44 (IM7), Foxp3 (FJK-16S), anti-CD3 (145-2C11),
anti-CD28 (37.51), IL-18Ra (P3TUNYA) phosphor p38 (4NIT4KK) from Thermofisher.
Phorbol myristate acetate (PMA) and Ionomycin from Sigma. Live/Dead staining kit (Life
Technologies), anti-mouse Amphiregulin (R&D), GolgiPlug (brefeldin A) and Stat4
(pY693) from BD biosciences. Recombinant mouse IL-2, IL-12, IL-6, IFN-γ, IL-33, IL-18,
Amphiregulin and TGF-β from R&D systems. P38 inhibitor-SB202190 (Tocris) and NFkB inhibitor-SN50 (emdmillipore).
In vitro Treg differentiation and Treg cultures
Treg were generated in vitro as previously described . Briefly, 1×106 naïve CD4 T cells
were cultured in the presence of plate bound anti-CD3/CD28 Ab (1 µg/ml) and complete
RPMI media containing rmIL-2 (100 U/ml) and TGFβ (5ng/ml) for 5 days at 37°C in a 5%
CO2 incubator. After 5 days, Foxp3, IL18Ra and Amp expression was determined by flow
cytometry as described above. For inducing IL18Ra expression, in vitro generated Treg
were cultured with either IL-12 (5ng/ml) or IL-18 (100ng/ml) orIL-33 (100ng/ml) or IFNgamma (10ng/ml) or IL-6 (25ng/ml) for 24 hours. For Amp induction experiments, iTreg
cells were cultured in the presence of IL-12 (5ng/ml) or IL-18 (100ng/ml) or together. For
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P38 MAPK inhibitor experiments, iTreg were cultured in the presence of IL-12 (5ng/ml)
and IL-18 (100ng/ml) in the presence or absence of SB 202190 (P38 inhibitor) at doses
indicated. After 5 days cells were re-stimulated with PMA/Ionomycin and analyzed for
Amp expression using flow cytometer.
Quantitative PCR (qPCR)
Taqman gene expression assays for DNMT3a from Applied Biosystems were performed
on iTreg populations using 7500 Fast Real-Time PCR system (Applied Biosystems) as
described previously .
Cytokine level measurements
Corneas were pooled (3 corneas per sample) and collected in PBS containing antiprotease cocktail. Corneas were homogenized with tissue homogenizer (Kontes Pellet
Pestle mortar). Levels of IL-18 were measured using Mouse IL-18 ELISA (R&D); other
cytokines were measured using multiplex analysis (Eve technologies).
Purification of CD4+ T cells
Naïve CD4+ T cells were purified using a mouse naïve CD4+ T cell isolation kit (Miltenyi
Biotec, Auburn, CA). The purity was achieved at least to an extent of 90%.
Over-expression plasmid preparation
IL-18 over expression plasmid was kindly provided by Dr. Seong Kug Eo, Chonbuk
National University and empty plasmid (PCDNA3.1) from Thermosfisher. Plasmid was
cloned and purified using Qiagen Maxi kit and 5 µg/eye was administered at 4 and 2 days
before infection.
Statistical Analysis
The statistical significance between the 2 groups was determined using unpaired, 1-tailed
Student’s t test. For experiments involving more than 2 groups, 1-way ANOVA with
Tukey’s multiple comparison tests was used to calculate the level of significance.
GraphPad Prism software (GraphPad Software, La Jolla, CA, USA) was used to calculate
the statistical significance.
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Figure 4.1. Corneal Treg have higher functional markers including IL-18R and
Amphiregulin.
C57BL/6 animals were infected with 1 x 104 PFU of HSV-RE and at day 15 pi, of individual
draining Lymph nodes (dLN) and pooled corneas were stained for flow cytometric
analysis. (A-B) Representative histograms depicting the expression of markers related to
Treg (CD4+ Foxp3+) function and activation on corneal Tregs and dLN Tregs (blue). (C)
Representative flow plots showing the expression of IL-18R and ST2 (IL-33R) on corneal
Treg at day 15pi. (D-E) Single cells suspension of dLN and cornea were stimulated with
PMA/Ionomycin, (D) representative flow cytometry plots and histogram showing the
Amphiregulin (Amp) expression in corneal and dLN Treg. (E) Representative flow
cytometry plots showing the IL-18R expression on Amphiregulin (Amp) expressing Treg
(gated on live cells). Data represents the mean±SEM of 3 independent experiments (n=3
mice/group). P≤0.01 (**).

90

Figure 4.2. IL-18R and Amphiregulin expression on Treg change over the course of
infection.
C57BL/6 animals were infected with 1 x 104 PFU of HSV-RE and at various time points
post infection (Day 8, 15, 21) single cell suspension of pooled corneas were stimulated
with PMA/Ionomycin. (A-C) Representative Flow cytometry plots and bar graphs showing
frequency and number of (A) IL-18R expressing Treg or (B) Amphiregulin (Amp)
expressing Treg or (C) both IL-18R and Amp expressing Treg. Data represents the
mean±SEM of 3 independent experiments (n=3 mice/group). P≤ 0.0001 (****),
P≤0.001(***), P≤0.01 (**), P≤0.05(*).
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Figure 4.3. IL-18 and IL-12 synergistically induce the expression of Amphiregulin
in Treg.
(A) C57BL/6 animals were infected with 1 x 104 PFU of HSV-RE. Bar graphs showing IL18 protein levels in the corneas at various time points post infection (Day 0, 8, 15, 21)
quantified by ELISA. (B, C) iTreg were differentiated from naïve CD4 T cells followed by
culturing with either IL-2 alone or with IL-2 in combination with indicated cytokines for 5
days. Representative flow cytometry plots and bar graph showing frequency of (B) IL-18R
expressing or (C) Amphiregulin (Amp) expressing Treg (gated on live CD4+ Foxp3+).
Data represents the mean±SEM of 2 independent experiments for (A) or at least 3
independent experiments for (B,C) where n= 3-4 samples/group). P≤ 0.0001 (****),
P≤0.001(***),P≤0.05(*).
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Figure 4.4. DNMT3a may regulate IL-18R expression in Treg.
(A,B) iTreg were differentiated from naïve CD4 T cells followed by culturing with either IL2 alone or with IL-2 in combination with indicated cytokines for 5 days. (A) Representative
flow cytometry plots and bar graphs showing phosphorylated STAT4 levels in Treg (gated
on live CD4+Foxp3+). (B) Representative line graph showing relative gene expression
levels of DNMT3a and Amp compared to beta-actin, quantified by QRT-PCR. (C, D) WT
(DNMT3a flx/flx) and DNMT3a KO (CD4 Cre+DNMT3a flx/flx) mice were ocularly infected
with HSV-RE and at day 8pi corneas were collected. Single cell suspensions of pooled
corneas were stimulated with PMA/Ionomycin followed by ICS assay. (C) Representative
flow cytometry plots and bar graph showing the frequency and number of Amphiregulin
expressing Treg (gated on Live CD4+ Foxp3+) and effector T cells (gated on Live CD4+
Foxp3-). (D) Representative flow cytometry plots and bar graphs showing frequency and
number of Treg double positive for IL-18R and Amp. Data represents the mean±SEM of
3 independent experiments where n= 3 samples/group. P≤ 0.0001 (****),P≤0.01 (**),
P≤0.05(*).
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Figure 4.5. IL-12 and IL-18 induced Amphiregulin expression may be P38 MAPK
dependent.
(A) C57BL/6 animals were infected with 1 x 104 PFU of HSV-RE and dLN were isolated
at day 15pi. Representative flow cytometry plots and bar graph showing gating strategy
and MFI of phosphorylated P38 in IL-18R high and IL-18R low Treg (gated on Live
CD4+Foxp3+) in dLN. (B) iTreg were differentiated from naïve CD4 T cells followed by
culturing with either IL-2 alone or with IL-2 in combination with indicated cytokines for 30
minutes. Representative histograms and bar graphs showing phopsho-P38 levels and
phosphor-P38 MFI respectively. (C) iTreg were cultured with IL-12 and IL-18 for 5 days
in the presence or absence of P38 inhibitor SB 202190 at different concentrations and
DMSO as control. Representative flow cytometry plots and bar graph showing the
frequency of Areg expressing Treg. Data represents the mean±SEM of 3 independent
experiments where n= 3 samples/group. P≤ 0.0001 (****),P≤0.01 (**), P≤0.05(*).
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Figure 4.6. IL-18R KO animals show higher lesion severity and reduced Amp Treg
in cornea.
(A-D) WT(C57BL/6) and IL18RKO animals were infected with 1 x 104 PFU of HSV-RE (A)
line graph showing comparison of SK lesion severity scores at different time points day 5
and day 8 post infection between WT and IL18RKO. (B-C) Representative FACS plots
and histogram showing frequency and number of Treg, Amp Treg cells in cornea (B) and
Amp Treg and Th1 cells in DLN (C) at day 8 pi. (D) Histogram showing MFI of key
suppressor molecules CTLA4, GITR and CD25 in DLN of WT and IL18RKO animals at
day 8pi. Data represents the mean±SEM of 3 independent experiments where n= 8
samples/group (A), n= 3 samples/group (B-D). P≤0.01 (**), P≤0.05(*).
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Figure 4.7. IL-18 expression plasmid increases the resolution of SK lesions and
Amp Treg in cornea.
(A-B) C57BL/6 mice were ocularly infected with HSV-1 after administering IL-18
expressing plasmid 4 and 2 days before infection. (A) SK lesion severity scores as
measured at day 15pi. (B) Representative FACS plots and bar graph showing Amp
expressing Treg and Amp expressing effector T cells at day 8pi. Data represents the
mean ± SEM of 3 independent experiments, where n=8 samples/group (A) and n=4
samples/group (B) P≤0.01 (**), P≤0.05(*).
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Figure S4.1.
(A) C57BL/6 animals were infected with 1 x 104 PFU of HSV-RE. Bar graphs showing IL12, IL-6 and IL-33 protein levels in the corneas at various time points post infection (Day
0, 8, 15, 21) quantified by multiplex assay. (B) iTreg were cultured with IL-2 alone or in
combination with either IFN-g, IL-6 or IL-33 for 5 days. Representative flow cytometry
plots and bar graph showing frequency of IL-18R expressing Treg. (C) iTreg were cultured
with IL-12 and IL-18 for 5 days in the presence or absence of NF-kB inhibitor SN50 at
different concentrations and DMSO as control. Bar graph showing the frequency of Areg
expressing Treg. Data represents the mean±SEM of 3 independent experiments where
n= 3-5 samples/group.
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CHAPTER 5
MANIPULATING GLUCOSE METABOLISM DURING DIFFERENT STAGES OF
VIRAL PATHOGENESIS CAN HAVE EITHER DETRIMENTAL OR BENEFICIAL
EFFECTS
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Abstract
This report deals with physiological changes and their implication following ocular
infection with herpes simplex virus (HSV). This infection usually results in a blinding
inflammatory reaction in the cornea orchestrated mainly by pro-inflammatory CD4 T cells
and constrained in severity by regulatory T cells (Treg). In the present report, we make
the unexpected finding that blood glucose levels change significantly during the course
of infection. Whereas levels remained normal during the early phase of infection when
the virus was actively replicating in the cornea, they increased around two fold during the
time when inflammatory responses to the virus was occurring. We could show that
glucose levels influenced the extent of induction of the inflammatory T cell subset in vitro
that mainly drives lesions, but not regulatory T cells. Additionally, if glucose utilization was
limited in vivo as a consequence of therapy in the inflammatory phase with the drug 2DG,
lesions were diminished compared to untreated infected controls. In addition, lesions in
2DG treated animals contained less pro-inflammatory effectors. Glucose metabolism also
influenced the acute phase of infection when replicating virus was present in the eye.
Thus, therapy with 2DG to limit glucose utilization caused mice to become susceptible to
the lethal effects of HSV infection, with virus spreading to the brain causing encephalitis.
Taken together, our results indicate that glucose metabolism changed during the course
of HSV infection and that modulating glucose levels can influence the outcome of
infection, being detrimental or beneficial according to the stage of viral pathogenesis.
Introduction
Virus infections cause tissue damage in several ways one of which is to induce an
inflammatory reaction orchestrated by T cells that respond to viral antigens. One such
example is the blinding immuno-inflammatory reaction called stromal keratitis (SK), which
occurs in the cornea of the eye following infection with herpes simplex virus (HSV) (1, 2).
In such reactions, the pro-inflammatory effector T cells may be more tissue damaging if
regulatory components of immunity, such as certain cytokines or cells with regulatory
functions, are deficient (3-6). Thus, one aim of therapy with these usually chronic tissue
damaging lesions is to shift the balance of different components involved in the immune
response to the infection. Few if any effective therapies are readily available to achieve
this objective. However, recent studies in the field of cellular metabolism have drawn
attention to the fact that nutrient uptake and their utilization may differ among cell types
involved in immune responses (7-9). Moreover, it has become evident that manipulating
metabolic pathways represents a potential means of rebalancing immune responses and
this approach is being mainly explored in the cancer and autoimmunity fields where the
imbalance largely involves different subsets of T cells (10-14).
Application of the metabolic reprogramming approach has focused on
manipulating glucose and fatty acid metabolism, which can show major differences
between immune cells involved in reactions (15). However, few if any studies so far, have
focused on infectious diseases, but this topic is highly relevant since many chronic tissue
damaging infections are not subject to control by effective vaccines, or by readily
acceptable (or affordable) means of therapy. In fact, targeting metabolic events
represents a logical approach to pathogen control since many cause major changes in
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metabolism not only in cells they infect, but also impact on the function of distant
uninfected organs such as the liver, kidney, cardiovascular system and even the brain
(16). Some of the general physiological consequences of systemic infections has been
highlighted by recent studies (16, 17). However, the general topic of how virus infections,
particularly those that cause local infections, influences physiological responses is still
poorly understood. Our present studies record some metabolic consequences of local
infections in the eye with HSV.
Our results show that ocular HSV infection in mice led to increased fed and fasted
blood glucose levels at the time when virus no longer persists in ocular tissues. In
addition, CD4 T cells from infected mice showed increased glucose uptake both at the
corneal lesion site and in the draining lymph node. The CD4 T cells from HSV infected
animals were highly metabolically active and displayed increased glucose uptake in vitro
compared to T cells from naïve animals. In vitro experiments also indicated that the
effector function of inflammatory T cells was dependent on glucose concentration.
Moreover, inhibition of glucose uptake by 2DG limited the differentiation of effector T cells
in vitro. In contrast, regulatory T cells (Treg) were unaffected by 2DG in vitro. Finally, and
of potential therapeutic relevance, in vivo administration of 2DG resulted in diminished
SK lesions, a consequence of reduced effector T cell responses. Taken together, we
show that local infection with HSV results in changes in glucose homeostasis causing
increased blood glucose levels, which may act to stimulate the generation and
sustenance of inflammatory CD4 effector T cells, which, in the special environment of the
eye, can result in damaging consequences. Although changes in blood glucose levels
were not evident during the acute phase of ocular infection, therapy with 2DG during that
phase resulted in death from herpes encephalitis in many animals. Possible explanations
for these findings are discussed.
Results
HSV-1 infection increases blood glucose levels
To ascertain if ocular infection with HSV led to changes in glucose metabolism,
blood glucose levels were measured in control and infected animals up to 15 days post
infection (pi), the time when inflammatory responses to the ocular infection were at their
peak. Elevated blood glucose levels were not observed in the initial period after infection
when replicating virus was present in the eye. However, a moderate increase (about 1.5
to 2 fold) in blood glucose levels occurred in samples from days 8, a time when ocular
inflammatory lesions first become evident in the corneal stroma, as well as at day 15 pi
(Fig.5.1A). However, at the latter time point the effect was more variable and differences
were not significant in some experiments. At day 15, comparisons of blood glucose levels
were also made between infected and uninfected animals following a 16-hour fasting
period. Once again glucose levels were significantly higher (p<0.01) in the infected
animals compared to uninfected controls in both the fed and fasting states. (Fig. 5.1B).
Previous studies indicated that low-grade inflammation can affect systemic
glucose levels by inducing gene expression changes in the liver (25, 26). Accordingly,
pro-inflammatory cytokine levels in the serum were measured at different time points pi.
The results indicated that IL-6, TNF-α and IFN-γ cytokine levels were significantly
increased in serum samples of day 4 pi animals compared to uninfected controls (Fig.
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1C). Measurement of gene expression changes in the liver at different time points pi
indicated a significant increase in the expression of genes in the signaling pathways of
pro-inflammatory cytokines at day 8 pi (about 3 fold) which included Il6ra, Tnfr2, Ifngr1
and Stat3 (Fig. 5.1D). A recent report suggests that systemic inflammation suppressed
CYP7A1 (Cholesterol 7 alpha-hydroxylase), the rate-limiting enzyme of the bile acid
biosynthesis in the liver (25). This led to the accumulation of intermediate metabolites of
the mevalonate pathway, resulting in stabilization of RHOC, a small GTPase induced by
inflammation. The outcome was fasting hyperglycemia. We also quantified the expression
of both CYP7A1 and RHOC in the liver at day 8 pi the time when blood glucose was at
its peak. While the expression of CYP7A1 was significantly reduced, the expression of
RHOC was higher in the livers at day 8 pi (Fig. 5.1E). These data indicate that ocular
infection with HSV-1 results in a change in glucose metabolism likely by effects on the
liver mediated by responses to inflammatory cytokines.
CD4 T cells display enhanced glucose uptake and glycolysis
As the inflammatory response in the eye to HSV infection is mainly orchestrated
by CD4+ T cells (1), changes in glucose uptake and glycolytic events was measured in
CD4 T cells of animals with SK lesions and compared to CD4 T cells in uninfected
animals. The first series of experiments compared glucose uptake in control uninfected
and animals with lesions (day 15 pi), following the administration of a fluorescently labeled
glucose
analog
2-NBDG
(2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)
Amino)-2Deoxyglucose). One hour later, the draining lymph nodes (DLN) were collected and the
fraction of CD4+ T cells that took up 2-NBDG was measured by flow cytometry. The
results indicated that the CD4+ T cells from mice with ocular lesions had significantly
more cells (approximately 6-fold) that took up the glucose compared to uninfected
controls (Fig. 5A, B). Of note, compared to uninfected animals, CD4+ T cells from infected
mice contained 4-fold more cells with the effector memory phenotype and 7-fold more
cells that produced IFN-γ when stimulated in vitro with PMA and Ionomycin (Supp. Fig.
S5.1). The glucose uptake receptor GLUT1, as measured by flow cytometry was also
increased in CD4 T cells at day 15 pi compared to cells from uninfected controls (Fig.
5.2C).
Given that the CD4+ T cells from infected animals exhibited enhanced glucose
uptake, a second set of experiments measured if these CD4+ cells also had changes in
glucose metabolism. This was done using seahorse technology by determining the
extracellular acidification rate (ECAR), which serves as an indicator of lactate production
and glycolytic activity (21). CD4+ T cells isolated from the DLN of infected animals (day
15 pi) had a higher basal and maximal glycolytic rate (>3-fold) compared to CD4+ T cells
from uninfected animals (Fig. 5.2D). Of note, measurements of basal oxygen
consumption rate (OCR), which serves as an indicator mitochondrial respiration (21),
indicated that the ratio of OCR to ECAR was significantly reduced (p<0.05) in cells from
infected animals. This result may indicate cellular preference for glycolysis over
mitochondrial respiration (Fig. 5.2E). These results imply that upon infection with HSV-1,
CD4+ T cells increase glucose uptake and glucose utilization (glycolysis), which might be
supported by higher glucose levels observed in animals with inflammatory lesions.
Treg and effector cells differentially use glucose
Since different T cell subsets participate in SK reactions (1), it was of interest to
determine the type of T cell subset in which changes in glucose metabolism was
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occurring. The focus was on CD4 effector and regulatory T cells since these are the two
major subsets which influence the extent of SK lesions (3, 4). The two cell types were
isolated from the DLN of day 15 infected mice, separating them based on their expression
levels of the IL-2 receptor CD25 with cells that were CD25+ taken to be mainly Treg. Thus
in separate experiments, we could show that on average ~93% of the CD25+ T cells were
Foxp3+ on day 15 pi, The CD4+CD25- population was considered to be predominantly
effector T cells (Supp. Fig. S5.2). The uptake of 2NBDG was significantly higher in the
CD25- population (mainly effector T cells) as compared to the CD25+ population (mainly
Treg) (Fig 5.3A).
Since, the mTOR pathway is also involved in the control of glucose uptake and
glycolysis in T cells (27), mTOR activity was compared in the two subsets. This was done
by measuring the phosphorylation of S6 kinase (a component of the mTOR down-stream
signaling cascade) (28). Higher glucose uptake in the CD25- CD4 effector population was
also associated with higher mTOR activity compared to the activity of the CD25+ CD4
Treg population (Fig. 5.3B).
To further determine if glucose requirements differed between the Th1 effector and
Treg subsets, experiments were done in vitro to generate Treg and Th1 populations from
naïve DLN populations. The populations obtained were approximately 80% enriched for
each subset. After 5 days, levels of glycolysis were compared in the two populations by
using a glycolysis stress test which measures extracellular flux analysis (ECAR). As
shown in Fig 5.3C, the basal ECAR levels were elevated in the Th1 population compared
to the Treg population (2.8-fold). In addition, the glycolytic capacity, as measured by an
increase in ECAR levels following inhibition of ATP synthase (using oligomycin) (21), was
around 3 fold higher in Th1 compared to the Treg cells (Fig. 5.3C). Accordingly, the two
major populations of CD4 T cells involved in SK lesions had distinct differences in glucose
metabolism, a pattern of events noted in some autoimmune and neoplastic diseases (11,
13).
Glucose availability affects Th1 differentiation in vitro
To begin to approach the question of the potential relevance of raised glucose
levels during the inflammatory response to HSV infection, in vitro experiments were done
to measure the influence of glucose levels on the efficiency of Th1 and Treg cell
differentiation, cell types critically involved in SK reaction (1, 4). For this naïve CD4 T cells
were TCR stimulated under either Treg or Th1 inducing conditions after which the effect
of supplementing cultures with different concentrations of glucose was measured. Levels
of glucose evaluated varied from below physiological levels to hyperglycemic (0.5mM to
20mM). As shown in the Fig 5.4A, B, increasing glucose levels elevated the magnitude
of Th1 responses, but had no significant influence on Treg responses, as noted previously
(29, 30). Curiously, increasing glucose from physiological levels (about 5mM) to that
observed in vivo in the infected mice at day 8 pi (maximum of 10mM) led to a significant
increase (P<0.05) in Th1 differentiation. (Fig. 5.4C). The above observation supports the
hypothesis that, a two-fold increase in the physiological levels of glucose in the periphery
might be relevant in terms of enhancing the generation of Th1 cells in vivo.
Inhibition of glucose utilization using 2-deoxyglusose inhibits the glycolysis
To further measure the influence of glucose levels during the inflammatory
response to HSV infection, experiments were done in vitro to measure the effect of the
molecule 2DG, which inhibits glucose utilization and hence glycolysis. Naïve CD4 T cells
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were activated in the presence of 2DG for 72 hours followed by measurement of basal
glycolysis using extracellular flux analysis The data indicated a 3-fold reduction in basal
ECAR levels indicating a decrease in basal glycolysis in cells activated in the presence
of 2DG when compared to control activated cells (Fig. 5.5A). Of note, no difference in cell
death was observed at the concentration of 2DG used (data not shown). Collectively, the
above results support the hypothesis that activated T cells upregulate glycolysis which
can be inhibited by 2DG.
Additional experiments were done to measure the expression of key genes
involved in the glycolytic pathway both in the presence or absence of 2DG. Naïve CD4 T
cells were activated in vitro by stimulating them with anti-CD3/CD28 for 24 hours and the
effect of 2DG (250µM) on gene expression changes was recorded. Compared to naïve
CD4 T cells, activated CD4 T cells expressed higher levels of several genes involved in
glycolysis. These included Hexokinase-1 (2-fold), Hexokinase-2 (20-fold) and Glut1 (4fold) (Fig. 5.5). However, when CD4 T cells were activated in the presence of 2DG, the
genes involved in glycolysis remained at the levels or even below those observed in nonactivated control cells. (Fig. 5.5B). The presence of 2DG in the cultures also served to
switch off the raised mTOR activity, as measured by levels of phosphorylated S6 kinase
using flow cytometry (Fig. 5.5C).
To measure the effect of inhibition of glycolysis on differentiation of the two CD4 T
cell subsets of interest (Th1 and Treg), naïve CD4+ T cells were cultured in Treg or Th1
differentiating conditions for 5 days in the presence or absence of 2DG (250µM).
Although, the differentiation of Treg was unaffected at the dose of 2DG used, a 20-fold
reduction in the numbers of Th1 cells induced was observed in the presence of 2DG (Fig.
5.6). These results support the above findings that effector T cell use glycolysis to a higher
extent than Treg. The results may also mean that 2DG therapy could be therapeutically
useful against SK by inhibiting T effectors but leaving Treg function intact. This notion is
tested in the next section.
Inhibition of glucose utilization limits SK lesion severity and diminishes effector T
cell responses
To measure the therapeutic potential of 2DG against SK, HSV infected animals
were given daily administrations of either 2DG or PBS (control) starting at day 5 pi. This
is the time point when there is at best minimal replicating virus detectable in the infected
corneas and early inflammatory reactions start to become evident. Animals were
examined at day 15 pi to record and compare the severity of SK lesions. The results were
clear cut with animals receiving 2DG therapy showing significantly reduced SK lesion
severity (P<0.01) compared to PBS treated control animals (Fig. 5.7A). At day 15 pi,
around 12% of 2DG treated animals showed a lesion score of ≥ 3.0 compared to 50% in
control treated animals. At the termination of experiments on day 15 pi, pools of corneas
were collected and processed to identify their cellular composition by FACS analysis.
There was a reduction in the number of total CD4 T cells (~10 fold) infiltrating the corneas
of 2DG treated animals compared to control animals (Fig. 5.7B).
In parallel experiments of similar design, pools of corneas, DLN and spleen were
collected at 15 days pi from 2DG treated and control animals. Single cell suspensions
were stimulated in vitro with PMA and ionomycin to activate T cells and to record the
numbers of cells that were either IFN-γ producers or expressed the transcription factor
Foxp3. In the corneas, the number of CD4 T cells expressing IFN-γ was reduced
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approximately 8-fold in 2DG compared to untreated controls (Fig. 5.7C). In the DLN and
spleen, 2DG treatment resulted in reduced frequency and numbers of IFN-γ producing
CD4 T cells by about 2-fold. Although the frequency of Tregs in the DLN remained the
same, their number decreased significantly. This might be explained by reduced
inflammatory responses in treated animals. However, the number and frequency of Treg
in the spleens of 2DG treated animals remained unchanged (Fig. 5.7D).
Taken together, our results indicate that daily administration of 2DG starting at day
5 pi significantly diminished HSV-1 induced immunopathology along with a reduction in
effector T cell numbers in both the cornea and lymphoid organs, which could in part
contribute to reduced lesion severity.
Inhibiting of glucose utilization is lethal in the acute phase of HSV infection
Although, we found no evidence for hyperglycemia in the acute phase of HSV
infection, experiments were done to measure the effects of 2DG therapy at the time when
virus was actively replicating in the infected cornea. Animals were ocularly infected with
HSV-1 and were either treated daily with 2DG or PBS control, starting from the day of
infection. Under the infection conditions used, HSV infection of untreated animals failed
to cause detectable illness or signs of encephalitis. However, in the 2DG treated animals
around 40–50% (in three separate experiments) of 2DG treated animals developed
encephalitis and most had to be terminated by day 10 pi (Fig. 5.8A). By 8 days pi, affected
animals became lethargic, lost weight, showed ruffled fur and hunched appearance along
with signs of incoordination. Brains were collected from encephalitic 2DG treated animals,
to quantify levels of virus present. High virus levels of HSV were detectable (>4 log) in
brain homogenates in all animals that showed signs of encephalitis by day 10 pi (Fig.
5.8B). These animals also had detectable virus in ocular swabs at day 6 pi which is one
day beyond the time when virus is regularly present in untreated infected animals.
Additionally, levels of virus in ocular swabs were around tenfold higher than in untreated
mice (Fig. 5.8C). Of note, virus could not be detected in the brains at day 10 pi or in the
ocular tissue at day 6 pi in the control animals when infected with the same dose of virus
that caused encephalitis in the 2DG treated animals.
The reduction in antiviral inflammatory cells or mediators could explain the
increased viral burden in the animals treated with 2DG. To test this possibility, pools of
corneas were isolated from animals treated with 2DG or PBS controls at day 2 pi and
were evaluated for the abundance of macrophages and neutrophils. In addition, the
effector function of macrophages and neutrophils was measured by the expression of
pro-IL-1β using flow cytometry. While the number and frequency of pro-IL-1beta
expressing neutrophils remained unchanged with 2DG treatment (Supp. Fig S5.3), the
frequency and the number of pro-IL-1beta expressing macrophages in the cornea were
significantly reduced in 2DG treated animals (>3-fold) (Fig. 5.8D). This might account for
the failure to stop the spread of virus to the CNS. To assess if molecules involved in
antiviral responses were affected upon 2DG treatment, the expression of IFN-β, IL-1α
and TNF-α genes was determined in the corneas of both control and 2DG treated animals
at day 2pi. The results indicated no significant differences in the expression of these
molecules (Fig. 5.8E). Taken together, the increase in viral load in the cornea as well as
the failure to stop the spread of virus to the brain could be in part explained by reduction
in the innate effector function of macrophages which also require glucose for their function
as demonstrated in the next section.
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2DG reduces the macrophage activation in the presence of LPS
Macrophages are reported to play an important role in early stages of infection by
controlling HSV-1 replication and dissemination within the TG (31). Hence, effects of 2DG
on macrophage activation were measured using LPS stimulation of bone marrow derived
macrophages (BMDM). BMDM’s were stimulated with LPS in the presence or absence of
2DG (250µM) for 24 hours, followed by measurement of pro-IL-1β expression using flow
cytometry. The results indicated that stimulation of macrophages with LPS in the
presence of 2DG resulted in a 2-fold reduction in both the frequency of macrophages
expressing pro-IL-1β and expression of pro-IL-1β per cell basis (MFI) as compared to
LPS stimulation alone (Fig. 5.8F), supporting the previous reports (32). In conclusion,
inhibition of glucose utilization in macrophages inhibited the effector function of
macrophages, which might partially explain the high viral burden in the animals treated
with 2DG.
Discussion
Inflammatory reactions are likely to be prolonged and cause excessive tissue
damage when the activity of the principal orchestrators, usually either CD4 or CD8 T cells,
are not constrained by inhibitory molecules or by cells that function as regulators (3-6).
This is the state of affairs in the viral infection model we have used in this report wherein
CD4 T cell driven inflammatory reactions in the eye cause a chronic vision-impairing
lesion called stromal keratitis. The challenge with SK is to understand the events that
result in lesions and to find therapies that limit the severity and duration of ocular damage.
In the present report, we make the unexpected finding that blood glucose levels change
significantly during the course of infection. Whereas levels remained normal during the
early phase of infection when the virus was actively replicating in the cornea, they
increased around two fold during the time when inflammatory responses to the virus was
occurring. We could show that glucose levels influenced the extent of induction of the
inflammatory T cell subset in vitro that mainly drives SK lesions, but not regulatory T cells.
Additionally, if glucose utilization was limited in vivo as a consequence of therapy in the
inflammatory phase with the drug 2DG, lesions were diminished compared to untreated
infected controls. In addition, lesions in 2DG treated animals contained less proinflammatory effectors. Glucose metabolism also influenced the acute phase of infection
when replicating virus was present in the eye. Thus, therapy with 2DG to limit glucose
utilization caused mice to become susceptible to the lethal effects of HSV infection, with
virus spreading to the brain causing encephalitis. Taken together, our results indicate that
glucose metabolism changed during the course of HSV infection and that modulating
glucose levels can influence the outcome of infection, being detrimental or beneficial
according to the stage of viral pathogenesis.
Few reports have noted any changes in blood glucose levels in response to virus
infections except in experimental situations where infection can set off diabetes mellitus
(33, 34). Moreover, in the situation we described the mild hyperglycemia was absent
during the time when virus was actively replicating in the eye or elsewhere in the body.
Instead, the hyperglycemia only occurred during the inflammatory reaction to the virus,
which in the case of HSV ocular infection becomes a vision-impairing lesion referred to
as stromal keratitis. Moreover, SK is a local lesion in the eye accompanied by an
inflammatory response in the innervating trigeminal ganglion (35). Two relevant questions
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emerge. These are, what accounts for the mild hyperglycemia and does the event have
any consequence.
With regard to causation, the likeliest explanation could be the production of factors
from the inflammatory site that caused the liver to change its level of glucose production.
Candidates could include hormones, cytokines, or the release of lipid mediators from
inflammatory cells (36-39). In a complex model of sustained inflammation induced by
LPS, elevated blood glucose levels were observed and these were shown to be mediated
by TNF-α (25). This cytokine acted on the liver to suppress the expression of the bile acid
biosynthesis enzyme CYP7A1 that normally functions to influence glucose production by
acting on the hepatic mevalonate pathway, resulting in the inhibition of insulin signaling
(25). In our system, components of the virus with Toll-like receptor components would
likely not be involved since virus is absent in the blood stream especially at the time of
raised glucose levels. However, we did observe increased blood levels of some cytokines,
which included TNF-α, IL-6 and IFN-γ at day 4 pi, as well as an increase in the expression
of their receptors in the liver at day 8 pi. Moreover, we could show that animals with high
blood glucose levels had reduced levels of CYP7A1, which could mean that the
mechanism inducing the hyperglycemia was similar to that described by the Medzhitov
group (25). Additional experiments are underway to further evaluate potential
mechanisms that could cause raised glucose levels in our system, which differs from the
systemic model used by the Medzhitov group (25) in being only a local inflammatory
lesion in a small organ, the eye.
The second question about the hyperglycemia observed was the issue of its
potential relevance. Two lines of indirect evidence implied that the effect could have
relevance. Firstly, the change of glucose levels was about two-fold and whether this
change in glucose concentration was potentially meaningful was tested in an in vitro
induction system. In this system, the levels of CD4 Th1 effector cells generated from
naïve precursors were compared using media with controlled concentrations of glucose.
Curiously increasing the glucose concentrations from physiological levels to the levels
observed in infected animals significantly increased the number of effector Th1 cells
induced and had no effect on the levels of Treg induction, confirming the previous
observations (29, 30). This could mean that the 2-fold increase in blood glucose observed
in vivo might also serve to enhance Th1 differentiation, but further studies are needed to
verify this possibility.
Another indirect approach also indicated that the change in glucose levels might
help drive the inflammatory T cell response. Accordingly, when glucose utilization was
suppressed by treating mice with 2DG from the time of onset of ocular inflammation, SK
lesions were significantly reduced in magnitude. Along with this, the composition of the
cellular constituents involved in ocular lesions was markedly changed with reduced
numbers of CD4 effectors. Other reports have also shown that 2DG therapy (13, 14) can
control both auto-inflammatory lesions and GVHD inflammatory reactions. However, in
these inflammatory models, therapy with 2DG alone was usually non-effective and
additional antimetabolite therapies such as metformin (13) and 6-Diazo-5-oxo-Lnorleucine - DON (14) were needed to be used in combination to counteract lesions. The
fact that 2DG alone was highly effective therapy against SK, could relate to the less
chronic nature of the SK lesion since viral antigen does not persist to drive lesions.
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However, in the autoimmune disease and GvHD system the inflammatory cells in the
lesions are under consistent activation.
One issue yet to be explained was the discrepancy with the dose of 2DG used to
achieve therapeutic effects in vivo with that found to selectively inhibit inflammatory T cell
responses in vitro. However, we could not measure the absolute concentrations of 2DG
in the blood and DLN after in vivo administration, and it is well known that 2DG is rapidly
metabolized in vivo (40). Another perplexing issue was the observation that 2DG could
inhibit the effects of glucose in vitro when the later was far in excess of 2DG
concentrations. Some data from studies with yeast at least partially explain such
observations. Thus 2DG may inhibit the function of glucose transporters (41) and it is
conceivable that 2DG has additional off target effects not mediated by glucose itself (42).
These issues needs to be further clarified.
Another unexpected observation made in this report was the dramatic
consequence of 2DG therapy administered during the acute phase of ocular HSV
infection. In such experiments, many of the animals succumbed to lethal consequences
with virus spreading to and replicating in the CNS. Herpetic encephalitis (HSE) is a very
rare outcome of HSV infections in adult humans unless they are genetically compromised
in some immune component (43-46). In animal models for HSV infection, HSE is a more
common event and can occur at higher doses of infection, or with some virulent strains
of virus, or if animals have one of several defects of either innate or adaptive immunity
(22, 47-50). We strongly suspect that the lethal consequences of HSV infection in 2DG
treated mice could be the result of impaired function of a protective component of innate
immunity. So far we have minimal support for this idea, but could show that the number
of IL-1b expressing macrophages but not neutrophils was reduced at the site of infection
as a consequence of 2DG therapy. In addition, that animals can suffer lethal
consequences when treated with 2DG as was noted with another viral model (16).
Accordingly, with influenza, the lethal effects were attributed to the increased expression
of the ER-stress-induced transcription factor CHOP protein and its target gene Gadd34
in the hindbrains of mice treated with 2DG. The increased expression of CHOP protein
caused apoptosis of neurons leading to neuronal dysfunction and death. This
phenomenon has yet to be evaluated in our HSE model, but we suspect to find differences
since HSV replication occurs in the CNS and can be very destructive resulting from both
direct viral and immune-pathological destructive events (22, 48, 49).
This study is one of the first to evaluate the use of a drug which influences
metabolic processes used by different immune components responding to an infection.
We show that modulating the main energy generating component of inflammatory T cells
has value to modulate the extent of viral immune inflammatory lesions. In our system, the
effect was particularly effective since 2DG therapy inhibited pro-inflammatory T effectors
but had no direct effect on cells such as Treg that play a protective function in SK lesions.
Our results also indicate that using metabolic modifying drugs should be used with caution
especially during virus infections. Thus when 2DG therapy was used when the virus was
still replicating, the viral replication was enhanced and this could have had lethal
consequences as a result of virus spreading to the brain.
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Materials and Methods
Mice and Virus
Female C57BL/6 mice were purchased from Harlan Sprague-Dawley, Inc.
(Indianapolis, IN), BALB/c DO11.10 RAG2-/- mice were purchased from Taconic and kept
in pathogen free facility where food, water, bedding and instruments were autoclaved. All
the animals were housed in American Association of Laboratory Animal Care–approved
facilities at the University of Tennessee, Knoxville, Tennessee. All investigations followed
guidelines of the Institutional Animal Care and Use Committee, and adhered to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research. HSV-l RE strain
was used in all procedures. Virus was grown in Vero cell monolayers (American Type
Culture Collection, Manassas, VA), titrated, and stored in aliquots at −80°C until used.
HSV-1 ocular infection and clinical scoring
Corneal infections of C57BL/6 were conducted under deep anesthesia induced by
intra peritoneal (i.p) injection of tribromoethanol (Avertin). Mice were scarified on cornea
with a 27-gauge needle, and a 3 µl drop containing 1x104 PFU of HSV-1 was applied to
the eye. The eyes were examined on different days post infection (dpi) with a slit-lamp
biomicroscope (Kowa Company, Nagoya, Japan), and the clinical severity of keratitis of
individually scored mice was recorded as previously described (18). Briefly, the scoring
system was as follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal
opacity or scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and
corneal ulcer; +5, corneal rupture and necrotizing keratitis. The naïve-uninfected mice
were scarified on cornea with a 27-gauge needle without addition of any virus.
2DG Administration
The 2-deoxy-glucose (2DG) (sigma) was dissolved in PBS and administered
intraperitoneally at 500mg/kg twice a day starting from either day 0 or day 5 pi until day
14 after infection. The control group either received an equal volume of PBS or left
untreated. The dose of 2DG was based on preliminary dose titrations.
Blood Glucose and cytokine quantification
Blood glucose levels were measured from tail blood at different time point pi using
Bayer Contour glucose meter and compared to naïve un-infected animals. For Fasting
blood glucose levels animals were fasted for 16 hours in a clean cage with water followed
by measurement of glucose levels in the blood from tail. For cytokine measurements,
serum was isolated from the blood collected using Retro-orbital bleeding. At least 10
mouse cytokines were profiled using a multiplex platform and data were extracted based
on cytokine-specific standards by Eve Technologies (Calgary). Five independent serum
samples were used from mice at different time points pi. Serum from control uninfected
after 4 days of scarification was used as control.
Flow Cytometric Analysis
At day 15 pi, corneas were excised, pooled group-wise, and digested with liberase
(Roche Diagnostics Corporation, Indianapolis, IN) for 45 minutes at 37°C in a humidified
atmosphere of 5% CO2. After incubation, the corneas were disrupted by grinding with a
syringe plunger on a cell strainer and a single-cell suspension was made in complete
RPMI 1640 medium. The single-cell suspensions obtained from corneal samples were
stained for different cell surface molecules for fluorescence-activated cell sorting (FACS)
analyses. Draining cervical lymph nodes were obtained from mice sacrificed at 15 dpi and
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single cell suspensions were used. All steps were performed at 4°C. Briefly, cells were
stained with respective surface fluorochrome-labeled Abs in FACS buffer for 30 minutes,
then stained for intracellular Abs. Finally, the cells were washed three times with FACS
buffer and resuspended in 1% paraformaldehyde. The stained samples were acquired
with a FACS LSR II (BD Biosciences, San Jose, CA) and the data were analyzed using
FlowJo software (Tree Star, Inc., Ashland, OR). To determine the number of IFN-γ
producing T cells, intracellular cytokine staining was performed. In brief, corneal cells
were either stimulated with PMA (50ng) and Ionomycin (500ng) for 4 hours in the
presence of brefeldin A (10 μg/mL) in U-bottom 96-well plates (18). After this period,
Live/Dead staining was performed followed by cell surface and intracellular cytokine
staining using Foxp3 intracellular staining kit (ebioscience) in accordance with the
manufacturer's recommendations. Dead cells were gated out using Live/Dead staining.
Cells are mentioned as Th1 if they are CD4+ IFN-γ+ and Treg if they are CD4+ Foxp3+.
For 2-NBDG uptake in vivo, mice were injected i.v. with 100 μg 2-NBDG/mouse diluted
in PBS to either naïve C57BL/6 animals or day 15 pi animals. 15 min following the
injection cervical DLNs were collected and single cell suspensions were stained as
described above and analyzed using flow cytometry (19).
Reagents and antibodies.
CD4 (RM4-5), CD45 (53-6.7), CD11b (M1/70), Ly6G (1A8), F4/80 (BM8), IFN-γ
(XMG1.2), CD25 (PC61), CD44 (IM7), Foxp3 (FJK-16S), anti-CD3 (145-2C11), antiCD28 (37.51), GolgiPlug (brefeldin A) and anti-pro-IL-1 beta (NJTEN3) from either
ebiosciences or BD biosciences. Anti-Mouse phospho-S6 Ribosomal (D57.2.2E) from
Cell signaling and hGlut1 from R&D. Phorbol myristate acetate (PMA) and Ionomycin
from sigma. Live/Dead staining kit and 2-NBDG from Life Technologies. Recombinant IL2, IL-12, IL-6 and TGF-b from R&D systems. Glucose free RPMI media (life technologies)
was prepared using dialyzed FBS and glucose (sigma) was added at concentrations (0.120mM).
Quantitative PCR (qPCR)
At day 2 post ocular infection with HSV-1, the corneas were isolated and two
corneas were pooled per sample/group. Naïve CD4 T cells or cells activated in vitro with
or without 2DG were taken at least 100,000 cells/sample. Total RNA from corneal and
isolated T cell populations was isolated using mirVana miRNA isolation kit (Ambion).
Liver (£30mg) was isolated at day 0, day 4, day 8 and day 15 pi and total RNA was
extracted using RNeasy® Fibrous Tissue Mini Kit (Qiagen) as per manufacturer's
recommendation. cDNA was made with 500ng of RNA (corneal samples) and entire RNA
(isolated T cells) by using oligo(dT) primer and ImProm-II Reverse Transcription system
(Promega). Taqman gene expression assays for Glut-1 (SLC2A1), HK1 (Hexokinase 1),
HK2 (Hexokinase 2), Il6ra, Tnfrsf1b, Stat3, Ifngr1, Cyp7a1, Rhoc, Il1a, Ifnb, Tnfa and Il1b
were purchased from Applied biosystems and quantified using 7500 Fast Real-Time PCR
system (Applied Biosystems). The expression levels of different molecules were
normalized to β-actin using ΔCt calculation. Relative expression between control and
experimental groups was calculated using the 2-ΔΔCt X 1000 formula.
Purification of CD4+ T cells.
CD4+ T cells (total or naïve) were purified from single cell suspension of pooled
draining cervical lymph nodes (DLNs) and spleen from HSV-infected or naïve C57BL/6
mice using manufacturer's instructions (Miltenyi Biotec).
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In vitro Treg and Th1 differentiation
For glycolysis measurements using seahorse extracellular flux analyzer, naïve
CD4 T cells were used in Treg and Th1 differentiation. For experiments evaluating the
effects of glucose concentrations or effects of 2DG, splenocytes from naïve DO11.10
RAG2 -/- mice were used as a precursor population for the induction of Treg and Th1
cells as previously described (18). Briefly, 1×106 splenocytes after RBC lysis and several
washings or 1 million naïve CD4 T cells were cultured in 1ml glucose sufficient RPMI
media or glucose free-RPMI media (dialyzed serum) containing rIL-2 (100 U/ml) and
TGFβ (1-5ng/ml) in the presence or absence of various concentrations of Glucose (0.520mM) with plate bound anti-CD3/CD28 Ab (1 µg/ml) for 5 days at 37°C in a 5% CO2
incubator. After 5 days, samples were characterized for Foxp3 intracellular staining
(ebioscience staining kit) analyzed by flow cytometry. For Th1 differentiation, cells were
cultured in the presence of recombinant mouse IL-12 (5-10ng/ml) and anti-IL-4 (10 µg/ml).
After 5-days samples were re-stimulated with PMA/Ionomycin and analyzed for the
production of IFN-γ by intracellular cytokine staining kit (BD biosciences) using flow
cytometer. 250µM-2DG dose was chosen based on the preliminary dose response
experiments and previous reports (20).
OCR and ECAR measurement
OCR and ECAR values were measured using a Seahorse XF24 metabolic
analyzer. Briefly, total CD4 T cells were purified from either infected or naïve female B6
mice or Treg/Th1 cells were differentiated and expanded from naïve CD4 T cells in vitro
as described above. 1×106 cells per well were plated on XF24 plate (Seahorse
Bioscience) pre-coated with 0.5 mg/ml poly-D lysine (Sigma). Cells were maintained in
RPMI media (corning) supplemented with 1mM sodium pyruvate (Sigma) and 10% FBS.
Before analyzing, cells were spun down and 530ul of XF media (with or without glucose)
was added to each well, followed by incubation for 30 minutes in CO2-free incubator at
37°C. Seahorse analyzer was then run per manufacture’s protocol with oligomycin (1uM),
FCCP (1uM), and antimycin A (1uM) injected through ports A, B, and C respectively for
mitochondrial stress test and glucose (10mM), oligomycin (1uM) and 2DG(10mM) for
glycolysis stress test (21).
Viral Plaque Assay
Virus titers were measured in the brain and corneas of HSV infected mice as
described previously by others (22). Virus titers in all samples were measured using
standard plaque assay as described previously (22, 23).
Cell Culture
Female C57BL/6 mice were used at 8–16 weeks of age. BMDMs were generated
as described previously (24) and grown in RPMI 1640 with 10% FCS. The media was
supplemented with macrophage-colony-stimulating factor (10 ng/ml). Cells were 98%
pure for macrophages (CD45+ CD11b+ F4/80+) and plated out on day 10 at 100,000
cells/well and stimulated with LPS (20ng/ml) for 24 hours.
Statistical Analysis
Statistical significance was determined by either Student's t-test (comparing two
groups) or One-way ANOVA (comparing three or more groups). A P-value of <0.05 was
regarded as a significant difference between groups: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA) was used for statistical
analysis.
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Figure 5.1. Blood glucose levels increase upon infection with HSV-1.
C57BL/6 animals were either infected with 1 x 104 PFU of HSV-RE or left alone. (A,B)
Blood glucose levels were measured at time points indicated post infection. (A) Line graph
showing kinetics of blood glucose levels (fed state) in control, day 4, day 8 and day 15 pi.
(B) Histogram showing fed state and fasting state blood glucose levels at day 15 pi. (C)
Line graph showing changes in serum cytokine levels at different time points pi. (D) Line
graph showing changes in gene expression in the liver at different time points pi. (E)
Histogram representing the expression of CYP7A1 and RHOC in liver of naïve and day 8
pi animals. Data represents the mean ± SEM of more than 8 independent experiments
for A, B (n = 5-8 mice/group) and 2 independent experiments for C-E (n=4-5 mice/group).
Data were analyzed with One-way ANOVA for A, C & D compared to the control or
student’s t-test for B & E. P≤ 0.0001 (****), P≤0.001(***), P≤0.01(**), P≤0.05(*).
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Figure 5.2. Glucose uptake in CD4 T cells increases at day 15 post infection.
(A-E) C57BL/6 animals were either infected with 1 x 104 PFU of HSV-RE or left
uninfected. (A, B) At day 15 pi animals showing SK lesions and naïve un-infected animals
were administered with 2-NBDG (i.v) and glucose uptake by CD4 T cells was measured
in DLNs. (A) Representative FACS plots and histogram (MFI) showing the 2-NBDG
uptake by CD4 T cell from day 15 pi or naïve animals. For fluorescence minus one (FMO),
mice were not injected with 2-NBDG. Cells were gated on live CD4+ T cells (B) Histogram
number of CD4 T cells in DLNs with 2-NBDG uptake. (C) DLN from naïve and day 15 pi
were stained with CD4 and Glut1 or Isotype. Representative FACS plots with Isotype
control and Histogram (MFI) showing GLUT-1 expression by CD4 T cells. Cells were
gated on live CD4+ T cells (D, E) Total CD4 T cells were purified from naïve and day 15
pi mice showing SK lesions and equal number of cells were used of extracellular flux
analysis (D) Line graph showing changes in Extracellular acidification rates (ECAR) by
CD4 T cells following addition of glucose, oligomycin and 2DG and Histograms showing
basal glycolysis, glycolytic capacity (E) Histogram showing the ratio of OCR to ECAR.
Data represents the mean ± SEM of more than 3 independent experiments for A-C (n=35 mice/group) and 2 independent experiments for D & E (n=5 replicates/group). All the
data were analyzed with student’s t test. P≤ 0.0001 (****), P≤0.01(**), P≤0.05(*)
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Figure 5.3. CD4 T cells from infected and naïve animals have different glucose
metabolism.
(A) C57BL/6 animals were infected with 1 x 104 PFU of HSV-RE and at day 15 pi animals
showing SK lesions were administered with 2-NBDG (i.v) and glucose uptake by different
CD4 T cell subsets was measured in DLNs. Representative FACS plots and histogram
(MFI) showing the 2-NBDG uptake in Live cells of Treg (CD4+CD25+) cells and Teff
(CD4+CD25-) cells as measured in DLNs at day15 pi. (B) DLNs at day 15 pi were
stimulated PMA/Ionomycin followed by ICS assay. Representative FACS with Isotype
control and histogram (MFI) of S6P in Treg (CD4+ Foxp3+) and Th1 (CD4+ IFN-γ+) cells.
Dead cells were gated out using Live/Dead staining. Data represents the mean ± SEM of
more than 3 independent experiments (n=3-5 mice/group) (C) Naive CD4 T cells purified
from C57BL/6 mice were cultured in either Treg or Th1 differentiating conditions. After 5
days, equal number of cells were used of extracellular flux analysis. Line graph showing
changes in extracellular acidification rates (ECAR) by CD4 T cells following addition of
glucose, oligomycin and 2DG and Histograms showing basal ECAR and glycolytic
capacity. Data represent the mean values ± SEM of two independent experiments of n = 4.
The level of significance was determined by Student’s t test (unpaired). P≤ 0.0001 (****)
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Figure 5.4. Increasing glucose levels increases Th1 but not Treg differentiation.
Splenocytes from DO11.10 RAG2−/− mice were cultured (1 million cells) in the presence
of 1 μg/ml of anti-CD3/CD28 antibody with either 100 U/ml of recombinant IL-2, 1ng/ml
TGF-β (Treg differentiating conditions) or IL-12 (5ng/ml), anti-IL-4 (10 μg/ml) (Th1
differentiating conditions) with increasing concentrations of glucose(0.5mM-20mM) in
glucose free conditions (A) Histogram showing frequency of IFN-γ during Th1
differentiation or (B) Foxp3 expression during Treg differentiation with increasing glucose
concentrations (C) Representative FACS plots and histogram showing IFN-γ expression
under Th1 differentiating conditions in the presence of glucose concentrations (5mM and
10mM). Cells were gated on live CD4+ T cells. Data represents means ± SEM from three
independent experiments (n = 3/group). The level of significance was determined by
Student’s t test (unpaired) P≤0.05(*).

122

Figure 5.5. 2DG inhibits the metabolic reprogramming of CD4 T cells following
activation.
(A) Naive CD4 T cells purified from C57BL/6 mice were cultured (500,000 cells/well) with
100U/ml IL-2, 1µg/ml anti-CD3/CD28 and in the presence or absence of 250µM 2DG for
3 days followed by extracellular flux analysis. Line graph showing changes in Extracellular
acidification rates (ECAR) by CD4 T cells following addition of oligomycin and Histograms
showing basal ECAR levels. (B) Naive CD4 T cells purified from C57BL/6 mice were
cultured (100,000 cells/well) with 1µg/ml anti-CD3/CD28 and in the presence or absence
of 250µM 2DG for 24 hours followed by gene expression analysis by QRT-PCR compared
to beta-actin. Histogram representing expression of genes involved in glucose
metabolism such as HK1, HK2 and Glut1 in naïve, activated and Activated in the presence
of 2DG (2DG). (C) Naïve CD4 T cells were cultured (100,000 cells/well) with 1µg/ml antiCD3/CD28 in the presence or absence of 250µM 2DG for 24 hours followed by
measurement of Phosphorylation of S6 using flow cytometry. Representative FACS plots
and histogram (MFI of S6P) of live CD4 T cells. Data represents means ± SEM from two
independent experiments (n = 3/group) and the level of significance was determined by
Student’s t test (unpaired) for A & C and One-way ANOVA for B. P≤ 0.0001 (****),
P≤0.001(***), P≤0.01(**), P≤0.05(*).
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Figure 5.6. Effect of 2DG treatment on glycolysis and T cell differentiation.
Splenocytes from DO11.10 RAG2−/− mice were cultured (1 million cells) in the presence
of 1 μg/ml of anti-CD3/CD28 antibody with either 100 U/ml of recombinant IL-2, 5ng/ml
TGF-β (Treg differentiating conditions) or IL-12 (5ng/ml), anti-IL-4 (10 μg/ml) (Th1
differentiating conditions) with or without 2DG (250µM). After 5 days of culture, cells were
analyzed for the expression of IFN-g and Foxp3 on CD4 T cells. Representative FACS
plots and histogram showing the frequency of Th1 and Treg. Cells were gated on live
CD4+ Foxp3+ T cells (Treg) and live CD4+ IFN-g + T cells (Th1). Data represents means
± SEMs of three independent experiments with n=3/group. Statistical significance was
calculated by Student’s t test (unpaired) P≤ 0.0001 (****).
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Figure 5.7. Therapeutic administration of 2DG diminishes SK severity.
C57BL/6 animals infected with 1 x 104 PFU of HSV-RE were given either 2DG or PBS
from day 5 pi to day 14 pi. The disease progression was analyzed in a blinded manner
using a scale described in materials and methods. (A) Individual eye scores of SK lesion
severity on day 15 pi. (B) Representative histogram showing the number of total CD4+ T
cells infiltrating the cornea at day 15 p.i (C) Pool of corneas were stimulated with
PMA/Ionomycin, representative histogram showing the number of Th1 (Live CD4+ IFNg) cells in the cornea at day 15 pi. (D) DLN and Spleen were stimulated with
PMA/Ionomycin, representative FACS plots and histogram showing frequency and
number of Treg (live CD4+ Foxp3+) and Th1 (live CD4+ IFN-g). (E) Histogram
representing Treg to Th1 ratio in the spleen at day15 pi. Data represents the mean ± SEM
of more than 3 independent experiments (n=3-10 mice/group). All the data were analyzed
with student’s t test. P≤ 0.0001 (****), P≤0.001(***), P≤0.01(**).
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Figure 5.8. 2DG administration during early HSV infection is lethal.
C57BL/6 animals infected with 1 x 104 PFU of HSV-RE were given either 2DG or PBS
from day 0 pi to day 15 pi. (A) Survival of 2DG and control treated was established over
15 days. (B) Brains were harvested from 2DG treated and control mice at day 10 pi and
homogenized, centrifuged, and the supernatants were tested for virus titers using plaque
assay. (C) The presence of virus in the cornea was measured at day 6 pi by swabbing
the HSV infected eye with a sterile swab and assaying for the virus by plaque assay. (D)
Corneas were isolated at day 2 pi from control and 2DG treated animals and inflammatory
macrophages (CD45+ CD11b+ F4/80+ Pro-IL-1b+) were identified using flow cytometry.
Representative FACS plots and histogram showing MFI of pro-IL-1b, frequency and
number of inflammatory macrophages in corneas of 2DG treated and control animals at
day 2 pi. (E) Corneas were isolated from control and 2DG treated animals at day 2 pi and
RNA was isolated followed by gene expression analysis by QRT-PCR. Histogram
representing the gene expression of IL-1α, IFN-β and TNF-α. (F) Bone marrow derived
macrophages (BMDM) were differentiated from naïve bone marrow progenitor cells (as
described in materials and methods). BMDMs were stimulated with LPS (20ng/ml) in the
presence or absence of 2DG (250µM) for 24 hours. Representative FACS plots and
histogram showing frequency of BMDM expressing Pro-IL-1b (CD45+ CD11b+ F4/80+
Pro-IL-1b+). Data represents mean values ± SEM (n = 4–8 mice/group) for A-F.
Experiments were repeated at least three times. The level of significance was determined
by Student’s t test (unpaired). P≤ 0.0001 (****), P≤0.01(**), P≤0.05(*).
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CHAPTER 6
HEXOKINASE II MAY BE DISPENSABLE FOR CD4 T CELL RESPONSES AGAINST
A VIRUS INFECTION.
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Abstract
Activation of CD4 T cells leads to their metabolic reprogramming which includes
enhanced glycolysis, catalyzed through hexokinase enzymes. Studies in some systems
indicate that the HK2 isoform is the most up regulated isoform in activated T cells and in
this report the relevance of this finding is evaluated in an infectious disease model.
Genetic ablation of HK2 was achieved in only T cells and the outcome was evaluated by
measures of T cell function. Our results show that CD4 T cells from both HK2 depleted
and WT animals displayed similar responses to in vitro stimulation and yielded similar
levels of Th1, Treg or Th17 subsets when differentiated in vitro. A modest increase in the
levels of proliferation was observed in CD4 T cells lacking HK2. Deletion of HK2 led to
enhanced levels of HK1 indicative of a compensatory mechanism. Finally, CD4 T cell
mediated immuno-inflammatory responses to a virus infection were similar between WT
and HK2 KO animals. The observations that the expression of HK2 appears non-essential
for CD4 T cell responses against virus infections is of interest since it suggests that
targeting HK2 for cancer therapy may not have untoward effects on CD4 T cell mediated
immune response against virus infections.
Introduction
Recently it has become evident that cells of the immune system show distinct
differences in the metabolic pathways they use [1,2]. This opens up the prospect of
manipulating metabolism to shape the nature of immunity. A well-studied metabolic
difference between cell types has been the glucose metabolic pathway by which T cells
mainly derive their energy [3]. Thus, some subsets of T cells generate their ATP mainly
by oxidative glycolysis, whereas others mainly use mitochondrial respiration [4]. With
regard to oxidative glycolysis, the process is critically influenced by enzymes which
include at least 4 hexokinase isoforms to generate glucose 6-phosphate from glucose
(the first rate limiting step of glycolysis). Of the 4 isoforms, mainly two, HK1 and HK2, are
expressed by T cells [5,6]. In addition, when T cells are activated, as occurs in some
autoimmune diseases, the fold change in expression of HK2 far exceeds that of HK1
when compared to resting cells [6,7]. Moreover, HK2 has two tandem catalytically active
domains whereas HK1 has only one catalytically active domain [8]. Taken together this
could mean that HK2 may be more relevant than HK1 for T cell function, although this
possibility has not been substantiated, particularly in vivo.
In an attempt to evaluate if HK2 is more relevant than HK1 in activated T cells, we
bred appropriate mice strains that would delete HK2 specifically in T cells from the onset
of the development. We could readily show that overall CD4 and CD8 T cell numbers
were unaffected by HK2 deletion and that the function of CD4 T cells in vivo in a virus
immunopathology model was basically unchanged. Nevertheless, some modest
differences in responsiveness were shown in vitro such as proliferative responses to T
cell receptor stimulation. However, overall the absence of HK2 had no major effect on
CD4 T cell functions. Moreover, expression of HK1 was upregulated in the absence of
HK2 which was likely compensating for HK2 deletion. The systemic deletion of HK2 in
adult mice does not elicit adverse physiological consequences but inhibits tumor
development in mouse models of cancers, where HK2 is highly expressed compared to
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normal cells [9]. The results presented here suggest that the systemic deletion of HK2 will
not interfere with the immune response towards such tumor cells.
Results and discussion
As mentioned, previous studies showed that in activated T cells HK2 is upregulated more than other hexokinases which could mean it is more relevant for T cell
function. We confirmed this observation using real time PCR showing that upon TCR
activation of CD4 T cells, the expression of HK2 was up-regulated 25-40 fold compared
to naïve cells, whereas HK1 was up-regulated only about 3 fold (Fig 6.1B). However, the
absolute expression level of HK1 in activated cells was still higher than HK2. The other
isoforms HK3 and HK4 were barely detectable either in resting or activated T cells. Of
note, resting T cells showed only minimal levels of HK2, whereas, the expression of HK1
was readily detectable (Fig. 6.1A).
To ascertain if the dramatic up regulation of HK2 in activated T cells had
physiological relevance compared to other hexokinases, mice were bred to delete the
expression of the HK2 isoform specifically in T cells. The deletion was achieved by
breeding CD4 Cre mice to HK2 flox/flox and homozygous pups (HK2 KO) were raised to
maturity to evaluate and compare T cell responses to HK2 flox/flox animals (WT). The
deletion of HK2 was confirmed by the absence of HK2 expression in enriched CD4 T cell
populations after TCR stimulation in vitro as measured by RT-PCR (Fig. 6.1C).
Interestingly, deletion of HK2 also resulted in elevated levels of HK1 mRNA (~3 fold) in
resting cells. Additionally, the expression of HK3 also increased although levels were still
minimal (Fig. 6.1C). These results were unexpected, since deletion of HK2 in several
tumors did not result in elevated HK1 [9] indicating that T cells might depend less on HK2
and have compensatory mechanisms distinct from cancer cells.
Experiments were also done to measure the impact of HK2 deletion in T cell
development and function. HK2 deletion showed no major effect on CD4 T cell
development, as the number of single positive (SP) CD4 and Treg in the HK2 KO and WT
mice in both the thymus and spleen showed no statistically significant differences (Fig.
6.2A, C). The number of SP CD8 T cells was only minimally increased in the thymus and
not in the spleen. However, no significant difference in expression of TCR beta on SP
CD8 T cell thymocytes was observed (Fig. 6.2B). Hence, HK2 might be dispensable for
CD4 T cell development. It remains to be known why HK2 deletion has resulted in minimal
changes in CD8 T cell numbers in the thymus. Curiously the deletion of HK2 in some
other tissue does have consequences to their development. These tissues include heart,
muscle and adipose tissue [10,11].
Additional experiments were done to measure the functional and metabolic
consequences of HK2 deletion. Isolated CD4 T cells from KO and WT were TCR
stimulated in vitro and responses were compared. Some modest differences were
observed. Thus KO CD4 T cells generated approximately 1.5 fold greater proliferative
responses to TCR stimulation compared to WT T cells (Fig. 6.3A). However, the response
to activation measured by induction of phosphorylated AKT and the phosphorylation of
S6 kinase (indicative of mTOR activity) revealed no significant differences between WT
and KO cells (Fig. 6.3B, C). In addition, no significant differences were observed when
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cells from KO and WT were differentiated in vitro into Th1, Th17 and Treg populations
(Fig. 6.3D).
The explanation for the higher proliferative response in KO CD4 T cells was not
resolved but it could relate to suppressive effects that HK2 may have on mitochondrial
function. Thus, activated T cells from HK2 KO animals displayed around 2-fold higher
mitochondrial ROS (mROS) production without affecting cellular ROS levels (Fig. 6.4A,
B). Also, the increased mitochondrial ROS is associated with only moderate increase in
mitochondrial membrane potential as measured my MitoTracker Red CM-H2Xros with
little or no change in mitochondrial mass as measured by MitoTracker green (Fig 6.4C).
This is in line with the observation in some cell lines and neurons that HK2 binds to
mitochondria via voltage-dependent anion channels and control mitochondrial function by
inhibiting mROS generation [12,13]. Moreover, T cells that lack the ability to generate
mROS display reduced proliferation and activation [14]. In conclusion, deletion of HK2
induced mROS which might have led to a modest increase in the proliferation of CD4 T
cells. Since intact mitochondrial function is critical for effective memory T cell responses
[15], the effects of HK2 deletion on established memory T cells needs to be evaluated
using an inducible Cre system in adult mice with existing memory responses.
With regard to metabolism, activated CD4 T cells from WT and HK2 KO mice
showed similar levels of glycolysis and glycolytic capacity as measured by extracellular
flux analysis (Fig. 6.4D). These data likely mean that the absence of HK2 was being
compensated by other hexokinase isoforms. This finding was in contrast to the findings
in some cancer cells where, deletion of HK2 did result in reduced proliferation and
glycolysis [9,16]. Although, the mechanistic reasons for such disparities were not
evaluated in this report, we speculate that HK1, whose levels were elevated in the
absence of HK2 could compensate for the function that HK2 was performing in activating
CD4 T cells.
Finally, the effects of HK2 deletion on the outcome of CD4 T cell function in vivo
were assessed. Age and sex matched WT and HK2 KO animals were ocularly infected
with HSV-1 and the severity of lesions of stromal keratitis were compared. The results
revealed no significant differences in responses in the two groups. Thus lesions were of
comparable severity and the number of T cells present in lesions was basically the same
including the proportion of infiltrating Th1 and Treg. (Fig. 6.5A-C). Similar to the in vitro
data, the number and frequency of Treg and IFN-γ producing CD4 T cells in the DLN
were not significantly different, despite some increased proliferation of both of CD4 T cell
subsets (effectors and regulators) as measured by Ki-67 staining (Fig. 6.5D, E).
Conceivably, the disparity between increased proliferation, yet similar inflammatory
reactions could mean that some of the proliferating T cells of HK2 KO animals were
undergoing apoptosis, an issue that is being further evaluated. Of note, the frequency
and the number of CD44 and CD62L expressing CD4 T cells in the DLN at day 15 pi
remained unchanged (Fig. 6.6A). To measure if HK2 deletion had an effect on HSV-1
specific CD8 T cell responses (a CD4 helper cell dependent response)[17], a wellestablished footpad immunization model was used [18]. Cell suspensions of draining
lymph nodes were stimulated with a gB peptide, which is the immuno-dominant peptide
recognized by B6 mice [19]. The results, measured by the ICS assay for HSV specific
IFN-gamma producing CD8 T cells, revealed no significant differences in responses by
WT and HK2 KO animals (Fig. 6.6B). In addition since HK2 deletion was done using CD4
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Cre mice, CD8 T cells and some subsets of APC would also be deficient of HK2. However,
such potential effect did not affect the outcome of a virus specific CD8 T cell response.
Concluding Remarks
Our finding that HK2 function can be dispensed with for CD4 T cell function could
come as welcome news to the cancer therapy field. Thus for some cancers targeting HK2
with inhibitory drugs is an objective [20]. Our results would argue that such therapy may
not be accompanied by negative effects on CD4 T cell functions which are necessary for
anti-microbial protection and in some cases for anti-tumor effects as well.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health and
guidelines of the Institutional Animal Care and Use Committee, and adhered to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research. The protocol was
approved by the University of Tennessee Animal Care and Use committee (IACUC)
(protocol approval numbers 1244). All procedures were performed under
Tribromoethanol (Avertin) anesthesia, and all efforts were made to minimize suffering.
Mice and Virus
Female C57BL/6 mice were purchased from Harlan Sprague-Dawley, Inc.
(Indianapolis, IN), CD4 Cre mice (C57BL/6 background) mice were purchased from
Jackson laboratories and HK2 flox/flox (C57BL/6 background) were a kind gift from Dr.
Nissim Hay (University of Illinois, Chicago)[9]. CD4 Cre mice were bred to HK2 flox/flox
mice and the pups that were positive for Cre and homozygous for HK2flox/flox (confirmed
by genotyping) were used as HK2 KO and mice that were homozygous for only
HK2flox/flox and negative for Cre were used as WT controls for all the experiments. HSVl RE strain was used in all procedures.
HSV-1 ocular infection and clinical scoring
Corneal infections of 5-6 week old mice were conducted as previously described
[21]. Briefly, mice were anesthetized by intra peritoneal (i.p) injection of Tribromoethanol
(Avertin). Mice were scarified on cornea with a 27-gauge needle, and a 3 µl drop
containing 1x104 PFU of HSV in 3μl volume was applied to the eye. The eyes were
examined on different days post infection (dpi) with a slit-lamp biomicroscope (Kowa
Company, Nagoya, Japan), and the clinical severity of keratitis of individually scored mice
was recorded as previously described [21].
Footpad Infection with HSV-1
Footpad infections on WT and HK2 KO (5-6 week old) animals were done as
previously described [22]. Briefly, mice were deep anesthetized as described above and
30μl of 4x105 PFU HSV-1 KOS was subcutaneously injected in each hind footpad. Mice
were sacrificed 4 days post infection and the draining popliteal lymph nodes for isolated
for ICS assay.
Flow Cytometric Analysis
The single-cell suspensions obtained from corneal samples, draining cervical
lymph nodes, Thymus and Spleen were stained for different cell surface molecules for
fluorescence-activated cell sorting (FACS) analyses as described previously [23].
Proliferation assays were performed using Cell Trace Violet (CTV) labelled naïve CD4 T
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cells (2 X 105 cells/well) from WT and HK2 KO stimulated with plate bound anti-CD3/CD28
Ab (1 µg/ml or 5 µg/ml) for 3 days. Naïve CD4 T cells (2 X 105 cells/well) were stimulated
for 72 hours in the presence of IL-2 and later labelled with MitoSOX (5µM), CM-H2DCFDA
(1.25µM), MitoTracker Red CM-H2Xros (100nM) or MitoTracker green (100nM) and
incubated for 30 min followed by live/dead staining and cytometric measurement. For
HSV-1 specific CD8 T cells responses, 1x106 single cell suspensions popliteal lymph
node were stimulated in a 96 well U-bottom plate. Cell were either left unstimulated or
stimulated with SSIEFARL peptide (1μg/ml), for 5 h at 37°C in 5% CO2 in the presence
of Brefeldin A (10μg/ml) followed by ICS assay.
Reagents and antibodies.
CD4 (RM4-5), IFN-γ (XMG1.2), CD25 (PC61, 7D4), CD44 (IM7), Annexin-V,
Foxp3 (FJK-16S), anti-CD3 (145-2C11), anti-CD28 (37.51), GolgiPlug (Brefeldin A) from
either ebiosciences or BD biosciences. P-AKT (S473-SDRNR) from ebiosciences and PS6 (S235/236-D57.2.2E) from cell signaling. Phorbol 12-myristate 13-acetate (PMA) and
Ionomycin from sigma. Cell Trace Violet, Live/Dead Fixable Violet Dead Cell Stain Kit,
MitoTracker Red CM-H2Xros, MitoTracker Green, MitoSOX and CM-H2DCFDA from Life
Technologies. Recombinant IL-2, IL-12, IL-6 and TGF-b from R&D systems. Glucose free
RPMI media (life technologies) was prepared using dialyzed FBS. HSV-1 gB498–505
peptide (SSIEFARL) was from Genscript.
Quantitative PCR (qPCR)
Taqman gene expression assays for HK1 (Hexokinase 1), HK2 (Hexokinase 2),
HK3 (Hexokinase 3) and HK4 (Hexokinase 4) from Applied Biosystems were performed
on using 7500 Fast Real-Time PCR system (Applied Biosystems) as described previously
(18).
Purification of CD4+ T cells.
Naïve CD4+ T cells were purified using a mouse naïve CD4+ T cell isolation kit
(Miltenyi Biotec, Auburn, CA). The purity was achieved at least to an extent of 90%.
In vitro Treg, Th17 and Th1 differentiation assays
Naïve CD4 T cells were isolated from splenocytes of WT and HK2 KO mice as
described above. Th1, Th17 and Treg cells were differentiated as described previously
with some modifications [21,24]. Briefly, 1×106 cells were cultured with plate bound antiCD3/CD28 Ab (1 µg/ml) containing either Treg differentiating conditions: rIL-2 (100 U/ml)
and TGFβ (5ng/ml) or Th1 differentiating conditions: IL-12 (5ng/ml) and anti-IL-4 (10
µg/ml) or Th17 differentiating conditions: IL-6 (25ng/ml) and TGFβ (5ng/ml) with anti-IL-4
(10 µg/ml) and anti-IFN-γ (10 µg/ml) for 5 days at 37°C in a 5% CO2 incubator. After 5
days, samples were re-stimulated with PMA and Ionomycin to measure Foxp3
expressing, IFN-γ and IL-17A producing CD4 T cells using flow cytometry.
OCR and ECAR measurement
Naïve CD4 T cells from WT and HK2 KO were activated for 3 days in the presence
of anti-CD3/CD28 (1 µg/ml). 1×106 cells per well were plated on XF24 plate (Seahorse
Bioscience). ECAR values were measured for glycolysis stress test using a Seahorse
XF24 metabolic analyzer as previously described [23].
Statistical Analysis
Statistical significance was determined by Student's t-test. A P-value of <0.05 was
regarded as a significant difference between groups: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
GraphPad Prism software (GraphPad Software) was used for statistical analysis.
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Figure 6.1. HK2 is up regulated upon CD4 T cell activation.
(A) Naive CD4 T cells purified from C57BL/6 mice were cultured (100,000 cells/well) with
1µg/ml anti-CD3/CD28 for 24 hours followed by gene expression analysis by QRT-PCR
compared to beta-actin. Bar graph representing expression of HK1, HK2 and HK3 in
naïve and activated cells. (B) Bar graph of fold change in gene expression in activated
cells compared to naïve cells (C) Naïve CD4 T cells were purified from WT and HK2 KO
mice were activated anti-CD3/CD28 for 24 hours. Bar graph representing gene
expression of HK, HK2 and HK3 compared to beta-actin. Data represents means ± SEM
from two independent experiments (n = 3/group) P≤ 0.0001 (****), P≤0.001(***),P≤0.05(*).
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Figure 6.2. T cell specific HK2 deletion is dispensable for T cell development.
Thymus and spleens from 5-6 week old naïve WT and HK2 KO animals were isolated.
(A) Representative FACS plots and bar graph showing the frequency and number of total
thymocytes, CD4+ CD8- T cells, CD4- CD8+ T cells, CD4+CD8+ T cells and CD4+CD8Foxp3+ Treg cells in Thymus. (B) Representative FACS plot showing the TCR-beta
expression gated on CD8+ CD4- T cells in the thymus. (C) Representative FACS plots
and histogram showing the frequency and number of CD4+ CD8- T cells, CD4- CD8+ T
cells and CD4+CD8- Foxp3+ Treg cells in Spleen. Gated on live cells. Data represents
the mean ± SEM of more than 2 independent experiments (n=3 mice/group). P≤0.001(*)
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Figure 6.3. HK2 deletion increased CD4 T cell proliferation.
(A-C) Naïve CD4 T cells from WT and HK2 KO mice were CTV labelled and activated for
72 hours. (A) Representative FACS plots and bar graph indicating CTV dilution (as a
measure of proliferation) gated on live CD4 T cells. Representative FACS plots and
Histogram representing the levels of (B) phosphorylated–AKT and (C) PhosphorylatedS6 kinase. (D) Naïve CD4 T cells from WT and HK2 KO mice were cultured in the
presence Treg or Th1 or Th17 differentiating conditions for 5 days followed by restimulation for 4 hours with PMA/Ionomycin. Histogram showing frequency of Th17, Th1
cells and Treg cells. All the measurements were made on live CD4 T cells. Data
represents means ± SEM from two independent experiments (n = 3/group) P≤0.001(***)
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Figure 6.4. HK2 deletion in T cells had minimal effect on T cell glycolysis and T cell
differentiation in vitro.
(A-C) Naïve CD4 T cells from WT and HK2 KO mice were activated for 72 hours. (A)
mROS (MitoSOX high) producing cells, (B) Cellular ROS (CM-H2DCFDA) producing cells
and (C) Mitrochondrial membrane potential (MitoTracker Red CM-H2Xros) and
mitochondrial mass (MitoTracker Green). Data represents means ± SEM from three
independent experiments (n = 3/group). FMO, fluorescence minus one. (D) Naïve CD4 T
cells were purified from WT and HK2 KO mice and cultured with 1µg/ml anti-CD3/CD28
for 72 hours. Line graph showing changes in Extracellular acidification rates (ECAR)
following addition of glucose, oligomycin and 2DG and bar graph showing basal
glycolysis, glycolytic capacity. n = 6-8/group.
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Figure 6.5. HK2 deletion displayed similar CD4 T cell responses upon ocular
infection with HSV-1.
WT and HK2 KO animals were infected with 1 x 104 PFU of HSV-RE. (A) Individual eye
scores of stromal keratitis lesion severity on day 15 pi. (B) Representative histogram
showing the number of total CD4+ T cells infiltrating the cornea at day 15 p.i (C) Pool of
corneas were stimulated with PMA/Ionomycin, representative histogram showing the
number of Th1 (Live CD4+ IFN-γ) cells and Treg (Live CD4+ Foxp3) cells in the cornea
at day 15 pi. (D) DLN were stimulated with PMA/Ionomycin, representative FACS plots
and histogram showing frequency and number of Th1 (live CD4+ IFN-γpos) and Treg (live
CD4+ Foxp3pos). Gated based on the Unstimulated control. (E) Representative FACS
plots and histogram showing frequency of proliferating (Ki-67pos) effector (Live CD4+
Foxp3neg) and regulatory T cells (Live CD4+ Foxp3pos). Gated based on the Isotype. Data
represents the mean ± SEM of more than 3 independent experiments (n=3-10
mice/group). P≤0.05(*).
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Figure 6.6. HK2 deletion in T cells had minimal effect on the expression of CD44
and CD62L on CD4 T cells after infection.
Representative FACS plots and bar graphs showing the frequency and number of
activated (CD44+CD62L-), naïve (CD44-CD62L+) and memory CD4 T cells
(CD44+CD62L+) in the DLN of WT and HK2 KO animals at day 15pi. Data represents
means ± SEM from three independent experiments (n = 3/group).
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS
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Herpetic stromal keratitis is the most common cause of infectious blindness in humans.
Adaptive immune responses dominated by Th1 cells drives the immunopathology in the
cornea whereas regulatory T cells (Treg) play a protective role. Thus approaches that
rebalance the Treg to effector T cell ratio to emphasize Treg can have potential clinical
benefits. However, the protection offered by Treg is often incomplete since they lose their
regulatory functions, resulting in more severe lesions. Hence, we sought to trace the fate
of the Treg phenotype and functionality after infection with HSV-1. Results indicated that
upon ocular infection with HSV-1, Treg may become unstable and take on an effector
phenotype. Thus about 50% of the Treg in the cornea that once expressed Foxp3 now
became IFN-gamma or IL-17A expressing effector cells. The functional and phenotypic
plasticity of Treg was observed predominantly by Treg that expressed low levels of the
receptor for IL-2 (CD25). This plastic nature of CD25 low Treg can be explained by
methylation changes which occurred in their TSDR region. The CD25 low Treg
expressed a methylated TSDR region whereas CD25 hi Treg had a demethylated TSDR.
Inhibiting methylation changes using DNA methyltransferase inhibitor-5-Azacytidine
rescued the unstable Treg and the Treg population showed enhanced
immunosuppressive functions. Consequently, treating animals with 5-Azacytidine from
the time when lesions commenced resulted in reduced lesion severity.
We also show that Treg in the cornea are not only important for immune
suppression but also are key components of tissue repair. Thus Treg in the cornea
secreted a key tissue repair molecule called Amphiregulin (Amp). We identified that IL18, a pro-inflammatory cytokine, can induce the expression of Amphiregulin by Treg.
Moreover, enhancing levels of IL-18 in the cornea using an expression plasmid resulted
in the increased representation of Amp Treg and more effective lesion control. Together
these observations explain that enhancing Treg function and stability can be useful for
better lesion control and repair.
Another novel approach to rebalance the Treg to effector ratio is by targeting their
metabolic requirements. Results from our studies and others indicate that effector T cells,
but not Treg mainly rely on glucose utilization for their function. Thus, inhibiting glucose
utilization using 2-deoxy glucose (2DG) diminished the effector T cell responses, leaving
Treg function intact and able to reduce lesion severity. However, when glucose utilization
was inhibited from the time of infection, anti-viral immune responses, both innate and
adaptive, were inhibited resulting in uncontrolled virus replication and death of animal.
These observations highlight the importance of metabolic requirements especially
glucose utilization by immune cells on the outcome of virus infection.
While our studies identified several new ways to control HSV induced
immunopathology, future studies must focus on evaluating the effects of these inhibitors
locally rather than systemic administrations. Local administration could reduce the offtarget effects and unnecessary complications. Although the role of Amp in corneal tissue
repair has been identified, the role of Treg specific Amp expression in cornea remains to
be established. Thus, mice that lack Amp specifically in Treg could be used to evaluate
such a role. In the current study, we highlighted the role of glucose utilization by immune
cells during virus infections. However, future studies must focus on the understanding
how other host metabolic pathways such as fatty acid and amino acid metabolism
influence immune responses and thus the outcome of HSV infection.
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Manipulating metabolism represents a viable new approach to control some virus
infections. We have argued that metabolic differences between individuals can be one
factor that explains the variable outcome of a virus infection. We also argue that
manipulating metabolic events could be useful to influence the outcome of some virus
infections. We also anticipate that the consequences of infection in each person may
differ because of differential metabolic changes ongoing during infection. Should this be
true then performing metabolic profiles on sick or perhaps even normal persons might
help predict the outcome of their infection. If abnormal profiles are detected, especially in
early infections or in uninfected persons as part of a personalized medicine workup,
targeted therapies might be developed that restore normalcy. Finally, metabolic
manipulation may find a place during vaccination. Accordingly, if optimal immunity
depends on the magnitude of one or another component of immune memory, metabolic
supplements might be used that shape induction of the required type of memory cells.
We speculate that an approach worth exploring is to administer polyunsaturated fatty
acids such as linoleic acid, a known FABP5 activator, at the vaccination site which would
favor the expansion of TRM cells over the central memory population, a situation
beneficial for mucosal infections. Just a note of caution: what is good to stop viruses may
act in an opposite way against bacteria.
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